<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002893.pub2" GROUP_ID="ENT" ID="838399100408475267" MERGED_FROM="" MODIFIED="2011-01-13 10:33:17 +0100" MODIFIED_BY="Jenny Bellorini" REVIEW_NO="0015" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2011-01-13 10:33:17 +0100" MODIFIED_BY="Jenny Bellorini">
<TITLE>Sublingual immunotherapy for allergic rhinitis</TITLE>
<CONTACT MODIFIED="2011-01-13 10:33:17 +0100" MODIFIED_BY="Jenny Bellorini"><PERSON ID="FAED931782E26AA2001B9B03AD28B586" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Suzana</FIRST_NAME><LAST_NAME>Radulovic</LAST_NAME><EMAIL_1>radulovics@yahoo.com</EMAIL_1><EMAIL_2>suzana.radulovic@kcl.ac.uk</EMAIL_2><MOBILE_PHONE>0783 772 8430</MOBILE_PHONE><ADDRESS><DEPARTMENT>LEAP Study Team</DEPARTMENT><ORGANISATION>Paediatric Allergy Research Department, King's College</ORGANISATION><ADDRESS_1>St. Thomas' Hospital</ADDRESS_1><ADDRESS_2>Lambeth Palace Road</ADDRESS_2><CITY>London</CITY><ZIP>SE1 7EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 188 9784</PHONE_1><PHONE_2>+44 207 188 9782</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-01-13 10:33:17 +0100" MODIFIED_BY="Jenny Bellorini"><PERSON ID="FAED931782E26AA2001B9B03AD28B586" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Suzana</FIRST_NAME><LAST_NAME>Radulovic</LAST_NAME><EMAIL_1>radulovics@yahoo.com</EMAIL_1><EMAIL_2>suzana.radulovic@kcl.ac.uk</EMAIL_2><MOBILE_PHONE>0783 772 8430</MOBILE_PHONE><ADDRESS><DEPARTMENT>LEAP Study Team</DEPARTMENT><ORGANISATION>Paediatric Allergy Research Department, King's College</ORGANISATION><ADDRESS_1>St. Thomas' Hospital</ADDRESS_1><ADDRESS_2>Lambeth Palace Road</ADDRESS_2><CITY>London</CITY><ZIP>SE1 7EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 188 9784</PHONE_1><PHONE_2>+44 207 188 9782</PHONE_2></ADDRESS></PERSON><PERSON ID="12214" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Moises</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Calderon</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Senior Clinical Fellow</POSITION><EMAIL_1>m.calderon@imperial.ac.uk</EMAIL_1><MOBILE_PHONE>07812 567435</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Allergy and Respiratory Medicine</DEPARTMENT><ORGANISATION>Royal Brompton Hospital</ORGANISATION><ADDRESS_1>Imperial College School of Medicine at the National Heart and Lung Institute</ADDRESS_1><CITY>London</CITY><ZIP>SW3 6LY</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7351 8024</PHONE_1></ADDRESS></PERSON><PERSON ID="12064" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Duncan</FIRST_NAME><LAST_NAME>Wilson</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>Duncan.Wilson@uhb.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Selly Oak Hospital</DEPARTMENT><ORGANISATION>University Hospitals Birmingham NHS Trust</ORGANISATION><ADDRESS_1>Raddlebarn Road</ADDRESS_1><CITY>Birmingham</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0171 352 8121 ext: 3362</PHONE_1></ADDRESS></PERSON><PERSON ID="8562" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stephen</FIRST_NAME><LAST_NAME>Durham</LAST_NAME><EMAIL_1>s.durham@imperial.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Allergy and Respiratory Medicine</DEPARTMENT><ORGANISATION>Royal Brompton Hospital</ORGANISATION><ADDRESS_1>Imperial College - NHLI</ADDRESS_1><ADDRESS_2>Dovehouse Street</ADDRESS_2><CITY>London</CITY><ZIP>SW3 6LY</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7351 8992</PHONE_1><FAX_1>+ 44 20 7351 8949</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-12-14 09:48:03 +0000" MODIFIED_BY="Jenny Bellorini">
<UP_TO_DATE>
<DATE DAY="14" MONTH="8" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="8" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="8" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-12-14 09:52:12 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-12-14 09:52:12 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details and conflict of interest statement updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-12-14 09:51:49 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-12-14 09:51:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>We included 38 new studies in the review, strengthening the conclusions. The authorship has also changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-14 09:51:46 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>New searches run 14 August 2009.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-11 12:00:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-11 12:01:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Correction submitted for Issue 2, 2004.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2010-05-11 12:02:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Feedback and authors' response incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-12-14 09:49:08 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-11-10 21:54:30 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-04-27 10:00:58 +0100" MODIFIED_BY="[Empty name]">Sublingual immunotherapy for allergic rhinitis (including hay fever)</TITLE>
<SUMMARY_BODY MODIFIED="2010-11-10 21:54:30 +0000" MODIFIED_BY="[Empty name]">
<P>Allergic rhinitis is characterised by red, itchy eyes, a blocked and runny nose, and sneezing. The most common causes of allergic rhinitis are different pollens (grass and tree), house dust mites, mould and animal dander. Allergic rhinitis can be intermittent (such as hay fever) or persistent (all year round). The treatment of allergic rhinitis depends on its severity and duration, and is usually based on the use of antihistamines and nasal corticosteroids. If these drugs cannot control symptoms immunotherapy is recommended. Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitise the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms.</P>
<P>In reviewing 60 trials we found a significant reduction in symptom and medication scores in patients treated with sublingual immunotherapy compared to placebo. There were no serious adverse reactions reported in the included trials and no patient needed the use of adrenaline. This updated Cochrane Review therefore reinforces the conclusions of the earlier review in confirming the efficacy and safety of sublingual immunotherapy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-10 21:54:08 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-05-11 12:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library</I> in Issue 2, 2003.</P>
<P>Allergic rhinitis is a common condition which can significantly impair quality of life. Immunotherapy by injection can significantly reduce symptoms and medication use but its use is limited by the possibility of severe systemic adverse reactions. Immunotherapy by the sublingual route is therefore of considerable interest.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-05-11 12:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of sublingual immunotherapy for allergic rhinitis in adults and children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-10 21:54:08 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane ENT Group Trials Register; CENTRAL (2010, Issue 3); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; <I>m</I>RCT and additional sources for published and unpublished trials. The date of the most recent search was 14 August 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-05-11 12:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trials of sublingual immunotherapy in adults or children. Primary outcome measures were symptom and medication scores. We also collected adverse event data.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-05-11 13:05:07 +0100" MODIFIED_BY="[Empty name]">
<P>Two independent authors selected studies and assessed risk of bias. One author extracted data which was rechecked by two other authors. We used the standardised mean difference (SMD) with a random-effects model to combine data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-06-11 15:08:18 +0100" MODIFIED_BY="Suzana Radulovic">
<P>We included a total of 60 randomised controlled trials in the review. Forty-nine were suitable for pooling in meta-analyses (2333 SLIT, 2256 placebo participants). Overall, we found a significant reduction in symptoms (SMD -0.49; 95% confidence interval (CI) -0.64 to -0.34, P &lt; 0.00001) and medication requirements (SMD -0.32; 95% CI -0.43 to -0.21, P &lt; 0.00001) in participants receiving sublingual immunotherapy compared to placebo. None of the trials included in this review reported severe systemic reactions or anaphylaxis, and none of the systemic reactions reported required the use of adrenaline.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-11 12:17:21 +0100" MODIFIED_BY="[Empty name]">
<P>This updated review reinforces the conclusion of the original 2003 Cochrane Review that sublingual immunotherapy is effective for allergic rhinitis and has been proven to be a safe route of administration. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-10 23:38:36 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-11-10 23:27:39 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in <I>The Cochrane Library</I> in Issue 2, 2003.</P>
<P>Allergic rhinitis is a common condition, affecting between 10% and 40% of people worldwide. The typical clinical features are sneezing, watery rhinorrhoea, nasal blockage, itchy, watery eyes and itchy throat. In clinical trials the severity of allergic rhinitis is usually assessed by numerical validation of nasal and eye symptoms, which takes into account subjective intensity, and whether the condition interferes with everyday life or school and work performance.</P>
<P>The ARIA guidelines (<LINK REF="REF-ARIA-2001" TYPE="REFERENCE">ARIA 2001</LINK>; <LINK REF="REF-ARIA-2008" TYPE="REFERENCE">ARIA 2008</LINK>)<SUP> </SUP>recommend allergen avoidance as first-line treatment, followed by pharmacotherapy aimed at symptom control (mainly antihistamines and topical nasal corticosteroids). For patients with more severe disease, who do not respond to usual therapy, specific immunotherapy is recommended.</P>
<P>Subcutaneous injection immunotherapy has been used for decades. The exact mechanism of action is not fully understood, but involves changes in serum antibody levels (<LINK REF="REF-Jutel-1995" TYPE="REFERENCE">Jutel 1995</LINK>; <LINK REF="REF-Rossi-2004" TYPE="REFERENCE">Rossi 2004</LINK>) and a number of cellular changes, including alteration of the T cell response, from Th2 to Th1 (<LINK REF="REF-Wachholz-2002" TYPE="REFERENCE">Wachholz 2002</LINK>). More recent work suggests that regulatory mechanisms could also play an important role (<LINK REF="REF-Francis-2003" TYPE="REFERENCE">Francis 2003</LINK>; <LINK REF="REF-Jutel-2003" TYPE="REFERENCE">Jutel 2003</LINK>). This immunomodulation results in significant reductions in symptoms and medication requirements (<LINK REF="REF-Calderon-2010" TYPE="REFERENCE">Calderon 2010</LINK>).</P>
<P>Though proven to be efficacious, the subcutaneous route can be uncomfortable and time-consuming. Local adverse events such as injection site itch or swelling are fairly common and, although rare, systemic reactions can be severe. For this reason alternative routes for the delivery of immunotherapy, with a better safety profile, were sought. In the last two decades attention has focused on the sublingual route.</P>
<P>A Cochrane Review of sublingual immunotherapy for allergic rhinitis was published in 2003 (<LINK REF="REF-Wilson-2003" TYPE="REFERENCE">Wilson 2003</LINK>) and included 22 randomised, placebo-controlled trials identified up to September 2002. Analysis of symptom and medication scores proved sublingual immunotherapy to be efficacious. Adverse events reported in these trials were minor and local, and no systemic reactions were reported.</P>
<P>Research in the field of sublingual immunotherapy has continued since 2002, resulting in the publication of many additional studies with increased numbers of participants. This review updates the original to give a more comprehensive evaluation of the efficacy and safety of sublingual immunotherapy.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-06-30 09:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy of sublingual immunotherapy compared with placebo in:</P>
<OL>
<LI>reducing symptoms and/or medication requirements during naturally occurring allergic rhinitis;</LI>
<LI>altering immunological markers in blood and immunological markers and allergen sensitivity in target organs (nose, eye, skin).</LI>
</OL>
<P>To evaluate the safety of sublingual immunotherapy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-10 21:56:43 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-10 21:55:16 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-05-11 12:55:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-11 12:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Studies with participants of any age (children and adults). All patients had a history of allergic rhinitis, with or without allergic conjunctivitis, and with or without allergic asthma. In all studies the allergen was clearly identified. Patients&#8217; sensitivity was proven by positive skin prick tests and/or high specific IgE to a particular allergen. The existence of other clinically relevant sensitivities was one of the exclusion criteria in the majority of studies.</P>
<P>We excluded trials dealing with asthma only from the review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-10 21:55:16 +0000" MODIFIED_BY="[Empty name]">
<P>Included studies were those investigating the efficacy and safety of sublingual immunotherapy. We analysed all trials regardless of treatment dose, duration, or whether the allergen was swallowed or spat out.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-11 12:57:14 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-11 12:56:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Symptom scores, however recorded (either daily or weekly, via symptom score diaries, visual analogue scales, number of well days or overall assessment).</LI>
<LI>Medication scores referring to the use of relevant anti-allergic medications, however recorded and scored.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-05-11 12:57:14 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Measurement of serum IgE and IgG (total and specific).</LI>
<LI>Assessment of allergen sensitivity (eye, nose or skin).</LI>
<LI>Quality of life.</LI>
<LI>Adverse event reports.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-10 21:56:15 +0000" MODIFIED_BY="[Empty name]">
<P>We conducted systematic searches for randomised controlled trials. There were no language, publication year or publication status restrictions. The date of the last search was 14 August 2009 following original searches in September 2002.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-11-10 21:55:38 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> 2009, Issue 3); PubMed; EMBASE; CINAHL; LILACS; KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Science; BIOSIS Previews; CNKI (China National Knowledge Infrastructure); <I>m</I>RCT (Current Controlled Trials); ICTRP (International Clinical Trials Registry Platform) and Google.</P>
<P>We modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, we combined subject strategies with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in <I>The Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.0.1, Box 6.4.b. (<LINK REF="REF-Handbook-2008" TYPE="REFERENCE">Handbook 2008</LINK>)).</P>
<SUBSECTION>
<HEADING LEVEL="4">CENTRAL search strategy</HEADING>
<P>#1 MeSH descriptor Immunotherapy explode all trees<BR/>#2 MeSH descriptor Desensitization, Immunologic explode all trees<BR/>#3 MeSH descriptor Allergens explode all trees with qualifiers: AD,IM<BR/>#4 immunotherap*<BR/>#5 ((allergen* OR immunologic*) AND (hyposensitiz* OR hyposensitis* OR desensitiz* OR desensitis*))<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Administration, Sublingual explode all trees<BR/>#8 (SUBLINGUAL* OR ORAL* OR TONGUE OR MUCOSA)<BR/>#9 (#7 OR #8)<BR/>#10 (#6 AND #9)<BR/>#11 SLIT<BR/>#12 (#10 OR #11)<BR/>#13 MeSH descriptor Rhinitis, Allergic, Perennial explode all trees<BR/>#14 MeSH descriptor Rhinitis, Allergic, Seasonal explode all trees<BR/>#15 MeSH descriptor Rhinitis explode all trees<BR/>#16 rhinti*<BR/>#17 MeSH descriptor Hypersensitivity explode all trees<BR/>#18 allerg* OR hypersensitiv*<BR/>#19 (( #15 OR #16 ) AND ( #17 AND #18 ))<BR/>#20 (perennial:ti OR persistent:ti OR nonseasonal:ti OR nose:ti OR nasal:ti OR cat:ti OR fur:ti OR hair*:ti OR dander:ti OR dust*:ti OR mite*:ti OR pet*:ti OR dog*:ti OR cockroach*:ti OR seasonal:ti OR intermittent:ti OR spring:ti OR summer:ti OR pollen:ti OR grass*:ti OR birch:ti OR ragweed:ti OR tree*:ti OR weed*:ti OR mugwort:ti OR willow:ti OR alder:ti)<BR/>#21 (( #17 OR #18 ) AND #19)<BR/>#22 (hayfever OR "hay fever" OR pollenosis OR pollinosis OR SAR OR PAR)<BR/>#23 (#13 OR #14 OR #19 OR #21 OR #22)<BR/>#24 (#12 AND #23)</P>
<P>Search strategies for other key databases including PubMed are shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-11-10 21:56:15 +0000" MODIFIED_BY="[Empty name]">
<P>We scanned reference lists of identified studies for further trials. We searched PubMed, TRIPdatabase, NHS Evidence - ENT and Audiology, and Google to retrieve existing systematic reviews possibly relevant to this systematic review, in order to search their reference lists for additional trials. We sought abstracts from conference proceedings via the Cochrane Ear, Nose and Throat Disorders Group Trials Register.</P>
<P>We identified additional trials through discussion with specialist allergists, or other professionals with an interest in the area. </P>
<P>We used papers written in English and other languages; translations were performed by the Cochrane ENT Group.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-10 21:56:43 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-06-30 09:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (SR and MC) independently screened the search results and selected studies which appeared to meet the review inclusion criteria. We obtained all such studies in full text for further assessment. Any disagreements about which studies to include in the review were resolved by further discussion with the other two authors (SRD and DW) where necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-11-10 21:56:43 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data from the included studies onto a standard form, covering study type and methodology, number and description of participants, details of type, dosage, schedule, duration of sublingual immunotherapy used, as well as the results, types, timing and method of outcome measures. One author (SR) extracted all data and values were checked by MC and SRD.</P>
<P>Where published manuscripts did not report data sufficiently or in suitable format for meta-analysis we sought further information directly from the authors.</P>
<P>As all the authors were previously familiar with the content of most of the studies, we did not remove the study author names before assessment and data extraction.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-06-30 09:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>Three authors (SR, MC and DW) assessed the identified studies separately and compared the results.</P>
<P>For the original 2003 review, quality assessment of the trials was performed using the Jadad scale (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). For the 2010 update, all the originally included studies were re-assessed by SR and MC, and scored again with the Jadad scale. We only included double-blind, placebo-controlled trials with a Jadad score &gt; 3/5 in the review.</P>
<P>For the 2010 update, two authors (SR and MC) also assessed all included studies for risk of bias using the Cochrane Collaboration 'Risk of bias' tool as guided by <I>The Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Handbook-2008" TYPE="REFERENCE">Handbook 2008</LINK>).</P>
<P>The following were taken into consideration:</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding;</LI>
<LI>incomplete outcome data;</LI>
<LI>selective outcome reporting; and</LI>
<LI>other sources of bias.</LI>
</UL>
<P>We described each of these domains as reported in the trial and then assigned a judgement about the adequacy of each entry. This involved answering a pre-specified question whereby a judgement of &#8216;Yes&#8217; indicates low risk of bias, &#8216;No&#8217; indicates high risk of bias, and &#8216;Unclear&#8217; indicates unclear or unknown risk of bias.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-06-30 09:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>Apart from adverse events, all the outcome data analysed were continuous. The most common way of recording data was through daily diary cards, recording and scoring symptoms (nasal, eye or less frequently chest) and medication use (antihistamine tablets, nasal sprays, eye drops). The data were subsequently totalled and averaged.</P>
<P>A wide range of different scoring systems and scales were employed by trial authors for both primary and secondary outcomes. This creates problems of significant heterogeneity but is unavoidable.</P>
<P>The outcome data extracted from the included studies were entered into RevMan 5 by SR and MC for the statistical analysis (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). A wide variety of scoring systems were used therefore we performed the analysis using the standardised mean difference (SMD) (the difference in means between two treatment groups, immunotherapy and placebo, in units of pooled standard deviation). </P>
<P>We used random-effect models for statistical analysis of the overall efficacy of sublingual immunotherapy. We presented the results as SMDs with the 95% confidence intervals (CI).</P>
<P>We analysed heterogeneity between studies using the Chi² test, with a P value of &lt; 0.1 indicating the significant heterogeneity between studies, and the I² statistic which describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error. We used the threshold values recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (0% to 40%: might not be important; 30% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable heterogeneity). </P>
<P>We carried out subgroup analysis according to the review protocol as follows:</P>
<OL>
<LI>seasonal versus perennial allergens;</LI>
<LI>children versus adults;</LI>
<LI>dosage of major allergen (&lt; 5 mcg of major allergen protein versus 5 to 20 mcg versus &gt; 20 mcg;</LI>
<LI>duration of immunotherapy (&lt; 6 months versus 6 to 12 months versus 12 months, to cover pre-seasonal, perennial and prolonged treatment);</LI>
<LI>sublingual spit versus sublingual swallow; and</LI>
<LI>sublingual drops versus tablets.</LI>
</OL>
<P>We analysed adverse events (AE) as discontinuous data, therefore we present only descriptive analysis.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-10 23:38:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-11-10 21:57:11 +0000" MODIFIED_BY="[Empty name]">
<P>The original 2003 version of this review included 22 studies; the 2010 update includes 60 studies.</P>
<SEARCH_RESULTS MODIFIED="2010-08-09 16:29:22 +0100" MODIFIED_BY="[Empty name]">
<P>The updated searches in 2009 identified 628 papers of potential interest. We discarded 498 papers after reading the abstracts (review articles or descriptive studies, papers investigating other routes of immunotherapy or not investigating allergic rhinitis). We therefore evaluated 130 papers in detail. Among these, 12 references were matched to studies already included or excluded from the review and these are grouped under the 'primary' reference for the study.</P>
<P>Following this evaluation we discarded another 68 papers. </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-11-10 21:57:01 +0000" MODIFIED_BY="[Empty name]">
<P>We thus identified 62 papers as potentially appropriate for the review and meta-analysis. We identified two studies as ongoing (<LINK REF="STD-Ingels-2002" TYPE="STUDY">Ingels 2002</LINK>; <LINK REF="STD-O_x0027_Hehir-2005" TYPE="STUDY">O'Hehir 2005</LINK>).</P>
<P>A total of 60 studies are now included in the 2010 update of this review, of which 49 studies are included in the updated meta-analyses. Eleven studies that did not contain efficacy data eligible for meta-analysis contained useful adverse event data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allergen</HEADING>
<P>Most trials were performed with grass pollen (23 studies). Other allergens used were <I>Parietaria</I> (five trials), ragweed (two trials), trees (nine trials: two olive, three cypress, two birch pollen, two mixed trees), house dust mite (eight trials) and cat (one trial).</P>
<P>One of the trials investigated the efficacy of grass and birch pollen immunotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Thirty-four studies were performed in adults and 15 investigated efficacy and safety in children.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment duration</HEADING>
<P>Treatment lasted for less than six months in 17 studies; six to 12 months in 16 studies and longer than 12 months in 16 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dose of allergen</HEADING>
<P>Of the 49 studies, 32 reported the major allergen dose in a manner suitable for meta-analysis. The rest of the trials either did not provide the sufficient data or reported the cumulative dose (weekly, monthly or a total cumulative dose over the complete treatment). Eight trials used daily doses of less than 5 mcg, in 12 studies the dose was between 5 and 20 mcg per day, and 12 papers reported a daily dose of more than 20 mcg.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allergen reactivity</HEADING>
<P>Nine trials reported data on skin sensitivity, but only six (skin prick test after treatment) could be included in the meta-analysis. Seven trials reported data eligible for meta-analysis of nasal reactivity. Data on conjunctival reactivity were not sufficient for meta-analysis.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-11-10 21:57:11 +0000" MODIFIED_BY="[Empty name]">
<P>At the 2010 update we excluded 14 further studies. We also excluded three studies that had been previously included in the original 2003 review and which did not satisfy the new risk of bias assessment criteria (<LINK REF="STD-D_x0027_Ambrosio-1996" TYPE="STUDY">D'Ambrosio 1996</LINK>; <LINK REF="STD-Mungan-1999" TYPE="STUDY">Mungan 1999</LINK>; <LINK REF="STD-Quirino-1996" TYPE="STUDY">Quirino 1996</LINK>). Two formerly excluded studies (<LINK REF="STD-Clavel-1998" TYPE="STUDY">Clavel 1998</LINK>; <LINK REF="STD-Sabbah-1994" TYPE="STUDY">Sabbah 1994</LINK>) are now included in the review. These two studies did not contain sufficient efficacy data, but they satisfied the review inclusion criteria and their adverse event data were analysed. A total of 24 studies are excluded from this updated version of the review (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Studies listed as excluded are those which satisfied the majority but not all of our inclusion criteria.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-08-09 16:39:12 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies were double-blind, placebo-controlled trials of parallel-group design. Concealment of treatment allocation was considered adequate in all studies, based on statements made by the original authors. Blinding of study subjects and investigators was almost universally maintained by the use of identical placebo preparations. It should, however, be noted that most investigators reported high levels of minor oral side effects (tingling, itching and swelling beneath the tongue) in actively treated subjects, which could influence blinding.</P>
<P>Full risk of bias assessments can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. A 'Risk of bias' summary of our judgements about each risk of bias item for each included study is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and as a graph in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-10 23:38:36 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Symptom scores</HEADING>
<P>A total of 49 studies were included in the meta-analysis. In total 2333 active (sublingual immunotherapy - SLIT) and 2256 placebo patients were included. The combined standardised mean difference (SMD) following sublingual immunotherapy (SLIT) was SMD -0.49 (95% confidence interval (CI) -0.64 to -0.34) favouring active treatment (P &lt; 0.00001). There was significant heterogeneity between the studies (Chi² = 256.76, P &lt; 0.00001, I² = 81%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: seasonal and perennial allergens</HEADING>
<P>We performed the first subgroup analysis in the two biggest subgroups: seasonal (39 trials) and perennial allergens (10 trials).</P>
<P>In the seasonal allergens group there were 2081 participants in the SLIT and 2003 in the placebo group. The combined SMD was -0.34 (95% CI -0.44, -0.25, P &lt; 0.00001). Significant heterogeneity between studies was indicated (Chi² = 68.54, P = 0.002, I² = 45%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>The perennial allergen studies involved 252 SLIT and 253 placebo patients, with SMD -0.93 (95% CI -1.69 to -0.17, P = 0.02). Significant heterogeneity between studies was indicated (Chi² 115.91, P &lt; 0.00001, I²= 92%) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: age</HEADING>
<P>We performed the age subgroup analysis for adults and children in eight studies. In studies with a mixed population the participants were considered as adults if the median age was &#8805; 20, otherwise they were not included in the age subgroup analysis.</P>
<P>Thirty-four studies were performed in adults, 1631 participants received SLIT and 1566 placebo. The combined SMD was -0.44 (95% CI -0.56 to -0.31, P &lt; 0.00001). Significant heterogeneity was indicated between studies (Chi² 77.81, P = 0.0001, I² = 58%) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>Fifteen studies were identified in children; 702 participants were included in the SLIT and 690 in the placebo group. The combined SMD was -0.52 (95% CI -0.94 to -0.10, P = 0.02). Highly significant heterogeneity between studies was indicated (Chi² = 177.60, P &lt; 0.00001, I² = 92%) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: treatment duration</HEADING>
<P>Seventeen trials reported treatment duration for less than six months; 890 patients received SLIT and 882 received placebo treatment. The combined SMD in this group was -0.54 (95% CI -0.86 to -0.21, P = 0.001). There was an indication of highly significant heterogeneity between these trials (Chi² 157.82 , P = 0.00001, I² = 90%) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>In 16 studies the treatment duration was between six and 12 months; 867 participants were in the SLIT and 869 in the placebo group. The SMD in this group was -0.31 (95% CI -0.46 to -0.16, P &lt; 0.0001). A significant level of heterogeneity was indicated (Chi² = 25.47, P = 0.04, I² = 41%) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>Treatment lasted for longer than 12 months in 16 studies; 580 received SLIT and 509 placebo. The SMD was -0.63 (95% CI -0.92 to -0.34, P &lt; 0.0001). Significant heterogeneity among the studies was indicated (Chi² = 74.88, P &lt; 0.00001, I² = 80%) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: major allergen dose</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content &lt; 5 mcg</HEADING>
<P>Eight trials in this group reported symptom score results; 141 patients received SLIT and 134 placebo. The SMD was -0.32 (95% CI -0.69 to 0.05, P = 0.09). Significant heterogeneity was shown between studies (Chi² = 15.18, P = 0.03, I²= 54%) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content 5 to 20 mcg</HEADING>
<P>There were 12 studies included in this subgroup, with 1006 patients receiving SLIT and 966 placebo. The SMD was -0.34 (95% CI -0.45 to -0.24, P &lt; 0.00001). A lack of heterogeneity between studies was indicated (Chi² was 13.52, P = 0.26, I²= 19%) (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content &gt; 20 mcg</HEADING>
<P>There were 12 studies in this subgroup, with 541 receiving SLIT and 500 placebo. The SMD in this group was -0.33 (95% CI -0.49 to -0.17, P &lt; 0.0001). No significant heterogeneity between studies was demonstrated (Chi² = 15.19, P = 0.17, I² = 28%) (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: individual allergens</HEADING>
<P>It was possible to perform individual subgroup analysis for one perennial (house dust mite) and four seasonal (grass pollen, <I>Parietaria</I>, ragweed, tree) allergens because they were investigated in more than one study.</P>
<P>Nine studies investigated house dust mite, with 232 patients in the SLIT and 232 in the placebo group. The SMD was -0.97 (95% CI -1.80 to -0.13, P = 0.02). There was an indication of highly significant heterogeneity between studies (Chi² = 110.42, P &lt; 0.00001, I² = 93%) (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
<P>Twenty-three studies were performed with grass pollen allergen. There were 1549 in the SLIT and 1464 patients in the placebo group. The combined SMD was -0.35 (95% CI -0.45 to -0.24, P &lt; 0.00001). Significant heterogeneity was indicated among studies (Chi² = 39.58, P = 0.01, I² = 44%) (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>).</P>
<P>There were only two studies investigating ragweed, involving 85 participants in the SLIT and 90 in the placebo group. The SMD was -0.44 (95% CI -0.74 to -0.14, P = 0.004). There was no heterogeneity shown between the studies (Chi² = 0.00, P = 0.96, I² = 0%) (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>).</P>
<P>
<I>Parietaria</I> was investigated in five trials, with 74 patients in the SLIT and 77 in the placebo group. The SMD was -0.36 (95% CI -0.69 to -0.04, P = 0.03). There was no heterogeneity shown between studies (Chi² = 2.95, P = 0.57, I² = 0%) (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</P>
<P>Nine different studies involved trees (two mixed trees, two birch, two olive and three cypress); 197 participants received SLIT and 183 placebo. The SMD was -0.42 (95% CI -0.77 to -0.06, P = 0.02). Significant heterogeneity was indicated among studies (Chi² = 20.17, P = 0.01, I² = 60%) (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: medication preparation</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Sublingual tablets</HEADING>
<P>Sublingual tablets were used in 11 studies, with 945 participants in the SLIT and 936 in the placebo group. The SMD in this subgroup was -0.48 (95% CI -0.58 to -0.38, P &lt; 0.00001). A significant level of heterogeneity between studies was indicated (Chi² = 39.07, P &lt; 0.0001, I² = 74%) (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sublingual drops</HEADING>
<P>There were 35 studies included in this subgroup, with 1270 patients receiving SLIT and 1194 placebo. The SMD was -0.35 (95% CI -0.42 to -0.28, P &lt; 0.00001). Highly significant heterogeneity between studies was indicated (Chi² = 436.12, P &lt; 0.00001, I² = 92%) (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>).</P>
<P>Three studies used both drops and tablets and were not included in the analysis.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Medication scores</HEADING>
<P>Thirty-eight trials reported medication score<B> </B>results, with a total of 1737 patients in the SLIT group and 1642 in the placebo group. The combined SMD was -0.32 (95% CI -0.43 to -0.21, P &lt; 0.00001). Significant heterogeneity was indicated (Chi² = 73.32, P = 0.0003, I² = 50%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: seasonal and perennial allergens</HEADING>
<P>In the seasonal allergens group 32 trials reported medication score, with 1557 patients receiving SLIT and 1457 placebo. The SMD was -0.30 (95% CI -0.41 to -0.19, P &lt; 0.00001). Significant heterogeneity among studies was indicated (Chi² = 55.80; P = 0.004, I² = 44%) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Six studies with perennial allergens involved 180 SLIT and 185 placebo patients. The SMD was -0.43 (95% CI -0.89 to 0.02, P = 0.06). Significant heterogeneity between studies was indicated (Chi² = 17.21, P = 0.004, I² = 71%) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: age</HEADING>
<P>Twenty-six studies which were performed in adults reported the medication score; 1168 participants received SLIT and 1067 placebo. The combined SMD was -0.40 (95% CI -0.53 to -0.26, P &lt; 0.00001). Significant heterogeneity was indicated (Chi² = 47.76, P = 0.004, I²= 48%) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>Twelve studies in children reported the medication score; 569 patients in the SLIT and 575 in the placebo group. The combined SMD was -0.16 (95% CI -0.32 to 0.00, P = 0.06). Heterogeneity was non-significant (Chi² = 17.31, P = 0.10, I² = 36%) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: treatment duration</HEADING>
<P>Fifteen out of 17 trials with a treatment duration of less than six months reported medication scores; 694 participants received SLIT and 672 placebo. The SMD was -0.32 (95% CI -0.45 to -0.18, P &lt; 0.00001). A lack of heterogeneity between studies was indicated (Chi² = 19.09; P = 0.16, I² = 27%) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>). </P>
<P>Medication score was reported in 13 studies with a treatment duration between six and 12 months. A total of 705 active and 693 placebo participants took part in these trials. The SMD was -0.31 (95% CI -0.50 to -0.12, P = 0.002). A significant level of heterogeneity was indicated (Chi² = 26.90, P = 0.008, I² = 55%) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
<P>Treatment lasted for longer than 12 months in 10 studies reporting medication scores; 338 patients received SLIT and 277 placebo. The SMD was -0.34 (95% CI -0.64 to -0.04, P = 0.03). Significant heterogeneity among the studies was indicated (Chi² = 27.13, P = 0.001, I² = 67%) (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: major allergen dose</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content &lt; 5 mcg</HEADING>
<P>Six trials in this group reported medication score; 110 patients received SLIT and 109 placebo. The SMD was -0.59 (95% CI -0.94 to -0.24, P = 0.0008). A lack of heterogeneity between studies was indicated (Chi² = 7.43, P = 0.19, I² = 33%) (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content 5 to 20 mcg</HEADING>
<P>Eleven studies were included in this subgroup analysis, with total of 992 patients receiving SLIT and 948 placebo. The SMD was -0.21 (95% CI -0.35 to -0.07, P = 0.003). Significant heterogeneity between studies was indicated (Chi² = 19.84, P = 0.03, I² = 50%) (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Major allergen content &gt; 20 mcg</HEADING>
<P>Ten studies from this group reported medication scores; 360 participants in the SLIT and 301 in the placebo group. The SMD in this group was -0.22 (95% CI -0.43 to 0.00, P = 0.05). Significant heterogeneity between studies was indicated (Chi² = 15.70, P = 0.07, I² = 43%) (<LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: individual allergens</HEADING>
<P>As with symptom scores, we performed meta-analysis for medication scores for one perennial (house dust mite) and four seasonal (grass pollen, <I>Parietaria</I>, ragweed, tree) allergens.</P>
<P>Medication scores were reported in five trials involving house dust mite; 95 patients received SLIT and 94 received placebo. The SMD was -0.52 (95% CI -1.09 to 0.05, P = 0.07). Highly significant heterogeneity was indicated between studies (Chi² test = 12.92, P = 0.01, I² = 69%) (<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>).</P>
<P>Seventeen studies were performed with grass pollen allergen. There were 1201 patients in the SLIT and 1107 in the placebo group. The combined SMD was -0.23 (95% CI -0.37 to -0.10, P = 0.0008). Significant heterogeneity among studies was indicated (Chi² = 34.55, P = 0.005, I² = 54%) (<LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>).  </P>
<P>Medication scores were also reported in two studies investigating ragweed, involving 85 patients in the SLIT and 90 in the placebo group. The SMD was -0.30 (95% CI -0.60 to 0.00, P = 0.05). No heterogeneity was shown between studies (Chi² 0.82, P = 0.37, I² = 0%) (<LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>).</P>
<P>
<I>Parietaria</I> was investigated in five trials, with 74 patients in the SLIT and 77 in the placebo group. The SMD was -0.62 (95% CI -1.00 to -0.24, P = 0.001). No heterogeneity was shown between studies (Chi² = 5.30, P = 0.26, I² = 25%) (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
<P>Nine different studies involved trees, with 197 participants receiving SLIT and 183 placebo. The SMD was -0.38 (95% CI -0.62 to -0.13, P = 0.002). There was a lack of significant heterogeneity among studies (Chi² = 10.24, P = 0.25, I² = 22%) (<LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis: medication preparation</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Sublingual tablets</HEADING>
<P>Sublingual tablets were used in nine trials, with 799 participants in the SLIT group and 779 in the placebo group. The SMD was -0.33 (95% CI -0.46 to -0.20, P &lt; 0.00001). Highly significant heterogeneity was shown between studies (Chi² = 50.39, P &lt; 0.00001, I² = 84%) (<LINK REF="CMP-020.02" TYPE="ANALYSIS">Analysis 20.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sublingual drops</HEADING>
<P>Medication score was reported in 27 studies using sublingual drops; 865 SLIT and 788 placebo participants took part in these trials. The SMD was -0.01 (95% CI -0.05 to 0.04, P = 0.74). A significant level of heterogeneity was indicated (Chi² = 82.89, P &lt; 0.00001, I² = 69%) (<LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Specific serum antibodies</HEADING>
<P>Fourteen studies reported increases in serum-specific IgE levels in a manner suitable for the meta-analysis, with 675 participants in the SLIT and 659 in the placebo group. The combined SMD was 0.27 (95% CI -0.01 to 0.55, P = 0.05). Significant heterogeneity was indicated between studies (Chi² = 68.63, P &lt; 0.00001, I² = 81%) (<LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>).</P>
<P>Total serum-specific IgG was measured in three studies, with 286 participants in the SLIT and 304 in the placebo group. The combined SMD was 0.95 (95% CI 0.78 to 1.12, P &lt; 0.00001). There was no significant heterogeneity between studies (Chi² = 1.01, P = 0.60, I² = 0%) (<LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>).</P>
<P>Serum-specific IgG4 was measured in 13 trials, with a total number of 588 in the SLIT and 599 in the placebo group. The total SMD was 0.46 (95% CI 0.29 to 0.63, P &lt; 0.00001). Highly significant heterogeneity was indicated (Chi² = 174.24, P &lt; 0.00001, I² = 93%) (<LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allergen sensitivity</HEADING>
<P>Six studies included skin reactivity data (skin prick test or early phase reaction) that were eligible for the meta-analysis; 183 participants were in the SLIT and 148 in the placebo group. The SMD was 0.12 (95% CI -0.26 to 0.51, P = 0.53). Significant heterogeneity was indicated among studies (Chi² was 12.47, P = 0.03, I² = 60%) (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>).</P>
<P>The results of nasal reactivity were reported in 10 studies, but only seven were suitable for meta-analysis. The analysis involved 111 participants in the SLIT and 109 participants in the placebo group. The SMD was 0.32 (95% CI -0.13 to 0.78, P = 0.17). Highly significant heterogeneity was indicated between studies (Chi² = 16.39, P = 0.01, I² = 63%) (<LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>).</P>
<P>We identified only one study each assessing conjunctive and bronchial provocation tests which were eligible for meta-analysis, therefore we could not perform these analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>We included 60 studies in our systematic review and all were analysed for safety results. Adverse events were the only discontinuous data analysed in our review.</P>
<P>Twenty-five studies reported data in a manner not suitable for our analysis (insufficient data, adverse events reported by system organ classification, data expressed in percentages, etc.) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Six studies with 125 participants in the SLIT and 126 in the placebo group reported no adverse events during the trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>Twenty-two studies reported different local and systemic reactions as a total number of single adverse events during the whole trial, hence we analysed these data.</P>
<P>Twenty-five studies reported different local events. Buccal pruritus was reported in 21 trials: 1126 participants experienced a total number of 1798 events in the SLIT group and 1075 participants experienced 492 events in the placebo group. Labial oedema was reported in 11 studies, with 604 participants/55 events in the SLIT group and 526 participants/7 labial swelling episodes in the placebo group.</P>
<P>Bucco-lingual oedema was reported in eight trials, with 648 participants/143 events in the SLIT group, and 606 participants/2 episodes in the placebo group. Throat irritation was reported in 10 trials, including 770 participants in the SLIT and 747 in the placebo group, with 243 and 29 episodes respectively. Local adverse events were also reported as oral non-specified in three and local non-specified in three trials (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Systemic reactions were reported by 18 studies (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Rhinitis was reported in 16 trials, with 965 participants/1403 events in the SLIT group and 912 participants/1034 events in the placebo group. Conjunctivitis alone was reported by eight trials, with 262 participants and 774 conjunctivitis episodes in the SLIT and 238 participants and 786 events in the placebo group. Cough was reported in eight trials: 337 participants treated with SLIT experienced 313 events and 304 participants in the placebo group reported 211 episodes of cough. Gastro-intestinal symptoms were described by 20 trials with 630 participants in the SLIT and 561 in the placebo group, with 88 and 10 events respectively. None of the studies reported anaphylaxis.</P>
<P>Fifteen studies reported adverse events which led to treatment discontinuation. In the SLIT group, 41 out of 824 patients and 12 out of 861 placebo participants were withdrawn because of adverse events. Troublesome local reactions were the most common cause, although systemic reactions were described (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
<P>Five studies reported adverse events by their severity, but not all of them considered the link with the treatment. The majority of adverse events were mild to moderate and did not require any treatment. None of the reactions required the administration of adrenaline. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Quality of life was reported by three studies, but assessment in those studies differed greatly and we considered that these data could not be included in our analysis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-11-10 23:13:23 +0000" MODIFIED_BY="[Empty name]">
<P>This systematic review of sublingually administered allergen immunotherapy (SLIT) represents an update of a review first published in <I>The Cochrane Library</I> in 2003 (<LINK REF="REF-Wilson-2003" TYPE="REFERENCE">Wilson 2003</LINK>). The original review included data from 22 randomised controlled trials (979 patients) and demonstrated the efficacy of this form of treatment based on meta-analysis of symptom severity scores (standardised mean difference (SMD) -0.42; 95% confidence interval (CI) -0.69 to -0.15). Ongoing research in this area has been considerable and this review has now been updated to include studies published since 2003. The number of studies included has almost trebled to 60 (with 49 being suitable for pooling in meta-analyses) and the number of patients in meta-analysis has increased over four-fold, reflecting a trend towards larger, better designed and more powerful trials.</P>
<P>The overall results of the meta-analysis differ little from those seen in 2003, with the overall effect for symptom scores (SMD -0.49; 95% CI -0.64 to -0.34) being of a similar magnitude, with tighter confidence intervals reflecting the greatly increased number of study subjects. The same is true for the analysis of medication scores, with SMD -0.32 (95% CI -0.43 to -0.21). These data continue to support the clinical efficacy of sublingual immunotherapy for allergic rhinitis.</P>
<P>In contrast to the original review, the greater number of studies has allowed more meaningful analyses of some of the pre-determined subgroups. In particular there are now 15 studies looking exclusively at children, some of which are large studies in their own right (<LINK REF="STD-Bufe-2009" TYPE="STUDY">Bufe 2009</LINK>; <LINK REF="STD-Wahn-2009" TYPE="STUDY">Wahn 2009</LINK>). The treatment effect within this subgroup of trials appears to be similar to that seen in adults, especially when considering symptom scores. SLIT represents a particularly attractive alternative to injection immunotherapy in this patient group and our findings are entirely consistent with those reported elsewhere (<LINK REF="REF-Calderon-2008" TYPE="REFERENCE">Calderon 2008</LINK>).</P>
<P>The protocol for the original review reflected the then classification of aero-allergens into seasonal and perennial. The ARIA classification (<LINK REF="REF-ARIA-2008" TYPE="REFERENCE">ARIA 2008</LINK>) now uses the terms intermittent and persistent but for this review this change makes no difference. In this meta-analysis there does appear to be a greater effect with perennial allergens (predominantly house dust mite) when compared to seasonal allergens although this is based on fewer studies. More studies of perennial rhinitis are needed to confirm or exclude this possibility.</P>
<P>It is not possible to differentiate between different doses on the basis of this meta-analysis. The difficulty in determining dose in terms of micrograms of major allergen, and standardising this information across a range of studies utilising allergen extracts from different sources, was acknowledged in the original review and remains problematic.</P>
<P>Although the difference is small, this review has shown a trend in symptom score reduction in trials which lasted for longer than 12 months, when compared with shorter treatment periods. Indeed, SLIT is now given for longer time periods (over 12 months in 32% of included studies compared with 19% in 2003), and more recent studies have shown that treatment for longer than 12 months provides consistent clinical improvement in symptom and medication scores (<LINK REF="REF-Dahl-2008" TYPE="REFERENCE">Dahl 2008</LINK>; <LINK REF="REF-Durham-2010" TYPE="REFERENCE">Durham 2010</LINK>). These data are encouraging and should be taken into consideration in future recommendations or guidelines for the use of SLIT in allergic rhinitis.</P>
<P>Looking at the total effect and SMD (95% CI) of sublingual immunotherapy for individual allergens, house dust mite appears to be more effective than treatment with other types of allergen, and even more effective than treatment with grass pollen. However, the majority of these trials are small, with five (out of nine) trials involving fewer than 20 participants. Heterogeneity in this group is amongst the highest in all the meta-analyses; when comparing P values for the overall effect, the level of significance appears to be lower than for the majority of other allergens. We therefore conclude that this finding should be interpreted with caution.</P>
<P>This review has shown that SLIT provokes significant changes in terms of allergen-specific IgG and IgG4 antibodies, which coincide with a clinical response in terms of symptom and medication scores. These findings are in complete concordance with the findings of the previous SLIT review (<LINK REF="REF-Wilson-2003" TYPE="REFERENCE">Wilson 2003</LINK>), as well as injection immunotherapy (<LINK REF="REF-Calderon-2007" TYPE="REFERENCE">Calderon 2007</LINK>). Unfortunately, changes detected in IgG and IgG4 values were not supported by changes in allergen sensitivity, and meta-analysis of data for skin and nasal reactivity after treatment showed no difference between the immunotherapy and placebo group. The exact role of IgG and IgG4 is still not completely clear. Although they are likely to have a certain 'protective' role, there is still an ongoing debate as to whether this increase in (particularly) IgG4 is just a consequence of exposure to a high dose of allergen or the real  immunomodulatory effect of sublingual immunotherapy. This review could not draw a definitive conclusion and only further mechanistic studies can enable us to answer this question.</P>
<P>This review explored the possible differences between different sublingual preparations (i.e. sublingual drops versus tablets). Although tablets proved to be more effective in terms of medication scores, and had similar efficacy in terms of symptoms, overlapping confidence intervals and the substantial heterogeneity between studies did not allow us to draw any firm conclusions. It seems both preparations are similarly effective.</P>
<P>An increasing number of studies report quality of life as a primary or secondary outcome measure as is the case in clinical trials in general. Nevertheless, there were big differences in quality of life scoring systems such that we were unable to analyse these data by meta-analysis.</P>
<P>It was acknowledged in the original review that many of the studies included were small, early publications that did not conform to the CONSORT (1996) guidelines for the publication of randomised controlled trials (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). The methodological quality of the studies included on this occasion has been scrutinised more closely using the new Cochrane criteria, including assessment of randomisation and allocation concealment.</P>
<P>The possible confounder of publication bias that exists in all meta-analysis (<LINK REF="REF-Calderon-2008" TYPE="REFERENCE">Calderon 2008</LINK>; <LINK REF="REF-Nieto-2009" TYPE="REFERENCE">Nieto 2009</LINK>) was acknowledged in the original review and has again been addressed on this occasion through extensive consultation with those active in the field of SLIT research. We are confident that no data have been excluded purely on the basis of negative outcome.</P>
<P>Funnel plot evaluations for the two main outcomes (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) showed that the plots were reasonably symmetrical and there did not appear to be a paucity of smaller trials with small or absent symptom reduction effect.</P>
<P>In the current review we withdrew three studies (<LINK REF="STD-D_x0027_Ambrosio-1996" TYPE="STUDY">D'Ambrosio 1996</LINK>; <LINK REF="STD-Mungan-1999" TYPE="STUDY">Mungan 1999</LINK>; <LINK REF="STD-Quirino-1996" TYPE="STUDY">Quirino 1996</LINK>) that had been included in the 2003 review as they did not satisfy the new Cochrane criteria for randomised, double-blind studies.</P>
<P>Heterogeneity between studies was acknowledged as a significant problem in the last review, and is a known problem in systematic reviews. This results largely from methodological and clinical heterogeneity (i.e. differences in scoring systems, sample sizes, type and dose of allergen, age groups, etc.) used across studies. Selection of the studies for this review was defined in our protocol and studies which satisfied our criteria were chosen. The method used by The Cochrane Collaboration for assessing heterogeneity has however changed and can now be expressed as an I<SUP>2</SUP> statistic. It remains the case that studies in this field are heterogeneous and data are expressed in a wide variety of different ways. However, certain subgroup analyses (e.g. seasonal allergens, individual allergens, subgroup analysis for major allergen content) have shown the significant reduction in heterogeneity even though these groups were prespecified by a protocol. This means that there will always be a degree of interpretation required when amalgamating studies in meta-analysis and further subgroup analysis could be performed in order to address better the problem of heterogeneity. Despite this, there is remarkable consistency in the outcomes of related systematic reviews (<LINK REF="REF-Casale-2009" TYPE="REFERENCE">Casale 2009</LINK>; <LINK REF="REF-Cox-2006" TYPE="REFERENCE">Cox 2006</LINK>; <LINK REF="REF-Wilson-2005" TYPE="REFERENCE">Wilson 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Adverse events</HEADING>
<P>Although considered as a secondary outcome, we felt analysis of adverse events to be crucial as a low incidence confers advantage on SLIT as an alternative to injection immunotherapy. Adverse event data were, by their nature, non-continuous. Authors mainly reported data as total number of events for a number of patients, rather than number of certain events per patient. Some papers reported their most common events as a percentage of total events, or as a percentage of patients who experienced particular events. These were therefore not suitable for meta-analysis and we were able to perform only descriptive analysis. A further problem is that unlike for the subcutaneous route there is currently no internationally standardised methodology for reporting local adverse events of sublingual immunotherapy.</P>
<P>With these reservations, local reactions are again shown to be common and reported much more frequently in SLIT recipients than in those receiving placebo. These are clearly unavoidable but are usually seen as an inconvenience and cause little distress and have no lasting effect, though rarely these adverse events were distressing enough to warrant withdrawal of treatment.</P>
<P>Systemic reactions were again largely confined to the upper respiratory tract and associated organs (rhinitis, conjunctivitis or rhinoconjunctivitis) and were more frequent in the SLIT than in the placebo groups. Asthma or wheeze was no more likely in SLIT recipients than in placebo recipients. Gastrointestinal effects (non-specified) were rare but more apparent in SLIT recipients and were largely confined to paediatric trials. None were considered serious.</P>
<P>There were no reports in clinical trials of severe systemic reactions or anaphylaxis and none of the systemic reactions needed the use of adrenaline. No fatalities were reported.</P>
<P>This review evaluates a large number of double-blind, placebo-controlled studies which, in total, give us a large number of doses. No incidences of life-threatening reactions were reported in the studies analysed. We conclude that SLIT remains a safe treatment with an extremely low incidence of significant side effects. Systemic adverse events were predominantly mild to moderate and their causality was unlikely to be related to SLIT. We have been unable to correlate adverse events with allergen dose.</P>
<P>There are no reports of fatalities following sublingual immunotherapy. Six isolated cases of severe reactions have been reported independently of clinical trials and all involved deviation from current recommended practice according to international guidelines (<LINK REF="REF-Antico-2006" TYPE="REFERENCE">Antico 2006</LINK>; <LINK REF="REF-Blazowski-2008" TYPE="REFERENCE">Blazowski 2008</LINK>; <LINK REF="REF-de-Groot-2009" TYPE="REFERENCE">de Groot 2009</LINK>; <LINK REF="REF-Dunsky-2006" TYPE="REFERENCE">Dunsky 2006</LINK>; <LINK REF="REF-Eifan-2007" TYPE="REFERENCE">Eifan 2007</LINK>). Numbers are too few to allow identification of risk factors for severe systemic reactions, whereas it can be noted that five out of six occurred in young females, five out of six had asthma, and two out of six had previously experienced severe reactions during subcutaneous immunotherapy. These data should be viewed in the context of the number of doses of sublingual immunotherapy that have been prescribed and administered worldwide.</P>
<P>Since the original systematic review in 2003 SLIT has become established as an effective and low-risk alternative to allergen injection immunotherapy, which carries a significant morbidity and a requirement for delivery within specialist centres capable of meeting CSM recommendations. SLIT is recommended to be initiated in secondary care and the first dose taken under medical supervision whereas maintenance treatment is recommended to be self-administered in the patient&#8217;s home.</P>
<P>Only two studies in the original review compared injection immunotherapy with sublingual immunotherapy directly (<LINK REF="REF-Mungan-1999" TYPE="REFERENCE">Mungan 1999</LINK>; <LINK REF="REF-Quirino-1996" TYPE="REFERENCE">Quirino 1996</LINK>). In the current review only one study compared injection immunotherapy versus SLIT. Although comparison of those two treatment options was not the objective of this review, the search process enabled us to identify papers comparing the efficacy of these treatment options. We found very few such papers: there appears to be insufficient data available to draw any conclusions and more definitive head-to-head trials are needed.</P>
<P>A Cochrane Review of allergen injection immunotherapy, which included 51 trials with 2871 participants (<LINK REF="REF-Calderon-2007" TYPE="REFERENCE">Calderon 2007</LINK>), showed a SMD of -0.73 (95% CI -0.97 to -0.5) for symptom scores compared to placebo and a SMD of -0.57 (95% CI -0.82 to -0.33) for medication scores. Although the SMDs are numerically different, the confidence intervals overlap with those for SLIT, indicating no apparent difference between the two therapies on this basis. However, it is not correct to perform a direct statistical comparison between these two meta-analyses. These data raise the importance of future double-blind, double-dummy trials that directly compare these two routes of immunotherapy.</P>
<P>Injection immunotherapy exerts its long-lasting effects through modulation of the response of the immune system upon allergen exposure, altering from an allergic response to one of immune tolerance as evidenced by alterations in Th cell cytokine profiles, numbers of effector cells at target sites and changes in humoral responses, including increases in putative blocking IgG4 class antibodies (<LINK REF="REF-Wilson-2001" TYPE="REFERENCE">Wilson 2001</LINK>). In the 2003 review there were only six studies that reported immunological outcomes, in terms of immunoglobulin levels, that were suitable for meta-analysis but available data did suggest consistent increases in allergen-specific IgG4 during SLIT treatment. Eleven studies (doubling the number of subjects) in the current review contained data on IgG4 levels and a consistent and significant two-fold increase in IgG4 levels was observed. The role of allergen-specific IgG4 antibodies remains controversial but the evidence points towards similar immunological mechanisms underlying the two forms of therapy. Further discussion on mechanisms is outside the scope of this review.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-06-11 16:12:03 +0100" MODIFIED_BY="Suzana Radulovic">
<IMPLICATIONS_PRACTICE MODIFIED="2010-06-11 16:12:03 +0100" MODIFIED_BY="Suzana Radulovic">
<P>This systematic review and meta-analysis is more powerful than the original review published in 2003, with over four times the number of patients. The data again strongly support the efficacy of sublingual immunotherapy compared with placebo in terms of a reduction in rhinitis symptom scores and anti-allergic medication requirements. Furthermore, the data now more strongly support the use of sublingual immunotherapy in children and in allergic rhinitis due to all aero-allergens.</P>
<P>Sublingual immunotherapy is now established as a viable alternative to allergen injection immunotherapy, with a significantly lower risk profile and, on the basis of meta-analyses, little difference in overall efficacy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-12 12:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>The optimum dose and duration of therapy remains an unanswered question and it is unlikely that meta-analysis will provide the answers. Ongoing clinical trials of prolonged therapy and increasing use of standardised tablet products may do.</P>
<P>The mechanism of action of both injection and sublingual immunotherapy remain under investigation, and injection immunotherapy has been proven to lead to long-term changes in the immunological response to allergen that may persist for years following discontinuation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Grateful thanks are extended to the authors of individual studies who provided additional data to allow meaningful meta-analysis to be performed.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-12-14 09:49:08 +0000" MODIFIED_BY="[Empty name]">
<P>The lead review author, Dr Suzana Radulovic, has received financial support from the ITN (Immune Tolerance Network) as an employee of the Paediatric Allergy Research Department at King's College London, UK.</P>
<P>The Department of Upper Respiratory Medicine, National Heart &amp; Lung Institute, London, UK, headed by Professor Durham, has received financial support from ALK Abello, Horsholm, Denmark - manufacturers of allergen extracts. Stephen Durham has received consultancy and lecture fees and research grants from Alk Abello, a manufacturer of allergy vaccines, via Imperial College.</P>
<P>There are no other conflicts of interest to be declared.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-06-30 09:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>SUZANA RADULOVIC: Lead review author, searching for trials, quality assessment of trials, design of data extraction form, data extraction, data analysis.</P>
<P>MOISES CALDERON: Review author, searching for trials, quality assessment of trials, data analysis, input at all other stages of review.</P>
<P>DUNCAN WILSON: Review author, protocol development, quality assessment of trials, design of data extraction form, data extraction, data analysis.</P>
<P>STEPHEN DURHAM: Protocol development, input at all other stages of review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-06-30 09:51:21 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Evaluation of safety has been noted as a primary objective of the review.</LI>
<LI>The I² statistic has now been used to quantify heterogeneity.</LI>
<LI>The Cochrane 'Risk of bias' tool has now been used to assess the methodological quality of the included trials.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-10 23:49:03 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-10 23:49:03 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-10 23:49:03 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Amar-2009" MODIFIED="2010-11-10 22:38:52 +0000" MODIFIED_BY="[Empty name]" NAME="Amar 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:38:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS</AU>
<TI>Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in multiallergen extract</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>1</NO>
<PG>150-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andre-2003" MODIFIED="2010-11-10 22:39:01 +0000" MODIFIED_BY="[Empty name]" NAME="Andre 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-10 22:39:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andre C, Perrin- Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, et al</AU>
<TI>A double- blind placebo- controlled evaluation of sublingual immunotherapy with standardized ragweed extract in patients with seasonal rhinitis</TI>
<SO>International Archives of Allergy and Immunology</SO>
<YR>2003</YR>
<VL>131</VL>
<PG>111-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ariano-2001" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Ariano 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ariano R, Spadolini I, Panzani RC</AU>
<TI>Efficacy of sublingual immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>2001</YR>
<VL>29</VL>
<PG>238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bahceciler-2001" MODIFIED="2010-11-10 22:39:23 +0000" MODIFIED_BY="[Empty name]" NAME="Bahceciler 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-10 22:39:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bahceciler NN, Isik U, Barlan IB, Basaran MM</AU>
<TI>Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double blind, placebo-controlled study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bowen-2004" NAME="Bowen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowen T, Greenbaum J, Charbonneu Y, Hebert J, Filderman R, Sussman G, et al</AU>
<TI>Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjuctivitis</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2004</YR>
<VL>93</VL>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bufe-2004" MODIFIED="2010-11-10 22:39:15 +0000" MODIFIED_BY="[Empty name]" NAME="Bufe 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-10 22:39:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bufe A, Ziegler-Kirbach E, Stoeckman E, Heidemann P, Gehlhar K, Holland-Letz T, et al</AU>
<TI>Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms, a double-blind, placebo-controlled study</TI>
<SO>Allergy</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-30 10:38:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bufe A, Ziegler-Kirbach E, Stoekmann E, Heidemann P, Braun W</AU>
<TI>Specific sublingual immunotherapy in children: results of double-blind, placebo controlled clinical trial [Abstract]</TI>
<SO>XX Congress of the European Academy of Allergology and Clinical Immunology</SO>
<YR>2001</YR>
<PG>Abstract No 829</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bufe-2009" MODIFIED="2010-11-10 22:39:40 +0000" MODIFIED_BY="[Empty name]" NAME="Bufe 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:39:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al</AU>
<TI>Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>1</NO>
<PG>167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Caffarelli-2000" NAME="Caffarelli 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caffarelli C, Sensi LG, Marcucci F, Cavagni G</AU>
<TI>Preseasonal local allergoid immunotherapy to grass pollen in children : a double-blind, placebo-controlled, randomized trial</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>1142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calderon-2006" MODIFIED="2010-06-30 12:27:20 +0100" MODIFIED_BY="[Empty name]" NAME="Calderon 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-30 12:27:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calderón M, Essendrop M</AU>
<TI>Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>6</NO>
<PG>338-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-30 12:26:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calderon MA, Rak S, Durham SR</AU>
<TI>Grass pollen tablets for sublingual immunotherapy in seasonal allergic rhinitis [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>S65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cao-2007" MODIFIED="2009-07-15 18:09:56 +0100" MODIFIED_BY="[Empty name]" NAME="Cao 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-15 18:09:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M, et al</AU>
<TI>Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides Farinae Drops</TI>
<SO>Zhonghua Er Ke Za Zhi.</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>10</NO>
<PG>736-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Casanovas-1994" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Casanovas 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC</AU>
<TI>Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>6</NO>
<PG>305-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clavel-1998" NAME="Clavel 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clavel R, Bousquet J, Andre C</AU>
<TI>Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis</TI>
<SO>Allergy</SO>
<YR>1998</YR>
<VL>53</VL>
<PG>493-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-D_x0027_Ambrosio-1999" NAME="D'Ambrosio 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purello-D'Ambrosio F</AU>
<TI>Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardised in mass units in patients with rhinoconjunctivitis, asthma, or both</TI>
<SO>Allergy</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>968-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahl-2006a" MODIFIED="2010-11-10 22:39:54 +0000" MODIFIED_BY="[Empty name]" NAME="Dahl 2006a" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:39:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahl R, Stender A, Rak S</AU>
<TI>Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahl-2006b" MODIFIED="2010-11-10 22:40:04 +0000" MODIFIED_BY="[Empty name]" NAME="Dahl 2006b" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:40:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, et al</AU>
<TI>Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>434-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-30 12:39:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dahl R, Kapp A, Ribel M, Durham SR</AU>
<TI>Sublingual immunotherapy with SQ standardized grass allergen tablets [Abstract]</TI>
<SO>Annual Meeting of the AAAACI</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-30 12:29:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durham SR, Riis B</AU>
<TI>Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage</TI>
<SO>Allergy</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>8</NO>
<PG>954-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-30 12:30:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emminger W, Dahl R, Kapp A, et al</AU>
<TI>The long-term efficacy and safety of a grass allergen tablet for sublingual immunotherapy: findings from a 3-year clinical trial</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2</NO>
<PG>S75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-de-Blay-2003" MODIFIED="2010-11-10 22:40:20 +0000" MODIFIED_BY="[Empty name]" NAME="de Blay 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:40:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>de Blay F, Purohit A, Kanny G, Le Sellin J, Wessel F, Leynadier F, et al</AU>
<TI>Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind placebo controlled study [Abstract]</TI>
<SO>XXII Congress of the European Academy of Allergology and Clinical Immunology (EAACI)</SO>
<YR>2003</YR>
<PG>780</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Di-Rienzo-2006" MODIFIED="2010-11-10 22:40:45 +0000" MODIFIED_BY="[Empty name]" NAME="Di Rienzo 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:40:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Rienzo V, Pucci S, D'Alo S, Di Cara G, Incorvaia C, Frati F, et al</AU>
<TI>Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study</TI>
<SO>Clinical and Experimental Allergy Reviews</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Didier-2007" MODIFIED="2010-11-10 22:40:54 +0000" MODIFIED_BY="[Empty name]" NAME="Didier 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-10 22:40:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, et al</AU>
<TI>Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>6</NO>
<PG>1338-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drachenberg-2001" MODIFIED="2010-11-10 22:41:07 +0000" MODIFIED_BY="[Empty name]" NAME="Drachenberg 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-10 22:41:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drachenberg KJ, Pfeiffer P, Urban E</AU>
<TI>Sublingual immunotherapy - results from a multi-centre, randomised, double-blind, placebo-controlled study with a standardised birch and grass/rye pollen extract</TI>
<SO>Allergologie</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>525-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dubakiene-2003" NAME="Dubakiene 2003" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dubakiene R, Kleinjans HAJ</AU>
<TI>Effectivness of specific sublingual IT (SLIT) with tree pollen. A placebo controlled study in 119 patients [Abstract]</TI>
<SO>XXII Congress of European Academy of Allergology and Clinical Immunology</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Durham-2006" MODIFIED="2010-11-10 22:41:33 +0000" MODIFIED_BY="[Empty name]" NAME="Durham 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:41:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S</AU>
<TI>Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>4</NO>
<PG>802-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Feliziani-1995" MODIFIED="2010-11-10 22:41:45 +0000" MODIFIED_BY="[Empty name]" NAME="Feliziani 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-10 22:41:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP</AU>
<TI>Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>5</NO>
<PG>224-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grosclaude-2002" MODIFIED="2010-11-10 22:41:58 +0000" MODIFIED_BY="[Empty name]" NAME="Grosclaude 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-10 22:41:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheimann P, Rufin P, et al</AU>
<TI>Safety of various dosage regimens during induction of sublingual immunotherapy: a preliminary study</TI>
<SO>International Archives of Allergy &amp; Immunology</SO>
<YR>2002</YR>
<VL>129</VL>
<PG>248-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Guez-2000" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Guez 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guez S, Vatrinet C, Fadel R, Andre C</AU>
<TI>House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hirsch-1997" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Hirsch 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch T, Sahn M, Leupold W</AU>
<TI>Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hordijk-1998" MODIFIED="2010-11-10 22:42:33 +0000" MODIFIED_BY="[Empty name]" NAME="Hordijk 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-10 22:42:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hordijk GJ, Antvelink JB, Luwema RA</AU>
<TI>Sublingual immunotherapy with a standardised grass pollen extract: a double-blind, placebo-controlled study</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1998</YR>
<VL>26[5]</VL>
<PG>234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibanez-2007" MODIFIED="2010-11-10 22:42:19 +0000" MODIFIED_BY="[Empty name]" NAME="Ibanez 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-10 22:42:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibañez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B, et al</AU>
<TI>Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>6</NO>
<PG>516-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ippoliti-2003" MODIFIED="2010-11-10 22:42:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ippoliti 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-10 22:42:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al</AU>
<TI>Immunomodulation during sublingual therapy in allergic children</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>216-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khinchi-2004" MODIFIED="2010-11-10 22:43:05 +0000" MODIFIED_BY="[Empty name]" NAME="Khinchi 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-10 22:43:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ</AU>
<TI>Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-</TI>
<SO>Allergy</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>45-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kleine_x002d_Tebbe-2006" MODIFIED="2010-11-10 22:43:17 +0000" MODIFIED_BY="[Empty name]" NAME="Kleine-Tebbe 2006" YEAR="">
<REFERENCE MODIFIED="2010-06-30 12:32:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleine-Tebbe J, Herold DA, Ribel M</AU>
<TI>Clinical safety of grass pollen allergen tablet for specific immunotherapy [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>S266</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 22:43:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kleine-Tebbe J, Ribel M, Herold DA</AU>
<TI>Safety of SQ-standardized grass allergen tablet for sublingual immunotherapy: a randomized, placebo controlled trial</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-La-Rosa-1999" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="La Rosa 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW</AU>
<TI>Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>425-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lima-2002" MODIFIED="2010-11-10 22:43:39 +0000" MODIFIED_BY="[Empty name]" NAME="Lima 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-10 22:43:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lima M, Wilson DR, Roberts A, Walker SM, Durham SR</AU>
<TI>Grass pollen sublingual immunotherapy (SLIT) for seasonal rhinoconjunctivitis: a randomised controlled trial</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>4</NO>
<PG>507-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Malling-2005" MODIFIED="2010-11-10 22:43:49 +0000" MODIFIED_BY="[Empty name]" NAME="Malling 2005" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malling HJ, Lund L, Ipsen H, Poulsen L</AU>
<TI>Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 22:43:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malling HJ, Lund L, Ipsen H, Poulsen LK</AU>
<TI>Safety and immunological changes during tablet based specific immunotherapy [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>S161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marcucci-2005" MODIFIED="2010-11-10 23:48:56 +0000" MODIFIED_BY="[Empty name]" NAME="Marcucci 2005" YEAR="">
<REFERENCE MODIFIED="2010-11-10 23:48:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S, et al</AU>
<TI>Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>519-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 23:48:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A, et al</AU>
<TI>Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites</TI>
<SO>Allergy</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1993" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A</AU>
<TI>A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1993</YR>
<VL>92</VL>
<NO>2</NO>
<PG>229-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ott--2009" MODIFIED="2009-07-15 17:24:10 +0100" MODIFIED_BY="[Empty name]" NAME="Ott  2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-15 17:24:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, et al</AU>
<TI>Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study</TI>
<SO>Allergy</SO>
<YR>2009</YR>
<VL>64</VL>
<NO>1</NO>
<PG>179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pajno-2003" MODIFIED="2010-11-10 23:49:03 +0000" MODIFIED_BY="[Empty name]" NAME="Pajno 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-10 23:49:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G</AU>
<TI>Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate</TI>
<SO>Clinical Experimental Allergy</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>1641- 7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Palma-Carlos-2006" MODIFIED="2010-11-10 22:44:30 +0000" MODIFIED_BY="[Empty name]" NAME="Palma Carlos 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-10 22:44:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME, et al</AU>
<TI>Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitis patients. A double-blind, placebo- controlled study</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>5</NO>
<PG>194-8</PG>
<IDENTIFIERS MODIFIED="2009-03-26 17:02:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Panzner-2008" MODIFIED="2010-11-10 22:44:44 +0000" MODIFIED_BY="[Empty name]" NAME="Panzner 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-10 22:44:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panzner P, Petrás M, Sýkora T, Lesná I</AU>
<TI>Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually</TI>
<SO>Respiratory Medicine</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>9</NO>
<PG>1296-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Passalacqua-1998" MODIFIED="2010-11-10 22:45:13 +0000" MODIFIED_BY="[Empty name]" NAME="Passalacqua 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-10 22:45:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, et al</AU>
<TI>Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>629-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Passalacqua-1999" MODIFIED="2010-11-10 22:45:22 +0000" MODIFIED_BY="[Empty name]" NAME="Passalacqua 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-10 22:45:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, et al</AU>
<TI>Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>964-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Passalacqua-2006" MODIFIED="2010-11-10 22:45:41 +0000" MODIFIED_BY="[Empty name]" NAME="Passalacqua 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:45:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lombardi C, Passalaqua G, Ariano R, Pasquali M, Baiardini I, Giardini A, et al</AU>
<TI>A 3-year randomized controlled study with sublingual immunotherapy in mite-induced respiratory allergy [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>S207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 22:45:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I, et al</AU>
<TI>Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>849-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Peter-2009" MODIFIED="2010-11-10 22:49:40 +0000" MODIFIED_BY="[Empty name]" NAME="Peter 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:49:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peter R, Kleinjans H, Hecker H</AU>
<TI>Significant increase in IgG(4) levels after slit grass treatment. A double-blind, placebo-controlled, multi-center study (twin grasses study)</TI>
<SO>Allergy</SO>
<YR>2009</YR>
<VL>90</VL>
<PG>352-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pfaar-2008" MODIFIED="2010-06-30 10:43:49 +0100" MODIFIED_BY="[Empty name]" NAME="Pfaar 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-30 10:43:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfaar O, Klimek L</AU>
<TI>Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>3</NO>
<PG>256-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pradalier-1999" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Pradalier 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, et al</AU>
<TI>Sublingual-swallow immunotherapy (SLIT) with a standardised five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis</TI>
<SO>Allergy</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>819-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rolinck_x002d_Werninghaus-2004" MODIFIED="2010-04-27 12:22:41 +0100" MODIFIED_BY="[Empty name]" NAME="Rolinck-Werninghaus 2004" YEAR="">
<REFERENCE MODIFIED="2010-04-27 12:22:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV</AU>
<TI>A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhino-conjuctivitis to grass pollen</TI>
<SO>Allergy</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>1285-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-R_x0151_der-2007" MODIFIED="2010-06-30 10:44:09 +0100" MODIFIED_BY="[Empty name]" NAME="R&#337;der 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-30 10:44:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R</AU>
<TI>Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>4</NO>
<PG>892-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabbah-1994" NAME="Sabbah 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H</AU>
<TI>A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract</TI>
<SO>Allergy</SO>
<YR>1994</YR>
<VL>49</VL>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2001" MODIFIED="2010-11-10 22:45:54 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchez 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-10 22:45:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez Palacios A, Schamann F, Garcia JA</AU>
<TI>Sublingual immunotherapy with cat extract, personal experience</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>2001</YR>
<VL>29</VL>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2004" MODIFIED="2010-08-09 16:44:39 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2004" YEAR="">
<REFERENCE MODIFIED="2010-06-30 12:35:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith H, White P, Annila I, Poole J, Andre C, Frew A</AU>
<TI>Randomized controlled trial of high- dose sublingual immunotherapy to treat seasonal allergic rhinitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>114</VL>
<PG>831- 7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-09 16:44:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith HE, White PJ, Poole J, Annila I, Andre C, Frew AJ</AU>
<TI>Sublingual immunotherapy for hay fever: a 2-year double-blind placebo-controlled trial</TI>
<SO>Allergy</SO>
<YR>2002</YR>
<VL>57</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tari-1990" MODIFIED="2010-11-10 22:49:54 +0000" MODIFIED_BY="[Empty name]" NAME="Tari 1990" YEAR="">
<REFERENCE MODIFIED="2010-06-30 12:36:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S</AU>
<TI>Immunologic evaluation of 24 month course of sublingual immunotherapy</TI>
<SO>Allergologia at Immunopathologia</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 22:49:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tari MG, Mancino M, Monti G</AU>
<TI>Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double-blind study</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tonnel-2004" MODIFIED="2010-11-10 22:50:01 +0000" MODIFIED_BY="[Empty name]" NAME="Tonnel 2004" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:50:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, et al</AU>
<TI>Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy</TI>
<SO>Allergy</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>491-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Troise-1995" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Troise 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC</AU>
<TI>Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valovirta-2006" MODIFIED="2010-11-10 22:50:08 +0000" MODIFIED_BY="[Empty name]" NAME="Valovirta 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:50:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J</AU>
<TI>Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>1177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vervloet-2006" MODIFIED="2010-11-10 22:51:18 +0000" MODIFIED_BY="[Empty name]" NAME="Vervloet 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:51:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie- Bouchat YP, et al</AU>
<TI>Safety and efficacy of Juniperus Ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: a double-blind, placebo-controlled study</TI>
<SO>International Archives of Allergy and Immunology</SO>
<YR>2007</YR>
<VL>142</VL>
<NO>3</NO>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Voltolini-2001" MODIFIED="2010-11-10 22:51:32 +0000" MODIFIED_BY="[Empty name]" NAME="Voltolini 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-10 22:51:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P, et al</AU>
<TI>Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>2001</YR>
<VL>29</VL>
<NO>4</NO>
<PG>103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Vourdas-1998" MODIFIED="2010-11-10 22:51:40 +0000" MODIFIED_BY="[Empty name]" NAME="Vourdas 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-10 22:51:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, et al</AU>
<TI>Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization</TI>
<SO>Allergy</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>7</NO>
<PG>662-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wahn-2009" MODIFIED="2010-11-10 22:51:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wahn 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:51:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al</AU>
<TI>Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>1</NO>
<PG>160-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wessner-2001" NAME="Wessner 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wessner DB, Wessner S, Mohrnschlager M, Rakoski J, Ring J</AU>
<TI>Efficacy and safety of sublingual immunotherapy in adults with allergic rhinoconjunctivitis: results after 2 years of controlled trial [Abstract]</TI>
<SO>Allergy</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>Suppl 68</NO>
<PG>88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wutrich-2003" MODIFIED="2010-11-10 22:52:12 +0000" MODIFIED_BY="[Empty name]" NAME="Wutrich 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:52:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wutrich B, Bucher C, Jorg W, Bircher A, Eng P, Schneider Y, et al</AU>
<TI>Placebo- controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>145-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 22:52:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wutrich B, Eigenmann P, Bircher A, Schneider F, Jorg W</AU>
<TI>Double-blind, placebo-controlled study with sublingual immunotherapy in children sensitized to grass pollen efficacy and tolerance [Abstract]</TI>
<SO>XX Congress of the European Academy of Allergology and Clinical Immunology (EAACI)</SO>
<YR>2001</YR>
<PG>Abstract No. 256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-10 22:58:39 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bernardis-1996" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Bernardis 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M</AU>
<TI>Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>1</NO>
<PG>55-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Black-2002" MODIFIED="2010-07-28 18:29:12 +0100" MODIFIED_BY="[Empty name]" NAME="Black 2002" YEAR="">
<REFERENCE MODIFIED="2010-07-28 18:29:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Black PN, Douglas R, Brodie S, Fitzharris P</AU>
<TI>Controlled trial of sublingual immunotherapy with grass pollen allergoids for the treatment of seasonal allergic rhinitis [Abstract]</TI>
<SO>XXI Congeress of the European Academy of Allergology and Clinical Immunology (EAACI)</SO>
<YR>2002</YR>
<PG>Abstract No. 72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corthay-1996" MODIFIED="2010-11-10 22:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="Corthay 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-10 22:52:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Corthay P, Gumowski PI, Bodmer R, Clot B</AU>
<TI>Efficacy of sublingual versus subcutaneous immunotherapy to pollen allergens after 3 consecutive years of treatment</TI>
<SO>Annual Meeting of the Swiss Society for Allergology and Immunology</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Ambrosio-1996" MODIFIED="2010-11-10 22:52:41 +0000" MODIFIED_BY="[Empty name]" NAME="D'Ambrosio 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-10 22:52:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Ambrosio FP, Ricciardi L, Isola S, Savi E, Parmiani S, Puccinelli P</AU>
<TI>Rush sublingual immunotherapy in Parietaria allergic patients</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4</NO>
<PG>146-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donato-1997" MODIFIED="2010-11-10 22:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="Donato 1997" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:52:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donato RM, Gutierezz NA, Pinilla V, Bagliano A</AU>
<TI>Sublingual immunotherapy (SLIT) as non-invasive treatment for allergic rhinitis in children [Abstract]</TI>
<SO>International Journal of Immunopathology and Pharmacology</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feliziani-1993" MODIFIED="2010-11-10 22:53:03 +0000" MODIFIED_BY="[Empty name]" NAME="Feliziani 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-10 22:53:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feliziani V, Marfisi RM, Parmiani S</AU>
<TI>Rush immunotherapy with sublingual administration of grass allergen extract</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gammeri-2004" MODIFIED="2010-11-10 22:53:12 +0000" MODIFIED_BY="[Empty name]" NAME="Gammeri 2004" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:53:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gammeri E</AU>
<TI>Safety and tolerability of ultra-rush (20 minutes) allergoid sublingual immunotherapy in patients with allergic rhinitis and/or asthma [Abstract]</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>2</VL>
<PG>S108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gozalo-1997" MODIFIED="2010-11-10 22:53:23 +0000" MODIFIED_BY="[Empty name]" NAME="Gozalo 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-10 22:53:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gozalo F, Martin S, Rico P, Alvarez E, Cortes C</AU>
<TI>Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy</TI>
<SO>Allergologia et Immunopathologia (Madrid)</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>5</NO>
<PG>219-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2004" MODIFIED="2010-11-10 22:53:30 +0000" MODIFIED_BY="[Empty name]" NAME="Hansen 2004" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:53:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen KS, Khinchi MS, Skov PS, Bindslev JC, Poulsen Lars K, Malling HJ</AU>
<TI>Food allergy to apple and specific immunotherapy with birch pollen</TI>
<SO>Molecular Nutrition &amp; Food Research</SO>
<YR>2004</YR>
<VL>48</VL>
<PG>441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horak-1998" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Horak 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horak F, Stubner P, Berger UE, Marks B, Toth J, Jager S</AU>
<TI>Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>3</NO>
<PG>165-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Inal-2009" MODIFIED="2010-11-10 22:54:58 +0000" MODIFIED_BY="[Empty name]" NAME="Inal 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:54:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inal A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc G</AU>
<TI>Effect of subcutaneous and sublingual immunotherapy on clinical improvement and quality of life in children with rhinitis and asthma monosensitised to house dust mite: a randomised, placebo-controlled, double-blind, double-dummy study</TI>
<SO>Allergy</SO>
<YR>2009</YR>
<PG>461</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Karakoc-2003" MODIFIED="2010-11-10 22:55:41 +0000" MODIFIED_BY="[Empty name]" NAME="Karakoc 2003" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:55:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karakoc GK, Altintas D, Yilmaz M, Kendirli SG</AU>
<TI>Conventional immunotherapy versus sublingual immunotherapy with standardized five-grass pollen in children with seasonal allergic rhinoconjuctivitis [Abstract]</TI>
<SO>Allergy and Clinical Immunology International</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>Abstract No. P-15-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitsch-1996" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Mitsch 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitsch A, Drachenberg KJ</AU>
<TI>Positive results in a primary multicentric study, specific immunotherapy administered sublingually</TI>
<SO>TW Padiatrie</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>628-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mungan-1999" MODIFIED="2010-11-10 22:55:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mungan 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mungan D, Misirligil Z, Gurbuz L</AU>
<TI>Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>5</NO>
<PG>485-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nanda-2004" MODIFIED="2010-11-10 22:56:06 +0000" MODIFIED_BY="[Empty name]" NAME="Nanda 2004" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:56:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nanda A, O'Connor M, Anand M, Dreskin SC, Zhang L, Hines B, et al</AU>
<TI>Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>6</NO>
<PG>1339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Okubo-2008" MODIFIED="2010-11-10 22:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Okubo 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-10 22:57:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, et al</AU>
<TI>A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis</TI>
<SO>Allergology International</SO>
<YR>2008</YR>
<VL>57</VL>
<NO>3</NO>
<PG>265-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quirino-1996" MODIFIED="2010-04-29 16:07:46 +0100" MODIFIED_BY="Suzana Radulovic" NAME="Quirino 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-29 16:07:46 +0100" MODIFIED_BY="Suzana Radulovic" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quirino T, Lemoli E, Siciliani E, Parmiani S, Milazzo F</AU>
<TI>Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>11</NO>
<PG>1253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radjenovic-2004" NAME="Radjenovic 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Radjenovic G</AU>
<TI>Rhinitis allergica due to house dust mite in children: long lasting effect of sublingual immunotherapy [Abstract]</TI>
<SO>5th European Congress of Oto Rhino Laryngology Head and Neck Surgery</SO>
<YR>2004</YR>
<VL>209</VL>
<PG>PP151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Russello-2004" NAME="Russello 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Russello M, Maurol M, Incorvaia C, D'Ingianna E, Gazzola GB</AU>
<TI>Subcutaneous and sublingual immunotherapy in birch pollinosis: a comparison of efficacy and safety [Abstract]</TI>
<SO>XXIII Congress of the European Academy of Allergology and Clinical Immunology (EAACI)</SO>
<YR>2004</YR>
<PG>Abstract No. 256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabbah-1993" MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" NAME="Sabbah 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-10 22:05:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabbah A, Lesellin J, Hassoun S, Sicard H, Andre C</AU>
<TI>Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens</TI>
<SO>Allergie et Immunologie (Paris)</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>6</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnel-2002" MODIFIED="2010-11-10 22:57:27 +0000" MODIFIED_BY="[Empty name]" NAME="Tonnel 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-10 22:57:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tonnel A, Vannimenus C, Douay B, Mellin B, Deroubaix C, Trochu G, et al</AU>
<TI>Rhinite aux acariens: evaluation de L'efficacite de L'immunotherapie allergenique par voie sublinguale</TI>
<SO>Allergie et Immunolgie</SO>
<YR>2002</YR>
<VL>34</VL>
<PG>60-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Troise-2009" MODIFIED="2010-11-10 22:57:36 +0000" MODIFIED_BY="[Empty name]" NAME="Troise 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-10 22:57:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troise C, Voltolini S, Incorvaia C, La Grutta S, Frati F</AU>
<TI>Efficacy and safety of sublingual immunotherapy with high dose birch extract: placebo-controlled study</TI>
<SO>Allergy</SO>
<YR>2009</YR>
<PG>465</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Niekerk-1987" MODIFIED="2010-11-10 22:58:16 +0000" MODIFIED_BY="[Empty name]" NAME="Van Niekerk 1987" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:58:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Niekerk CH, De Wet J</AU>
<TI>Efficacy of grass-maise pollen oral immunotherapy in patients with seasonal hay-fever: a double blind study</TI>
<SO>Clinical Allergy</SO>
<YR>1987</YR>
<VL>17</VL>
<PG>507-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuksel-1999" MODIFIED="2010-11-10 22:58:39 +0000" MODIFIED_BY="[Empty name]" NAME="Yuksel 1999" YEAR="">
<REFERENCE MODIFIED="2010-11-10 22:58:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuksel H, Tanac R, Gousseinov A, Demir E</AU>
<TI>Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>5</NO>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-07-28 18:28:11 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Ingels-2002" MODIFIED="2010-05-12 14:54:15 +0100" MODIFIED_BY="[Empty name]" NAME="Ingels 2002" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-O_x0027_Hehir-2005" MODIFIED="2010-05-12 14:54:24 +0100" MODIFIED_BY="[Empty name]" NAME="O'Hehir 2005" YEAR="">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-10 23:03:05 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-10 23:03:05 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Antico-2006" MODIFIED="2010-04-27 11:26:47 +0100" MODIFIED_BY="[Empty name]" NAME="Antico 2006" TYPE="JOURNAL_ARTICLE">
<AU>Antico A, Pagani M, Crema A</AU>
<TI>Anaphylaxis by latex sublingual immunotherapy</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>1236-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ARIA-2001" MODIFIED="2010-04-27 11:45:31 +0100" MODIFIED_BY="[Empty name]" NAME="ARIA 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization</AU>
<TI>Allergic Rhinitis and it impact on Asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>Suppl 5</NO>
<PG>S147-334</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ARIA-2008" MODIFIED="2010-04-27 11:45:43 +0100" MODIFIED_BY="[Empty name]" NAME="ARIA 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al</AU>
<TI>Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)</TI>
<SO>Allergy</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>Suppl 86</NO>
<PG>S8-160</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2010-11-10 22:59:55 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blazowski-2008" MODIFIED="2010-04-27 11:28:06 +0100" MODIFIED_BY="[Empty name]" NAME="Blazowski 2008" TYPE="JOURNAL_ARTICLE">
<AU>Blazowski L</AU>
<TI>Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose</TI>
<SO>Allergy</SO>
<YR>2008</YR>
<VL>63</VL>
<PG>374</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calderon-2007" MODIFIED="2010-04-27 11:32:33 +0100" MODIFIED_BY="[Empty name]" NAME="Calderon 2007" TYPE="COCHRANE_REVIEW">
<AU>Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S</AU>
<TI>Allergen injection immunotherapy for seasonal allergic rhinitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-04-27 11:32:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-27 11:32:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001936. DOI: 10.1002/14651858.CD001936.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Calderon-2008" MODIFIED="2010-04-27 11:17:35 +0100" MODIFIED_BY="[Empty name]" NAME="Calderon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Calderon MA</AU>
<TI>Meta-analyses of specific immunotherapy trials</TI>
<SO>Drugs Today (Barc)</SO>
<YR>2008</YR>
<VL>44</VL>
<NO>Suppl B</NO>
<PG>31-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calderon-2010" MODIFIED="2010-04-27 11:08:18 +0100" MODIFIED_BY="[Empty name]" NAME="Calderon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Calderon M, Mösges R, Hellmich M, Demoly P</AU>
<TI>Towards evidence-based medicine in specific grass pollen immunotherapy</TI>
<SO>Allergy</SO>
<YR>2010</YR>
<VL>65</VL>
<PG>420-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casale-2009" MODIFIED="2010-11-10 23:00:21 +0000" MODIFIED_BY="[Empty name]" NAME="Casale 2009" TYPE="JOURNAL_ARTICLE">
<AU>Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al</AU>
<TI>Recommendations for appropriate sublingual immunotherapy clinical trials</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>4</NO>
<PG>665-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-2006" MODIFIED="2010-11-10 23:00:35 +0000" MODIFIED_BY="[Empty name]" NAME="Cox 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS</AU>
<TI>Sublingual immunotherapy: a comprehensive review</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2006</YR>
<VL>117</VL>
<NO>5</NO>
<PG>1021-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dahl-2008" MODIFIED="2010-11-10 23:00:49 +0000" MODIFIED_BY="[Empty name]" NAME="Dahl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dahl R, Kapp A, Colombo G, De Monchy JG, Rak S, Emminger W, et al</AU>
<TI>Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>512-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Groot-2009" MODIFIED="2010-04-27 11:31:02 +0100" MODIFIED_BY="[Empty name]" NAME="de Groot 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Groot H, Bijl A</AU>
<TI>Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet</TI>
<SO>Allergy</SO>
<YR>2009</YR>
<VL>64</VL>
<NO>6</NO>
<PG>963-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunsky-2006" MODIFIED="2010-04-27 11:29:02 +0100" MODIFIED_BY="[Empty name]" NAME="Dunsky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA</AU>
<TI>Anaphylaxis to sublingual immunotherapy</TI>
<SO>Allergy</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>1235</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durham-2010" MODIFIED="2010-11-10 23:00:57 +0000" MODIFIED_BY="[Empty name]" NAME="Durham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al</AU>
<TI>Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>1</NO>
<PG>131-8.e1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eifan-2007" MODIFIED="2010-04-27 11:30:07 +0100" MODIFIED_BY="[Empty name]" NAME="Eifan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Eifan AO, Keles S, Bahceciler NN, Barlan IB</AU>
<TI>Anaphylaxis to multiple pollen allergen sublingual immunotherapy</TI>
<SO>Allergy</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>567-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Francis-2003" MODIFIED="2010-04-27 11:06:36 +0100" MODIFIED_BY="[Empty name]" NAME="Francis 2003" TYPE="JOURNAL_ARTICLE">
<AU>Francis N, Till SJ, Durham SR</AU>
<TI>Induction of IL-10 + CD4 + CD25 + T cells by grass pollen immunotherapy</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>6</NO>
<PG>1255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2008" MODIFIED="2010-06-30 11:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Handbook 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jutel-1995" MODIFIED="2010-11-10 23:01:26 +0000" MODIFIED_BY="[Empty name]" NAME="Jutel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR</AU>
<TI>Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures</TI>
<SO>Journal of Immunology</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>8</NO>
<PG>4187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jutel-2003" MODIFIED="2010-11-10 23:01:41 +0000" MODIFIED_BY="[Empty name]" NAME="Jutel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al</AU>
<TI>IL-10 and TGF-b cooperate in regulatory T cell response to mucosal allergens in normal immunity specific immunotherapy</TI>
<SO>European Journal of Immunology</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>1205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2010-04-27 11:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Ba' Pham, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2010-04-27 11:22:52 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>357</NO>
<PG>1191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mungan-1999" MODIFIED="2010-11-10 23:01:55 +0000" MODIFIED_BY="[Empty name]" NAME="Mungan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mungan D, Misirligil Z, Gürbüz L</AU>
<TI>Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma-a placebo controlled study</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>5</NO>
<PG>485-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nieto-2009" MODIFIED="2010-11-10 23:02:06 +0000" MODIFIED_BY="[Empty name]" NAME="Nieto 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A</AU>
<TI>Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>1</NO>
<PG>157-161.e1-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quirino-1996" MODIFIED="2010-04-29 16:06:56 +0100" MODIFIED_BY="Suzana Radulovic" NAME="Quirino 1996" TYPE="JOURNAL_ARTICLE">
<AU>Quirino T, Lemoli E, Siciliani E, Parmiani S, Milazzo F</AU>
<TI>Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>11</NO>
<PG>1253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-05-11 13:12:38 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-2004" MODIFIED="2010-11-10 23:02:24 +0000" MODIFIED_BY="[Empty name]" NAME="Rossi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rossi RE, Monasterolo G</AU>
<TI>Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients</TI>
<SO>International Archives of Allergy and Immunology</SO>
<YR>2004</YR>
<VL>135</VL>
<PG>44-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wachholz-2002" MODIFIED="2010-11-10 23:02:34 +0000" MODIFIED_BY="[Empty name]" NAME="Wachholz 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, et al</AU>
<TI>Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios</TI>
<SO>Immunology</SO>
<YR>2002</YR>
<VL>105</VL>
<NO>1</NO>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2001" MODIFIED="2010-11-10 23:02:51 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, Schwartz LB, et al</AU>
<TI>Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>11</NO>
<PG>1705-13</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-11-10 23:03:05 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Wilson-2003" MODIFIED="2010-04-27 11:09:48 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 2003" TYPE="COCHRANE_REVIEW">
<AU>Wilson DR, Torres LI, Durham SR</AU>
<TI>Sublingual immunotherapy for allergic rhinitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-04-27 11:09:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-27 11:09:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002893. DOI: 10.1002/14651858.CD002893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2005" MODIFIED="2010-11-10 23:03:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wilson DR, Lima MT, Durham SR</AU>
<TI>Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis</TI>
<SO>Allergy</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>1</NO>
<PG>4-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-08-09 16:50:04 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Andre-2002" MODIFIED="2010-08-09 16:49:09 +0100" MODIFIED_BY="[Empty name]" NAME="Andre 2002" TYPE="JOURNAL_ARTICLE">
<AU>Andre C, Perrin-Fayolle M, Grosclaude M, Couturier P, Bassett D, Cornillon J, et al</AU>
<TI>A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardised ragweed extract in patients with seasonal rhinitis, evidence for a dose-response relationship</TI>
<SO>Allergy</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>S73</NO>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bufe-2009" MODIFIED="2010-08-09 16:49:47 +0100" MODIFIED_BY="[Empty name]" NAME="Bufe 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al</AU>
<TI>Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>1</NO>
<PG>167-73.e7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creticos-1985" MODIFIED="2010-08-09 16:50:00 +0100" MODIFIED_BY="[Empty name]" NAME="Creticos 1985" TYPE="JOURNAL_ARTICLE">
<AU>Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM</AU>
<TI>Nasal challenge with ragweed pollen in hay fever patients</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1985</YR>
<VL>76</VL>
<PG>2247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CSM-1986" MODIFIED="2010-08-09 16:50:04 +0100" MODIFIED_BY="[Empty name]" NAME="CSM 1986" TYPE="JOURNAL_ARTICLE">
<AU>Committee on Safety of Medicines</AU>
<TI>Desensitising vaccines</TI>
<SO>British Medical Journal</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>948</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durham-1996" MODIFIED="2010-08-09 16:48:33 +0100" MODIFIED_BY="[Empty name]" NAME="Durham 1996" TYPE="JOURNAL_ARTICLE">
<AU>Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA</AU>
<TI>Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon gamma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1996</YR>
<VL>97</VL>
<PG>1356-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durham-1999" MODIFIED="2010-08-09 16:48:37 +0100" MODIFIED_BY="[Empty name]" NAME="Durham 1999" TYPE="JOURNAL_ARTICLE">
<AU>Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT</AU>
<TI>Long-term clinical efficacy of grass pollen immunotherapy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>468-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EAACI-2000" MODIFIED="2010-08-09 16:48:49 +0100" MODIFIED_BY="[Empty name]" NAME="EAACI 2000" TYPE="JOURNAL_ARTICLE">
<AU>EAACI Position Paper</AU>
<TI>Consensus statement on the treatment of allergic rhinitis</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>116-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lichtenstein-1973" MODIFIED="2010-08-09 16:48:53 +0100" MODIFIED_BY="[Empty name]" NAME="Lichtenstein 1973" TYPE="JOURNAL_ARTICLE">
<AU>Lichtenstein LM, Ishizaka K, Norman PS, Hill BM</AU>
<TI>IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1973</YR>
<VL>52</VL>
<PG>472-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcucci-2003" MODIFIED="2010-08-09 16:48:56 +0100" MODIFIED_BY="[Empty name]" NAME="Marcucci 2003" TYPE="JOURNAL_ARTICLE">
<AU>Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A, et al</AU>
<TI>Effects on inflamation parameters of a double blind, placebo controlled one- year course of SLIT in children monosensitized to mites</TI>
<SO>Allergy</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>657- 62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varney-1991" MODIFIED="2010-08-09 16:49:41 +0100" MODIFIED_BY="[Empty name]" NAME="Varney 1991" TYPE="JOURNAL_ARTICLE">
<AU>Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR</AU>
<TI>Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs</TI>
<SO>British Medical Journal</SO>
<YR>1991</YR>
<VL>302</VL>
<NO>6771</NO>
<PG>265-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahn-2009" MODIFIED="2010-08-09 16:49:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wahn 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al</AU>
<TI>Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>1</NO>
<PG>160-6.e3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2010-08-09 16:49:15 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bousquet J, Lockey RF, Malling H-J eds</AU>
<TI>WHO Position Paper. Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases</TI>
<SO>Allergy</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>suppl. 44</NO>
<PG>1-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-10 23:14:42 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-10 23:14:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-10 23:10:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amar-2009">
<CHAR_METHODS MODIFIED="2010-05-12 12:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:11:59 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>58 participants randomised<BR/>53 participants analysed<BR/>Timothy grass monotherapy 19; losses to f/u 0<BR/>Mixed grass 17; losses to f/u 3<BR/>Placebo 17; losses to f/u 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:12:07 +0000" MODIFIED_BY="[Empty name]">
<P>10 months SLIT<BR/>Monotherapy: timothy grass 680 mcg/ml Phl p5<BR/>Multiple allergen group: timothy grass, maple, ash, juniper, American elm, cottonwood, kochia, ragweed, sagebrush, Russian thistle<BR/>Daily maintenance dose 19 mcg Phl p5; cumulative monthly dose 571 mcg Phl p5<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 23:10:53 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores, medication scores, titrated skin prick tests, titrated nasal challenge, allergen-specific IgE and IgG4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:39:58 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 23:10:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andre-2003">
<CHAR_METHODS MODIFIED="2010-05-12 12:42:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:12:21 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children<BR/>Age range 7 to 55 years<BR/>55 active (22 m); losses to f/u 12<BR/>55 placebo (23 m); losses to f/u 6<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:12:43 +0000" MODIFIED_BY="[Empty name]">
<P>7.5 months<BR/>Pre-seasonal (start at March)<BR/>SLIT<BR/>Sublingual drops and tablets<BR/>Standardised ragweed extract<BR/>Dose: 100 IR/ml solution = 1 tablets = 160 mcg of Amb a 1<BR/>Maintenance dose 1, 2 or 3 tablets 3 times a week, depending on patient's tolerance<BR/>Cumulative dose over maintenance phase: 1300 to 30,500<BR/>Max maintenance dose 480 mcg/day 3 times a week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 23:10:56 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores based on diary cards (nose, eyes)<BR/>Medication scores<BR/>Global assessment<BR/>Skin prick test<BR/>Allergen-specific IgE and IgG4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 22:13:14 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:13:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ariano-2001">
<CHAR_METHODS MODIFIED="2010-05-12 12:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:44:09 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>10 active (5 m)<BR/>10 placebo (4 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:13:33 +0000" MODIFIED_BY="[Empty name]">
<P>8 months SLIT<BR/>250,000U RAST</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:13:27 +0000" MODIFIED_BY="[Empty name]">
<P>Diary scores<BR/>Nasal provocation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:13:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bahceciler-2001">
<CHAR_METHODS MODIFIED="2010-05-12 12:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>8 active (4 m)<BR/>7 placebo (4 m)<BR/>Children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>5 months SLIT<BR/>0.56 mg DP<BR/>0.98 mg DF</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>SPT<BR/>Total IgE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:14:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowen-2004">
<CHAR_METHODS>
<P>Randomised<BR/>DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children</P>
<P>43 active; loses to follow up 15<BR/>40 placebo; losses to follow up 11<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>3.5 months SLIT, 2 weeks pre-seasonal<BR/>Sublingual drops<BR/>Dose 116 mcg Amb 1/100 IR<BR/>Max dose: 314 mcg Amb 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores (rhinitis and conjunctivitis)<BR/>Number of days with asthma symptoms<BR/>Medication score<BR/>Overall evaluation<BR/>Levels of ragweed-specific IgE and IgG4<BR/>Adverse events description</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 22:14:24 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>15 patients asthma; 9 in treatment and 6 in placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:14:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bufe-2004">
<CHAR_METHODS>
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:47:28 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>83 active; losses to follow up 15<BR/>78 placebo; losses to follow up 14</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:14:34 +0000" MODIFIED_BY="[Empty name]">
<P>1 year<BR/>Pre-seasonal period:<BR/>Sublingual drops<BR/>Maintenance dose 2500 AU~<BR/>9.1 mcg<BR/>Cumulative dose 2,625,000 AU (9.6 mg of Phl p 5)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:14:59 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical symptoms assessed by questionnaire in a structured interview by an independent person by phone at 6 different points (nose, eye and lung symptoms)<BR/>Visual analogue scale recorded by patients<BR/>Medication score (medication index)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:48:04 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>Asthma symptoms 68; 35 in treatment and 33 in placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:15:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bufe-2009">
<CHAR_METHODS MODIFIED="2010-05-12 12:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:15:07 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active: 126 (83 male); data analysed for 117 participants; withdrawn 12<BR/>Placebo: 127 (83 male); data analysed for 121 participants; withdrawn 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:15:13 +0000" MODIFIED_BY="[Empty name]">
<P>6 months<BR/>8 to 23 weeks pre-seasonal (mean 17.1 weeks)<BR/>Sublingual tablets grass pollen (<I>Phleum pratense</I>)<BR/>Daily dose 75000 SQ; 15 mcg Phl p 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:15:24 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Specific IgE, IgG4 and IgE blocking factor<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:15:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caffarelli-2000">
<CHAR_METHODS MODIFIED="2010-05-12 12:50:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:50:55 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>24 active (12 m); losses to follow up 0<BR/>20 placebo (13 m); losses to follow up 4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>3.5 months<BR/>All pre-seasonal<BR/>Sublingual tablets - allergoid (mixture 33% <I>Holcus lanatus</I>; 33% <I>Phleum pratense</I>, 33% <I>Poa pratense</I>)<BR/>Max dose of allergen: 1000 AU<BR/>Cumulative dose 37,250 AU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:15:39 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores on daily dairy cards (nasal, eye and bronchial symptoms)<BR/>Medication score<BR/>Adverse events description<BR/>ECP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:16:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calderon-2006">
<CHAR_METHODS MODIFIED="2010-11-10 22:16:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:16:06 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Active 9 (6 male); withdrawn 0<BR/>Placebo 11 (6 male); withdrawn 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:16:09 +0000" MODIFIED_BY="[Empty name]">
<P>28 days; all pre-seasonal<BR/>Sublingual tablet</P>
<P>Grass pollen (<I>Phleum pratense</I>) 75000 SQ-T<BR/>Daily dose 15 mcg Phl p 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 16:30:16 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:16:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2007">
<CHAR_METHODS MODIFIED="2010-05-12 12:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:16:19 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active 139<BR/>Placebo 139<BR/>Age range 4 to 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:16:23 +0000" MODIFIED_BY="[Empty name]">
<P>SLIT drops <I>Dermatophagoides farinae</I>
<BR/>25 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:16:34 +0000" MODIFIED_BY="[Empty name]">
<P>Rhinitis symptom score<BR/>Medication score for rhinitis<BR/>Asthma symptom scores<BR/>Lung function tests<BR/>Skin sensitivity<BR/>Mite-specific IgE and IgG4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 18:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Full paper published in Chinese, but authors have provided data for total symptom and medication scores for rhinitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-11 16:38:48 +0100" MODIFIED_BY="Suzana Radulovic" STUDY_ID="STD-Casanovas-1994">
<CHAR_METHODS MODIFIED="2010-05-12 12:54:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-11 16:38:48 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Adults</P>
<P>9 active (3 m)<BR/>6 placebo (1 m)<BR/>Minimum age 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 months pre-seasonal SLIT<BR/>Dose n/s</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>SPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-27 12:51:18 +0100" MODIFIED_BY="Suzana Radulovic" STUDY_ID="STD-Clavel-1998">
<CHAR_METHODS MODIFIED="2010-05-12 12:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:56:52 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>62 active<BR/>58 placebo<BR/>Age range 27 +/- 10 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:57:03 +0100" MODIFIED_BY="[Empty name]">
<P>6 months SLIT<BR/>5 mixed grasses (orchard grass, meadow grass, rye grass, sweet vernal grass, timothy grass)<BR/>Cumulative dose 2.6 mg timothy grass<BR/>Updosing period 25 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 12:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>Daily dairy: symptom scores<BR/>Medication scores<BR/>Specific IgE and IgG4<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-27 12:51:18 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Jadad scale 3/5. Data insufficient for meta-analysis. Included in the systematic review only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:16:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<CHAR_METHODS MODIFIED="2010-05-12 12:57:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:57:35 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>14 active (7 m)<BR/>16 placebo (7 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:16:54 +0000" MODIFIED_BY="[Empty name]">
<P>9 months SLIT<BR/>12.77 mcg Parj 1 0.12 mcg/day solution of standardised extract</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:57:53 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:18:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dahl-2006a">
<CHAR_METHODS MODIFIED="2010-11-10 22:18:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial<BR/>Multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:58:29 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>74 active (53 m); dropped out 13<BR/>40 placebo (24 m); dropped out 8<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:17:12 +0000" MODIFIED_BY="[Empty name]">
<P>3 to 3.5 months SLIT<BR/>Sublingual tablet<BR/>Grass pollen 75000 SQ-T daily<BR/>Plp p5 15 mcg<BR/>Pre-seasonal 10 to 14 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Asthma symptom score (pre-seasonal and in season)<BR/>Asthma medication score (pre-seasonal and in season)<BR/>Rhinoconjunctivitis symptom scores and medication score; all reported through daily diaries<BR/>Number of well days<BR/>Adverse events reports</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:02:09 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>All patients had mild to moderate seasonal asthma and rhinoconjunctivitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:18:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dahl-2006b">
<CHAR_METHODS MODIFIED="2010-11-10 22:18:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial; multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:02:41 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>316 active (179 m); losses to f/u 42<BR/>318 placebo (193 m); losses to f/u 46<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:17:20 +0000" MODIFIED_BY="[Empty name]">
<P>12 months SLIT<BR/>Sublingual tablet<BR/>Grass pollen<BR/>75 000 SQ-T<BR/>Phl p 5 15 mcg<BR/>Daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rhinoconjunctivitis symptom score<BR/>Medication score<BR/>Global assessment<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:18:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Blay-2003">
<CHAR_METHODS MODIFIED="2010-11-10 22:18:29 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial; multicentre study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-03 16:07:06 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Adults and children</P>
<P>61 active<BR/>57 placebo</P>
<P>Mean age 24.9 +/- 7.6<BR/>29 mild persistent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:17:40 +0000" MODIFIED_BY="[Empty name]">
<P>10 months SLIT (8 months pre-season)<BR/>Drops<BR/>3 grass pollen extract: <I>Dactylis glomerata</I>, <I>Phleum pratense</I> and <I>Lolium perenne</I>
<BR/>Average cumulative dose: 2.75 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical score<BR/>Rhinitis score<BR/>Conjunctivitis score<BR/>Rescue medication score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5<BR/>ITT 104 patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:17:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Rienzo-2006">
<CHAR_METHODS MODIFIED="2010-05-12 13:07:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>19 active; losses to f/u 1<BR/>15 placebo; losses to f/u 1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:17:58 +0000" MODIFIED_BY="[Empty name]">
<P>4 months SLIT<BR/>Drops<BR/>
<I>Juniperus ashei</I> extract<BR/>Maintenance<BR/>8 drops of 300 IR/ml<BR/>Dose of major allergen 70 mcg/ml of Jun a1 at 100 IR conc</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:06:52 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Quality of life<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:18:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Didier-2007">
<CHAR_METHODS MODIFIED="2010-05-12 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
<P>Multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:18:46 +0000" MODIFIED_BY="[Empty name]">
<P>Adults (age range 18 to 45 years)<BR/>Active 155 (ITT 136)<BR/>Active discontinued 22<BR/>Placebo 156 (ITT 148)<BR/>Placebo discontinued 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:18:50 +0000" MODIFIED_BY="[Empty name]">
<P>Sublingual tablets mixed grass (orchard, meadow, perennial rye, sweet vernal, timothy grass)<BR/>4 months pre-seasonal and co-seasonal treatment<BR/>Mean dosage 25 mcg/ml of the group 5 major allergens</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:18:56 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Quality of life<BR/>Grass pollen specific IgE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:19:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drachenberg-2001">
<CHAR_METHODS MODIFIED="2010-05-12 13:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:08:48 +0100" MODIFIED_BY="[Empty name]">
<P>Children and adults</P>
<P>49 active (28 m): 21 birch, 28 grass/rye pollen<BR/>19 placebo (9 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:19:05 +0000" MODIFIED_BY="[Empty name]">
<P>6 months SLIT<BR/>SL drops<BR/>27 days of updosing phase maintenance dose: 16 drops of 100,000 SOU/ml for both allergens</P>
<P>Cumulative dose of major allergen<BR/>For grass pollen: Phl p 1: 1913.6 mcg<BR/>For birch pollen: Bet v 1: 1535.23 mcg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>Combined symptom/medication score<BR/>Titrated SPTs<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>Placebo group 19<BR/>Active treatment:<BR/>Grass/rye 28<BR/>Birch 21</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:19:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubakiene-2003">
<CHAR_METHODS MODIFIED="2010-05-12 13:10:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:19:15 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>59 active; losses to f/u 12<BR/>60 placebo; losses to f/u 7<BR/>3 trees</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>4 months SLIT<BR/>15 days updosing<BR/>Sublingual drops tree pollen (birch, hazel, alder)<BR/>Maintenance dose 2500 AU/ day Bet v 1 13 mcg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>Rhinoconjunctivitis Clinical Index Score (combined from symptom and medication score)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:19:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durham-2006">
<CHAR_METHODS MODIFIED="2010-05-12 13:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-03 16:07:46 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Adults</P>
<P>141 active (84 m)<BR/>136 placebo (89 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:19:30 +0000" MODIFIED_BY="[Empty name]">
<P>18 weeks<BR/>No updosing phase<BR/>Sublingual tablets<BR/>75,000 SQ-T<BR/>15 mcg Phl p 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:19:38 +0000" MODIFIED_BY="[Empty name]">
<P>Rhinoconjunctivitis symptom score<BR/>Medication score<BR/>Post-treatment specific IgE levels<BR/>Post-treatment specific IgG<BR/>Number of well days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:13:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feliziani-1995">
<CHAR_METHODS MODIFIED="2010-05-12 13:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>18 active<BR/>16 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>3 months SLIT<BR/>Dose n/s in mcg<BR/>Maintenance dose 20 BU daily 3 times a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:13:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diary scores<BR/>Rhinoconjunctivitis symptom score<BR/>Medication scores for rhinoconjunctivitis<BR/>Asthmatic symptoms<BR/>Overall symptoms<BR/>Overall drug consumption</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5<BR/>The data published in previous review reporting overall symptom and medication score</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:20:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grosclaude-2002">
<CHAR_METHODS MODIFIED="2010-05-12 13:14:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:14:27 +0100" MODIFIED_BY="[Empty name]">
<P>Children and adults</P>
<P>47 active: 15; 16; 16 (29 m)<BR/>15 placebo (11 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:20:09 +0000" MODIFIED_BY="[Empty name]">
<P>8 months SLIT<BR/>5 mixed grasses pollen tablets and drops<BR/>5 months pre-seasonal<BR/>3 different updosing regimens<BR/>18 days updosing<BR/>Maintenance<BR/>300 IR 3 times a day, drops<BR/>Average cumulative dose 18,000 IR; 0.88 mg Lol p 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 3/5<BR/>The study included in the review but not the meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:15:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guez-2000">
<CHAR_METHODS MODIFIED="2010-05-12 13:15:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:15:16 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children</P>
<P>36 active (14 m)<BR/>36 placebo (15 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:15:21 +0100" MODIFIED_BY="[Empty name]">
<P>24 months SLIT</P>
<P>Sublingual drops<BR/>2.2 mg D.Pt<BR/>1.7 mg D.f</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>SPT<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:20:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hirsch-1997">
<CHAR_METHODS MODIFIED="2010-05-12 13:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>15 active (10 m)<BR/>15 placebo (10 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:20:28 +0000" MODIFIED_BY="[Empty name]">
<P>12 months SLIT cumulative dose 570 mcg Derp 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diary scores<BR/>SPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:17:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hordijk-1998">
<CHAR_METHODS MODIFIED="2010-05-12 13:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:17:16 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>27 active (14 m)<BR/>30 placebo (13 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>SLIT drops mixed grasses<BR/>3 months pre-seasonal <BR/>Dose n/s</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:20:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ibanez-2007">
<CHAR_METHODS MODIFIED="2010-05-12 13:17:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active 45 (28 male); withdrawn 2<BR/>Placebo 15 (12 male); withdrawn 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:20:52 +0000" MODIFIED_BY="[Empty name]">
<P>28 days (pre-seasonal)<BR/>Grass pollen (<I>Phleum pratense</I>)<BR/>Sublingual tablet 75,000 SQ-T<BR/>Daily dose 15 mcg Phl p 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 16:54:26 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>This paper involves 2 studies performed with the identical study protocols</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:21:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ippoliti-2003">
<CHAR_METHODS MODIFIED="2010-05-12 13:18:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:21:05 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active 47 (28 m); losses to f/u 0<BR/>Placebo 39 (22 m); losses to f/u 0<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 months<BR/>Sublingual drops<BR/>Dose:<BR/>2.4 mcg/ml of Der p 1 and<BR/>1.2 mcg/ml of<BR/>Der p2 per week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores from diary cards<BR/>Expression of CD40 on B cells<BR/>Serum IL-13, ECP, prolactin<BR/>Adverse events description</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 3/5<BR/>33 children with rhinoconjunctivitis<BR/>18 in treatment<BR/>15 in placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:21:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khinchi-2004">
<CHAR_METHODS MODIFIED="2010-05-12 13:19:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, double-dummy, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>Active SLIT 23; losses to f/u 9<BR/>Active SCIT 24; losses to f/u 5<BR/>Placebo 19; losses to f/u 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:19:40 +0100" MODIFIED_BY="[Empty name]">
<P>2 years<BR/>Bet v 1<BR/>SLIT drops<BR/>Max dose:<BR/>SLIT 49.2 mcg every second day<BR/>SCIT 3.38 mcg monthly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:19:45 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Medication score<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 22:21:24 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad scale 4/5<BR/>3 groups of patients: SLIT, SCIT and placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:21:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<CHAR_METHODS MODIFIED="2010-05-12 13:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Active 63; no losses to f/u<BR/>Placebo 21; no losses to f/u<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:21:48 +0000" MODIFIED_BY="[Empty name]">
<P>4 weeks SLIT tablets<BR/>Grass pollen<BR/>25,000 SQ-T, 75,000 SQ-T, 150,000 SQ-T, 300,000 SQ-T, 500,000 SQ-T, 750,000 SQ-T, 1,000,000 SQ-T and placebo<BR/>100,000 SQ-T correspond to 20 mcg Phl p 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:21:28 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>Study included in review, but not meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:48:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Rosa-1999">
<CHAR_METHODS MODIFIED="2010-05-12 13:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:48:43 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>20 active (13 m)<BR/>21 placebo (12 m)<BR/>Losses to f/u 4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>24 months SLIT<BR/>52.5 mg Parj1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rhinitis symptom scores<BR/>Medication score<BR/>Ig<BR/>SPT<BR/>Conjunctival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:49:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lima-2002">
<CHAR_METHODS MODIFIED="2010-05-12 13:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:49:51 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>28 active<BR/>28 placebo<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>12 to 18 months SLIT<BR/>900 mcg Phlp5 per month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:22:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malling-2005">
<CHAR_METHODS MODIFIED="2010-05-12 13:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:22:15 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>5 updose groups: 2500, 25,000, 75,000, 125,000, 375,000 SQ-T</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>SLIT tablets<BR/>Maximum dose 375000 SQ-T</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Phleum pratense</I> specific: IgE, IgA and IgG<BR/>Adverse events description - local and systemic</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:52:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcucci-2005">
<CHAR_METHODS MODIFIED="2010-05-12 13:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:52:06 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active 13 (6 m); losses to f/u 0<BR/>Placebo 11 (10m); losses to f/u 0<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 13:52:26 +0100" MODIFIED_BY="[Empty name]">
<P>12 months<BR/>SLIT<BR/>Sublingual drops<BR/>Maintenance dose: 0.8 mcg of mite allergen group 1 and 0.4 mcg of mite allergen group 2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 13:52:32 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores for rhinitis and asthma<BR/>Medication scores<BR/>Nasal tryptase<BR/>Nasal IgE<BR/>Specific nasal challenge test<BR/>Nasal ECP<BR/>Sputum ECP<BR/>Sputum tryptase<BR/>Serum IgE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 13:53:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelson-1993">
<CHAR_METHODS MODIFIED="2010-05-12 13:53:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:53:31 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>20 active (7 m)<BR/>21 placebo (6 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-28 16:01:18 +0100" MODIFIED_BY="Suzana Radulovic">
<P>65 days SLIT drops<BR/>450-900 Feld1 units</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cat room scores<BR/>Ig<BR/>Titrated SPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:23:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ott--2009">
<CHAR_METHODS MODIFIED="2010-05-12 13:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:23:03 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Total mean age 33.3+/- 10.4 yrs (7.9 to 64.7)<BR/>Active total 142<BR/>Active full analysis set (FAS) 123<BR/>Active ITT 99<BR/>Active per protocol 58<BR/>Active losses to f/u 43<BR/>Placebo total 67<BR/>Placebo full analysis set (FAS) 60<BR/>Placebo ITT 46<BR/>Placebo per protocol 33<BR/>Placebo losses to f/u 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>3 consecutive grass pollen seasons<BR/>SLIT grass pollen (mixture of 5 grasses; orchard, meadow, perennial rye, sweet vernal and timothy grass)<BR/>Sublingual drops<BR/>Rush updosing of 30, 90, 150 and 300 IR at 20 minutes intervals, followed by a daily intake of 300 IR for the duration of pollen season<BR/>300 IR/ml = 21 mcg/ ml og Phl p 5 major allergen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Combined symptom/medication score<BR/>Specific IgE and IgG4<BR/>Compliance<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:24:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pajno-2003">
<CHAR_METHODS>
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 13:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>15 active (7 m); losses to f/u 1<BR/>15 placebo (6 m); losses to f/u 2<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:23:51 +0000" MODIFIED_BY="[Empty name]">
<P>13 months<BR/>SLIT <I>Parietaria</I> pollen<BR/>Sublingual drops<BR/>Maintenance dose 5 drops of 10 BU/ ml sol<BR/>Cumulative dose of major allergen<BR/>20.3 mcg Par j 1 ~ 0.15 mcg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:24:00 +0000" MODIFIED_BY="[Empty name]">
<P>Total symptom score<BR/>Chest symptom score<BR/>Nose symptom score<BR/>Medication score<BR/>Early and late-phase skin reaction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>Active group: SLIT+ fluticasone<BR/>Placebo group: placebo + fluticasone<BR/>Control group: asthma medications as needed only</P>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:24:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palma-Carlos-2006">
<CHAR_METHODS MODIFIED="2010-05-12 13:58:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:24:15 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Active 17; loss to follow up 4<BR/>Placebo 16; loss to follow up 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:24:17 +0000" MODIFIED_BY="[Empty name]">
<P>24 months sublingual tablets<BR/>Allergoid mixture (33% <I>Holcus lanatus</I>, 33% <I>Phleum pratense</I>, 33% <I>Poa pratensis</I>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:24:22 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Nasal reactivity (allergen nasal challenge)<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 13:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Major allergen protein dose not possible to measure as this is an allergoid</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 23:14:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panzner-2008">
<CHAR_METHODS MODIFIED="2010-05-12 13:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:24:41 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children</P>
<P>Total mean age 19.5<BR/>Age range 7 to 50 years<BR/>Active sublingual 20 (11 m)<BR/>Placebo sublingual 15 (9 m)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 23:14:42 +0000" MODIFIED_BY="[Empty name]">
<P>Sublingual and supralingual drops 6 grasses: oat grass (<I>Arrhenatherum elatius</I>), orchard grass (<I>Dactylis glomerata</I>), fescue (<I>Festuca sp.</I>), rye grass (<I>Lolium sp.</I>), timothy grass (<I>Phleum pratense</I>) and rye (<I>Secale cereale</I>)</P>
<P>1 year</P>
<P>Updosing scheme from 1 to 10 drops. Maximal dose 10 drops of 10,000 JSK/ml (1.265 mcg of Lol p1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores (nasal, ocular and bronchial)<BR/>Medication scores<BR/>Skin prick tests<BR/>Grass pollen specific IgE and IgG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 19:10:52 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed grasses drops were delivered sublingually or supralingually. Only sublingual immunotherapy data were used for the purpose of this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 14:02:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passalacqua-1998">
<CHAR_METHODS MODIFIED="2010-05-12 14:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>10 active (3 m)<BR/>10 placebo (4 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>24 months SLIT<BR/>Tablets<BR/>Dose n/s</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 14:03:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passalacqua-1999">
<CHAR_METHODS MODIFIED="2010-05-12 14:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:03:12 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>15 active (10 m)<BR/>15 placebo (3 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 months SLIT<BR/>16 mcg Parj1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>Nasal challenge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:25:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Passalacqua-2006">
<CHAR_METHODS MODIFIED="2010-05-12 14:03:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>34 active (11 m); losses to f/u 6<BR/>34 placebo (11 m); losses to f/u 6<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 14:03:49 +0100" MODIFIED_BY="[Empty name]">
<P>25 months<BR/>SLIT allergoid<BR/>Soluble tablets<BR/>1000 AU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Quality of life questionnaire<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:25:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peter-2009">
<CHAR_METHODS MODIFIED="2010-05-12 14:04:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:25:20 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Active 176; lost to f/u unknown<BR/>Placebo 189; lost to f/u unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:25:24 +0000" MODIFIED_BY="[Empty name]">
<P>SLIT drops<BR/>Grass pollen mixture (<I>Lolium perenne</I>, <I>Phleum pratense</I> and <I>Poa pratensis</I>)<BR/>16 weeks pre-seasonal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:25:35 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical index score<BR/>Symptom score<BR/>Medication score<BR/>Specific IgE for grass pollen mixture<BR/>Specific IgE for Phl p 1 and Phl p 5<BR/>Specific IgG and IgG4 for grass pollen mixture<BR/>Specific IgG and IgG4 for Phl p 1 and Phl p 5</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 14:05:06 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:26:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfaar-2008">
<CHAR_METHODS MODIFIED="2010-05-12 14:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:25:48 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>Active 49; losses to f/u 7<BR/>Placebo 55; losses to f/u 7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:26:21 +0000" MODIFIED_BY="[Empty name]">
<P>Sublingual immunotherapy with 6 grasses pollen mixture (<I>Holcus lanatus</I>, <I>Dactylis glomerata</I>, <I>Lolium perenne</I>, <I>Phleum pratense</I>, <I>Poa pratensis</I> and <I>Festuca elatior</I>)<BR/>Sublingual drops<BR/>Dose escalation was performed at the day 1 of the treatment, with doubling of a dose every 60 minutes. Initial dose, 1 drop, 2 drops, 4 drops (100%), corresponding to 10, 20 and 40 mcg of the group 5 grass allergen<BR/>The group 5 allergen content of the maintenance dose was 40 mcg (ELISA) and 20 mcg (CREATE)<BR/>Once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:26:12 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Specific IgE<BR/>Specific IgG1 and IgG4<BR/>Compliance<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-21 17:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>A block randomisation was performed, and there was a stratification procedure with respect to asthma</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 14:06:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pradalier-1999">
<CHAR_METHODS MODIFIED="2010-05-12 14:06:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:06:38 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>63 active (29 m)<BR/>63 placebo (36 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 14:06:44 +0100" MODIFIED_BY="[Empty name]">
<P>5 months pre-seasonal SLIT drops and tablets<BR/>Cumulative dose 0.935 mg Phlp5<BR/>Daily maintenance dose ~ 8.5 mcg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>SPT<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:26:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<CHAR_METHODS MODIFIED="2010-05-12 14:07:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Age range 3 to 14</P>
<P>Active 49 (30 m); losses to f/u 11<BR/>Placebo 48 (35 m); losses to f/u 11<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:26:43 +0000" MODIFIED_BY="[Empty name]">
<P>32 months<BR/>SLIT<BR/>sublingual drops<BR/>Mixed grasses (<I>Dactylis glomerata</I>, <I>Festuca pratensis</I>, <I>Lolium perenne</I>, <I>Phleum pratense</I> and <I>Poa pratensis</I>)<BR/>Maintenance dose: 5 drops of 1000 STU/ml solution 3 times a week<BR/>Cumulative dose 188 mcg of major allergens<BR/>The potency in STU; 1000 STU equivalent to 25 BU (2.5 mcg of major allergens)<BR/>Study started in January 1999</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores (nasal, eyes, lung)<BR/>Medication scores<BR/>Total IgE, specific IgE and IgG4<BR/>Skin prick test<BR/>Conjunctival provocation test<BR/>Nasal provocation test<BR/>Lung function test<BR/>Exhaled nitric oxide concentrations<BR/>SCORAD<BR/>Adverse events descriptions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:27:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-R_x0151_der-2007">
<CHAR_METHODS MODIFIED="2009-03-20 17:40:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:26:55 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Age range 6 to 18<BR/>Active 108 (91 ITT); losses to follow up 26<BR/>Placebo 96 (77 ITT); losses to follow up 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:26:59 +0000" MODIFIED_BY="[Empty name]">
<P>Sublingual drops - mixed grasses<BR/>5 grasses extract (<I>Lolium perenne</I>, <I>Phleum pratense</I>, <I>Dactylis glomeratein</I>, <I>Anthoxatum odoratum</I>, <I>Holcus lanatus</I>)<BR/>Treatment duration 2 years. Maintenance dose 21 mcg of Lol p 5 twice a week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:27:07 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Percentage of symptom-free days<BR/>Percentage of medication-free days<BR/>Quality of life evaluation<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 14:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:27:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sabbah-1994">
<CHAR_METHODS MODIFIED="2010-06-16 00:10:29 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>Children and adults</P>
<P>Age range 13 to 51<BR/>Active 29<BR/>Placebo 29</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 10:15:15 +0100" MODIFIED_BY="[Empty name]">
<P>Sublingual drops - 5 grass pollen extracts or placebo</P>
<P>The updosing phase duration was 40 days. It started with 1 drop of 1 IR/ml up to 10 drops on day 10, while on days 11 to 20, 1 to 10 drops of 10 IR/ml were given. Finally, from days 20 to 40, the patients took 1 to 20 drops of 100 IR/ml. Once this dose of 20 drops was reached, maintenance treatment was continued every day for 30 days and then every 2 days for the following 30 days. The cumulative dosage received by the patients was therefore 4500 IR.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:27:22 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Medication scores<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-27 12:52:44 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Study included in review, but not meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:27:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez-2001">
<CHAR_METHODS MODIFIED="2010-06-15 23:02:21 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:27:39 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>40 participants<BR/>Mean age: 24.5 years old<BR/>Male 16 and female 24<BR/>Active 20 patients<BR/>Placebo 20 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-30 10:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>SLIT: active therapy contained an aqueous extract of the major cat allergen Fel d 1 (CBF-Leti). Five vials were provided containing: 0.00032, 0.0016, 0.008, 0.04, 0.02 and 1 HEP equivalent/mL. Saline solution, glycerine 50% and phenol 0.4% was used as vehicle. SLIT was provided daily and kept under the tongue during 3 minutes. After 1 year of treatment the cumulative dose was 3.6 &#956;g of Fel d 1.<BR/>
</P>
<P>Placebo: saline solution, glycerine 50% and phenol 0.4%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:27:50 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Medication scores<BR/>Skin prick tests<BR/>Nasal provocation tests<BR/>IgE and IgG4<BR/>Eosinophil cationic protein</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-30 10:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:27:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2004">
<CHAR_METHODS MODIFIED="2010-05-12 14:11:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>44 active treatment for 2 years (21 m)<BR/>45 active treatment then placebo (22 m)<BR/>45 placebo in both years (27 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:27:59 +0000" MODIFIED_BY="[Empty name]">
<P>2 years SLIT from February until 31 July each year<BR/>Sublingual drops and tablets for maintenance<BR/>Mixed grasses (orchard, meadow, rye, sweet vernal and timothy grass)<BR/>100 IR contained 24 mcg Lolp1 and 14 mcg Dacg5<BR/>Cumulative annual dose<BR/>26.100 IR<BR/>6264 mcg Lolp1<BR/>3654 mcg Dacg5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores; daily diary<BR/>Medication scores; dairy cards<BR/>Conjunctival provocation threshold<BR/>Skin tests<BR/>Specific IgE and IgG4<BR/>Side effects reported by patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 14:13:16 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>Participants were randomised into 3 groups<BR/>Active treatment for 2 years<BR/>Active treatment for a year, then placebo and placebo for 2 years<BR/>Treatment every year from February until 31 July</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:28:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tari-1990">
<CHAR_METHODS>
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:28:12 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>34 active<BR/>32 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:28:27 +0000" MODIFIED_BY="[Empty name]">
<P>18 months SLIT 2340 drops of 5BU/ml mcg dose n/s</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Diary scores<BR/>Ig</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:29:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tonnel-2004">
<CHAR_METHODS MODIFIED="2010-05-12 14:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Adults and children</P>
<P>15 active (8 m); losses to f/u 5<BR/>17 placebo (10 m); losses to f/u 9<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:29:30 +0000" MODIFIED_BY="[Empty name]">
<P>24 months SLIT<BR/>Der p 1 and Der f 1 50/50 drops and tablets<BR/>Progression phase for 2 weeks<BR/>Max dose 100 IR tablet<BR/>Mean cumulative dose<BR/>47500 IR<BR/>1.28 mg Der p1<BR/>1.47 mg Der f 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Medication scores<BR/>Skin prick tests<BR/>Nasal provocation test<BR/>Levels of specific IgE and IgG4<BR/>Adverse events reports and descriptions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:29:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Troise-1995">
<CHAR_METHODS MODIFIED="2010-05-12 14:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>15 active (6 m)<BR/>16 placebo (6 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:29:39 +0000" MODIFIED_BY="[Empty name]">
<P>10 months SLIT<BR/>
<I>Parietaria</I> extract 6.3 mcg Parj1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:30:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valovirta-2006">
<CHAR_METHODS MODIFIED="2010-05-12 14:16:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>35 active<BR/>Dose group one 33 patients (19 m); losses to f/u 1<BR/>Dose group 2: 32 patients (13 m); losses to f/u 7</P>
<P>33 placebo (18 m); losses to f/u 6<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:29:59 +0000" MODIFIED_BY="[Empty name]">
<P>18 months SLIT<BR/>Group 1: accumulated weekly dose<BR/>3.6 mcg Bet v 1/ Aln g 1/ Cor a 1<BR/>Group 2: accumulated weekly dose<BR/>30 mcg of Bet v 1/ Aln g 1/ Cor a 1<BR/>5 weeks updosing schedule</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:18:07 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 22:30:03 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>2 treatment groups<BR/>Mixed tree pollen</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:30:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vervloet-2006">
<CHAR_METHODS MODIFIED="2010-05-12 14:18:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:30:20 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>38 active (22 m); losses to f/u 2<BR/>38 placebo (17 m); losses to f/u 4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>4 months SLIT<BR/>Sublingual drops Ultra rush treatment<BR/>Maintenance dose 300 IR daily<BR/>Dose of major allergen 228 mcg Jun a 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Medication scores<BR/>Adverse events reports</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 5/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:30:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Voltolini-2001">
<CHAR_METHODS MODIFIED="2010-05-12 14:20:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:30:32 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
<P>15 active (7 m)<BR/>15 placebo (4 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:30:37 +0000" MODIFIED_BY="[Empty name]">
<P>Rush pre-seasonal and co-seasonal maintenance<BR/>445 mcg Bet v 1</P>
<P>Tree pollen extract</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>Ig<BR/>SPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:30:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vourdas-1998">
<CHAR_METHODS MODIFIED="2010-05-12 14:20:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:21:05 +0100" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>34 active (25 m)<BR/>32 placebo (24 m)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:30:45 +0000" MODIFIED_BY="[Empty name]">
<P>6 months SLIT per year for 2 years<BR/>4.05 mg Olee 1</P>
<P>Olive pollen extract solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Diary scores<BR/>SPT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad scale 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:31:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahn-2009">
<CHAR_METHODS MODIFIED="2010-05-12 14:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 22:30:51 +0000" MODIFIED_BY="[Empty name]">
<P>Children</P>
<P>Active 131 (65.6% male); withdrawn 8<BR/>Placebo 135 (63.0% male); withdrawn 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 22:31:03 +0000" MODIFIED_BY="[Empty name]">
<P>&lt; 6 months<BR/>Sublingual tablets<BR/>Mixed grasses (<I>Dactylis glomerata</I>, <I>Poa pratensis</I>, <I>Lolium perenne</I>, <I>Anthoxanthum odoratum</I>, <I>Phleum pratense</I>)<BR/>Daily dose 300 IR; 20 mcg of group 5 major allergens</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:31:28 +0000" MODIFIED_BY="[Empty name]">
<P>Symptom score<BR/>Medication score<BR/>Timothy grass specific IgE<BR/>Grass pollen specific IgG4<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 14:23:06 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 22:31:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wessner-2001">
<CHAR_METHODS MODIFIED="2010-05-12 14:23:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>22 active; losses to f/u 8<BR/>23 placebo; losses to f/u 5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>12 months<BR/>SLIT drops maintenance dose 2000 AU per day <BR/>8 mcg major allergen per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Symptom scores<BR/>Daily cards<BR/>Nasal provocation tests</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 22:31:52 +0000" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>The study was performed for 2 years<BR/>Only first year was performed as a DBPC trial; in the second year all participants received verum therapy for another year<BR/>Data analysed only for the first year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 14:26:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wutrich-2003">
<CHAR_METHODS MODIFIED="2010-05-12 14:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised DBPC trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:24:56 +0100" MODIFIED_BY="[Empty name]">
<P>Children<BR/>Age range 4 to 11 years</P>
<P>Active 14 (7 m); losses to f/u 2<BR/>Placebo 14 (9 m); losses to f/u 0<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 14:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>24 months<BR/>SLIT<BR/>Sublingual drops<BR/>Mixed grasses (<I>Dactylis glomerata</I>, <I>Festuca pratensis</I>, <I>Lolium perenne</I>, <I>Phleum pratense</I>, <I>Poa pratensis</I>)<BR/>Build-up phase 30 days - cumulative dose of major allergen was 1.88 mcg<BR/>Maintenance phase - cumulative dose of major allergen 6 mcg<BR/>The first year the cumulative dose was 67.88 mcg and 139.88 mcg of major allergen in total</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:26:19 +0100" MODIFIED_BY="[Empty name]">
<P>Conjunctival provocation test<BR/>Skin prick test<BR/>Symptom scores - diary cards<BR/>Medication scores - diary cards</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 14:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad scale 5/5<BR/>4 children were not included in data analysis because of their incomplete diary cards</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>DBPC = double-blind, placebo-controlled; f/u= follow up; mcg = microgram; ITT = intention-to-treat; m = male; n/s = not specified; SCIT = subcutaneous (injection); immunotherapy; SL = sublingual; SLIT = sublingual immunotherapy; SPT = skin prick test<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-10 22:36:11 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bernardis-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-09 16:17:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-09 16:17:46 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data available for the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corthay-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data available for the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:28:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Ambrosio-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:28:00 +0100" MODIFIED_BY="[Empty name]">
<P>Open study design; not a randomised DBPC trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:28:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donato-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:28:26 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective study; not a randomised DBPC trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feliziani-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:29:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gammeri-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gozalo-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised, controlled or blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:29:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>Other outcomes investigated (food allergy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:29:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horak-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:29:38 +0100" MODIFIED_BY="[Empty name]">
<P>No symptom data. Not seasonal exposure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 17:06:08 +0000" MODIFIED_BY="Suzana Radulovic" STUDY_ID="STD-Inal-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 17:06:08 +0000" MODIFIED_BY="Suzana Radulovic">
<P>Insufficient data available for the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:29:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karakoc-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Not randomised, not blinded and not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mitsch-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:30:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mungan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:30:33 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised DBPC trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nanda-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>SCIT trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:30:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okubo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:30:37 +0100" MODIFIED_BY="[Empty name]">
<P>Additional data not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-29 16:10:55 +0100" MODIFIED_BY="Suzana Radulovic" STUDY_ID="STD-Quirino-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-29 16:10:55 +0100" MODIFIED_BY="Suzana Radulovic">
<P>Not truly randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:30:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Radjenovic-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>Not DBPC trial; prospective parallel-group study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:30:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Russello-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:30:51 +0100" MODIFIED_BY="[Empty name]">
<P>Not blinded </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-30 10:21:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sabbah-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-30 10:21:22 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate study (same as <LINK REF="STD-Sabbah-1994" TYPE="STUDY">Sabbah 1994</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-10 22:35:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tonnel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-10 22:35:36 +0000" MODIFIED_BY="[Empty name]">
<P>Data published in <LINK REF="STD-Tonnel-2004" TYPE="STUDY">Tonnel 2004</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-24 17:09:08 +0000" MODIFIED_BY="Suzana Radulovic" STUDY_ID="STD-Troise-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-24 17:09:08 +0000" MODIFIED_BY="Suzana Radulovic">
<P>Insufficient data available for the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:31:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Niekerk-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not sublingual immunotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 14:31:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuksel-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 14:31:53 +0100" MODIFIED_BY="[Empty name]">
<P>This study does not investigate outcomes evaluated by this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DBPC = double-blind, placebo-controlled; SCIT = subcutaneous immunotherapy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-10 22:36:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-05-12 14:34:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ingels-2002">
<CHAR_STUDY_NAME>
<P>A placebo controlled, double-blind, randomized study to assess efficacy of sublingual immunotherapy in patients with grass pollen allergy through assessment of its immunological effects on the mucosal tissue of the nose</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-05-12 14:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Expected 38</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 14:34:33 +0100" MODIFIED_BY="[Empty name]">
<P>Sublingual immunotherapy with Oralgen<BR/>Further procedures:<BR/>Nasal biopsy<BR/>Nasal washing<BR/>PNIF</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 14:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Decrease of IgE specific cells and Th2 mediator release<BR/>Increase in Th 1 mediator release<BR/>Rescue medication<BR/>Determining the effects on decongestion<BR/>Assessment of treatment compliance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Study start 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-05-12 14:33:08 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-05-12 14:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-11-10 22:36:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Hehir-2005">
<CHAR_STUDY_NAME MODIFIED="2010-05-12 14:33:23 +0100" MODIFIED_BY="[Empty name]">
<P>A trial of immunological outcomes of sublingual immunotherapy for house dust mite (<I>D. pteronyssinus</I>)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-05-12 14:33:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 14:33:32 +0100" MODIFIED_BY="[Empty name]">
<P>Expected enrolment 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 14:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Sublingual immunotherapy for house dust mite</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 22:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>Immunoregulatory cytokine production and T cell phenotype and function<BR/>Symptom diary <BR/>Medication use<BR/>Visual analogue score<BR/>Disease-specific rhinoconjunctivitis<BR/>Quality of life questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-11-10 22:36:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allesandra Sandrini MD, PhD<BR/>a.sandrini@alfred.org.au<BR/>+61 3 9276 2000 ext 2350</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-05-12 14:33:50 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-10 22:31:58 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-10 22:15:46 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-24 16:36:33 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:13:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:44:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:40:58 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:47:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:48:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>Block-wise randomisation was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:16:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>Randomisation was performed by stratification according to trial centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:15:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>Children were randomly assigned by a computer-generated list to receive either grass-pollen allergoid oral soluble tablets or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:53:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>Participants were randomly assigned by a computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:54:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:56:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:51:56 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>Patients were randomised, but it details were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:57:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:02:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>The allocation sequence was generated by the sponsoring company and blinded for the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:03:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>The allocation sequence was generated by the sponsoring company and blinded for the investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:54:28 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>Patients were randomised, but the details about randomisation were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:08:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>Computer-generated randomisation list utilised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:55:01 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>Randomisation in blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:11:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>Randomisation in blocks of 4 was performed (2 SLIT and 2 placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:13:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>The allocation sequence was generated by the sponsoring company and blinded for the investigators (computer-generated schedule)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:13:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>Treatments were coded according to a key unknown to the clinician and to the patient and they were assigned randomly to each patient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 17:00:54 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>Patients were randomised, but no details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 17:01:09 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>Patients were randomised, but details were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:16:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>Subjects were randomised according to a code provided by the manufacturer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:17:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>Stratified randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:18:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>Patients were randomised, but no details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:26:41 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>Patients were randomised, but the full details were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:20:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>Randomisation was performed by minimisation based on disease severity during the baseline season, gender and age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:21:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>Computer-generated randomisation list was provided by a manufacturer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:49:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:50:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>Randomisation to active or placebo treatment was performed by the manufacturer of the grass pollen vaccine using a system of computer-generated random numbers in blocks of 12</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:29:08 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>Patients were randomised, but no details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:53:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>Patients were randomised, but no details about randomisation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:54:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>Patients were randomised, but the details were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:57:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>The randomisation to the active, placebo or control group was obtained by means of a computer-generated key-code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>Central randomisation. The randomisation key was generated by the GraphPad Software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>Random codes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>A computer-generated list was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:11:50 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:06:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>A block randomisation was performed, and there was a stratification procedure with respect to asthma</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:07:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:08:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>Randomisation was conducted for age and history of asthma in consecutive order at inclusion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:10:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>A computer-generated randomisation list stratifying for symptom score and participating general practice was utilised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:34:33 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>Patients were randomised, but no details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:13:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:35:20 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>Patients were randomised, but further details were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:15:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>A random computer-generated code was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:15:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>Randomisation in blocks was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:21:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>Patients were randomised but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:23:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>The randomisation list was stratified by study centre and organised in blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:24:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>Randomisation blocks of 4 containing 2 of each treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:26:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>Patients were randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:05:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>Patients were randomised but not stated in the paper how was it done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-10 22:28:07 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:12:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>This was not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:13:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>It was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>This was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:13:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>This was not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:15:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>This was not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:48:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>Not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:50:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>Not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:15:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>Stated in a paper that neither the investigators nor the patients were aware of the treatment assignments, but no details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:51:14 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:54:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>Not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:56:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>Not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:51:45 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:57:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:29:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:30:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:54:13 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:33:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:55:20 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:34:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:35:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>Not reported in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:55:47 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 17:01:14 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:40:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 17:02:08 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:25:10 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:26:32 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:20:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:28:27 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>Central allocation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:44:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 17:00:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:29:00 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:59:00 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:56:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>No details were stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:33:19 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>No details were stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:51:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>It was not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>It was not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:04:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>Not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:13:40 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 16:54:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:07:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:08:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:10:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>A pharmacist allocated medication in accordance with a computer-generated randomisation list stratifying for symptom score and participating general practice. Participants, parents, investigators and caregivers were unaware of the group assignment and could not make a distinction between verum and placebo treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:34:12 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:28:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>Authors stated that groups were checked for homogeneity regarding demographics, symptom scores and relevant clinical parameters</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:35:07 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:35:48 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:16:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>It was not specified in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 17:04:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:21:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 17:09:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>Central allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:36:42 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>Not stated in paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-11-10 22:31:37 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 22:12:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Caramelised sugar was added to placebo and timothy grass monotherapy extract in order to mimic the colour of the active treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 22:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:44:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-26 13:42:07 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>Investigators and patients were blinded to treatment but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:47:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>Investigators and patients were blinded to treatment but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:48:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:50:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-26 13:53:53 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>Placebo tablets were indistinguishable from active treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-11 16:51:17 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:54:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:56:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Placebo consisted of glycerol-saline diluent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 12:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:02:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 16:30:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>Unblinded efficacy and safety assessments on subject level were available only for a biostatistician at the Contract Research Organization. All personnel associated with the study and participants remained blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:07:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>Placebo treatment consisted of identical vials containing only the diluent (a glycero-saline solution)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 16:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>Both investigators and participants were blinded to allocation. To maintain the blinding, patients took 2 tablets per day during the first 5 days of titration and 1 tablet per day from day 6 until the end of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:10:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>The placebo consisted of the allergen-free solution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:11:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>Investigators and patients were blinded to treatment but how this was done was not stated in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:13:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Tablet similar in taste, smell and appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:14:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-11 16:56:55 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>The placebo consisted of tablets (cellulose, magnesium stearate, lactose) and drops (glycerinated saline) that were indistinguishable from active treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:16:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>The placebo preparation was identical to active treatment in terms of composition, appearance, presentation, taste and colour, but did not contain allergens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:16:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:17:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. The placebo consisted of the non-active ingredients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-14 16:25:10 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>A placebo tablet similar in taste, smell and appearance was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-14 16:26:45 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>Placebo consisted of the same glycerine/phenol diluent used in active group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:20:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>All study personal and participants were blinded to treatment assignment for the 2-year duration of treatment in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-14 16:28:28 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:49:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:50:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>The treatment schedule and assessments were performed double-blind, with treatment allocations kept in sealed envelopes by the principal investigator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-14 16:29:12 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:53:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>The placebo preparation was identical to active treatment in terms of composition, appearance, presentation, taste and colour, but did not contain allergens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:54:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Those randomised to the placebo group received histamine phosphate (1 mg/ml histamine base in 50% glycerine with caramelised sugar for colour).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:56:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>Investigators and patients were blinded to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 22:24:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment. The placebo was indistinguishable from the active treatment in appearance, colour and taste.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>Investigators and patients were blinded to treatment but how this was done was not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:02:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:02:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:04:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:05:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:06:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:07:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:08:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:10:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:11:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:13:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Placebo tablets and drops were physically identical to active medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:14:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>The placebo contained only the phosphate buffered physiological solution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:15:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>Blinding was done using solutions and tablets of identical appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:16:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>The study was conducted under double-blind conditions. There was no difference in colour and viscosity between the study drug and placebo. All blinding procedures were performed by the Quality Assurance Department at ALK-Abello A/S.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:20:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 17:06:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Placebo was prepared as saline solution in vials with exactly the same appearance, colour and taste, but without allergens, in order to guarantee the double-blind design of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 17:09:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. The placebo was a glycerinated phenolated saline solution with an appearance similar to that of the active agent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 22:31:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study. Excipients used in both active and placebo tablets include lactose, sodium stearate and sodium croscarmellose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-14 16:36:42 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>No details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 14:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 13:05:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>Investigators and participants were blinded to treatment assignment for the duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-11-10 22:31:43 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 09:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>Additional information was sought and obtained from the authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:43:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-05 16:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-26 13:45:23 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>All participants completed treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:48:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-26 13:46:41 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>Described the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Stated whether attrition and exclusions were reported, the numbers in each intervention group and reasons for attrition/exclusions where reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 22:15:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>Described the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Attrition and exclusions were reported, the numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-11 16:51:19 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>All randomised patients completed the trial and the adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:56:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:57:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>Outcome data for each main outcome completed and attrition and exclusions were reported; the numbers in each intervention group and reasons for attrition/exclusions were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:58:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:02:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 09:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:07:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:10:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:10:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:11:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:10:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:14:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 22:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>Participants lost to follow-up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:18:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>It is not clear if any patients lost during follow up occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:20:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>All randomised subjects received intervention and all completed the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:49:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:11:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:51:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>Data completed for each main outcome, including attrition and exclusions from the analysis. Attrition and exclusions were reported, the numbers in each intervention group and reasons for attrition/exclusions where reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>Participants excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 22:22:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported; the numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 13:59:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:02:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:12:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:03:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:13:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-26 13:17:03 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>Outcome data were completed for each main outcome. Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:07:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:14:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:14:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-16 00:37:54 +0100" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>No details were provided in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:14:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:17:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:16:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods. The specified outcomes in the methodology were reported in the results section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 22:30:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>Outcome data for each main outcome completed, including attrition and exclusions from the analysis. Attrition and exclusions were reported; the numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:20:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:20:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:21:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 22:31:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>Outcome data for each main outcome completed, including attrition and exclusions from the analysis. Attrition and exclusions were reported; the numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:24:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 14:26:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>Participants lost to follow up or excluded were accounted for along with patients followed to designated follow-up periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-30 10:09:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>Attrition and exclusions were reported. The numbers in each intervention group and reasons for attrition/exclusions were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-07-28 18:29:12 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:19:53 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:43:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:44:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:45:25 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:47:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:48:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:50:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:57:50 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:53:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:56:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:57:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:58:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:02:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:04:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:07:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:08:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:10:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>Not reported in the abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:13:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:14:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:15:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:17:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:18:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:19:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:21:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:49:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:51:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:53:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:32:43 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:56:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:58:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:59:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:02:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:04:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:18:21 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:06:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:07:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:09:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:10:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:14:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:18:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:23:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:24:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:26:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:05:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>The specified outcomes in the methodology were reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-10 22:31:58 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:19:48 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Amar-2009">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:43:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andre-2003">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ariano-2001">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:46:02 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Bahceciler-2001">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:47:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bowen-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bufe-2009">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:57:54 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Caffarelli-2000">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:51:22 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Calderon-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:54:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cao-2007">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:56:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casanovas-1994">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists. Small number of patients across each trial group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:53:08 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Clavel-1998">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:58:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Ambrosio-1999">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:02:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006a">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:04:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dahl-2006b">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:54:34 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Di-Rienzo-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:08:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Didier-2007">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:55:26 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Drachenberg-2001">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:11:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubakiene-2003">
<DESCRIPTION>
<P>This paper has not been published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:13:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durham-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:14:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feliziani-1995">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:57:13 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Grosclaude-2002">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:16:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guez-2000">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:17:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1997">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 17:02:15 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Hordijk-1998">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:21:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ibanez-2007">
<DESCRIPTION>
<P>2 studies were pooled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:26:50 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Ippoliti-2003">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khinchi-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:28:33 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Kleine_x002d_Tebbe-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Rosa-1999">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lima-2002">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:29:18 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Malling-2005">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 16:59:07 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Marcucci-2005">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:32:44 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Nelson-1993">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:56:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ott--2009">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-14 16:33:20 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="UNKNOWN" STUDY_ID="STD-Pajno-2003">
<DESCRIPTION>
<P>A second drug other than SLIT was considered in the study design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:59:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Palma-Carlos-2006">
<DESCRIPTION>
<P>39.4% of participants withdrew during follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:02:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panzner-2008">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1998">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:03:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-1999">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:04:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Passalacqua-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-26 13:18:57 +0000" MODIFIED_BY="Suzana Radulovic" RESULT="YES" STUDY_ID="STD-Peter-2009">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:06:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfaar-2008">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pradalier-1999">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:09:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:10:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x0151_der-2007">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabbah-1994">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:11:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2001">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:13:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:14:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tari-1990">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:15:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tonnel-2004">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:16:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Troise-1995">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Valovirta-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vervloet-2006">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:20:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voltolini-2001">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vourdas-1998">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:23:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wahn-2009">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 22:31:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wessner-2001">
<DESCRIPTION>
<P>The study has not been published after its presentation at a meeting in 2001</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 14:26:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wutrich-2003">
<DESCRIPTION>
<P>Small number of patients across each trial group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 13:05:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Blay-2003">
<DESCRIPTION>
<P>No other sources of bias were detected or suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-11-10 22:38:20 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-11-10 22:37:05 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-04-27 10:32:14 +0100" MODIFIED_BY="[Empty name]">Adverse events: data not suitable for analysis</TITLE>
<TABLE COLS="4" ROWS="27">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Sublingual immunotherapy</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Additional comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bowen-2004" TYPE="STUDY">Bowen 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>43</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD>
<P>Report by SOC</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Casanovas-1994" TYPE="STUDY">Casanovas 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD>
<P>Grading according to EAACI</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cao-2007" TYPE="STUDY">Cao 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER">
<P>91</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dahl-2006a" TYPE="STUDY">Dahl 2006a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD>
<P>AE reported as percentage of patients</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Blay-2003" TYPE="STUDY">de Blay 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>33</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
</TD>
<TD>
<P>AE reported as percentage of patients</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Di-Rienzo-2006" TYPE="STUDY">Di Rienzo 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Drachenberg-2001" TYPE="STUDY">Drachenberg 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>49</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD>
<P>AE reported as difference between SLIT and placebo group (P values)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dubakiene-2003" TYPE="STUDY">Dubakiene 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>59</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Durham-2006" TYPE="STUDY">Durham 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD>
<P>AE reported by severity</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Feliziani-1995" TYPE="STUDY">Feliziani 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guez-2000" TYPE="STUDY">Guez 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>36</P>
</TD>
<TD ALIGN="CENTER">
<P>36</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hirsch-1997" TYPE="STUDY">Hirsch 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hordijk-1998" TYPE="STUDY">Hordijk 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>27</P>
</TD>
<TD ALIGN="CENTER">
<P>30</P>
</TD>
<TD>
<P>AE reported SOC</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ippoliti-2003" TYPE="STUDY">Ippoliti 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>47</P>
</TD>
<TD ALIGN="CENTER">
<P>39</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lima-2002" TYPE="STUDY">Lima 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD ALIGN="CENTER">
<P>28</P>
</TD>
<TD>
<P>Data reported in percentages</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Malling-2005" TYPE="STUDY">Malling 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>36</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD>
<P>Trial design</P>
<P>Data reported in percentages</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marcucci-2005" TYPE="STUDY">Marcucci 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mungan-1999" TYPE="STUDY">Mungan 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ott--2009" TYPE="STUDY">Ott 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>142</P>
</TD>
<TD ALIGN="CENTER">
<P>67</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Palma-Carlos-2006" TYPE="STUDY">Palma Carlos 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Panzner-2008" TYPE="STUDY">Panzner 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Passalacqua-1998" TYPE="STUDY">Passalacqua 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sanchez-2001" TYPE="STUDY">Sanchez 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tari-1990" TYPE="STUDY">Tari 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Voltolini-2001" TYPE="STUDY">Voltolini 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD>
<P>Insufficient data</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-11-10 22:37:32 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-04-27 10:37:02 +0100" MODIFIED_BY="[Empty name]">No adverse events reported</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Sublingual immunotherapy</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ariano-2001" TYPE="STUDY">Ariano 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bahceciler-2001" TYPE="STUDY">Bahceciler 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-D_x0027_Ambrosio-1999" TYPE="STUDY">D'Ambrosio 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>16</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Passalacqua-1998" TYPE="STUDY">Passalacqua 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Passalacqua-1999" TYPE="STUDY">Passalacqua 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pradalier-1999" TYPE="STUDY">Pradalier 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-04-27 10:44:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-04-27 10:38:51 +0100" MODIFIED_BY="[Empty name]">Adverse events - local reactions</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Type of reaction</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>No of studies reported the event</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Sublingual immunotherapy</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of patients</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of events</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of patients</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of events</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Labial oedema</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>604</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>55</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>536</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Buccal pruritus</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1126</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1798</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1075</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>492</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bucco- lingual oedema</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>648</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>143</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>606</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Throat irritation</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>770</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>243</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>747</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>29</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Oral - non-specified</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>143</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>71</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>24</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Non-specified</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>119</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>116</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2010-06-30 10:24:23 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-04-27 10:44:16 +0100" MODIFIED_BY="[Empty name]">Adverse events - systemic reactions</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Type of reaction</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>No of studies reported the event</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Sublingual immunotherapy</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of patients</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of events</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of patients</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Total No of events</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Urticaria</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>204</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>199</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pruritus/rash</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>363</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>222</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Conjunctivitis</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>262</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>774</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>238</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>786</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rhinitis</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>965</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1403</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>912</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1034</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rhino-conjunctivitis</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>184</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>176</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>58</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Asthma/wheezing</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>488</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>450</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cough</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>337</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>313</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>304</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>211</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gastro-intestinal</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>630</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>88</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>561</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Headache</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>535</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>548</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>68</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Anaphylaxis</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>291</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>288</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Systemic - non-specified</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>330</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2010-11-10 22:38:20 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-04-27 10:49:51 +0100" MODIFIED_BY="[Empty name]">Adverse events leading to treatment discontinuation</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Sublingual immunotherapy</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>n</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>AE description</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>N</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>n</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>AE description</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Andre-2003" TYPE="STUDY">Andre 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sublingual burning</P>
<P>Oral pruritus, vomiting, headache</P>
<P>Pruritus, lingual oedema, gastralgia, diarrhoea</P>
<P>Asthma and gastralgia</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>53</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gastralgia</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dahl-2006b" TYPE="STUDY">Dahl 2006b</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>316</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Angioedema on the base of the tongue</P>
<P>Inferior lip angioedema pharyngeal hyperemia, cough, mild dyspnoea</P>
<P>Pharynx oedema, voice changes</P>
<P>Swelling throat</P>
<P>Angioedema of lips </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>318</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Durham-2006" TYPE="STUDY">Durham 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>141</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>136</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Khinchi-2004" TYPE="STUDY">Khinchi 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain in fingers and visible veins</P>
<P>Gastrointestinal complaints</P>
<P>Itching in the mouth</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain and weakness in both arms</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-La-Rosa-1999" TYPE="STUDY">La Rosa 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lima-2002" TYPE="STUDY">Lima 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Troublesome local side effects</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Malling-2005" TYPE="STUDY">Malling 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sting and blisters in the mouth</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mouth itching</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pajno-2003" TYPE="STUDY">Pajno 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Systemic reaction (abdominal pain, shortness of breath, wheezing)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pradalier-1999" TYPE="STUDY">Pradalier 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Worsening symptoms</P>
<P>Marked reactions</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Worsening symptoms</P>
<P>Marked reactions</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rolinck_x002d_Werninghaus-2004" TYPE="STUDY">Rolinck-Werninghaus 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>49</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute asthma exacerbation needed hospitalisation</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Smith-2004" TYPE="STUDY">Smith 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 patients with systemic but not life-threatening AE</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>45</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Insufficient data</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tonnel-2004" TYPE="STUDY">Tonnel 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Itching/burning of the mouth</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Respiratory tract infection</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vervloet-2006" TYPE="STUDY">Vervloet 2006</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gastric pain and vomiting</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>38</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vourdas-1998" TYPE="STUDY">Vourdas 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>33</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Worsening of allergic disease</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>29</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Voltolini-2001" TYPE="STUDY">Voltolini 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Exacerbation of rhinitis and OAS</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dyspnoea</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-11-10 16:30:57 +0000" MODIFIED_BY="Suzana Radulovic">
<COMPARISON ID="CMP-001" MODIFIED="2010-05-12 15:01:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>SLIT versus placebo - all</NAME>
<CONT_OUTCOME CHI2="256.7550066090828" CI_END="-0.3365882409800958" CI_START="-0.6374256834638432" CI_STUDY="95" CI_TOTAL="95" DF="48" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4870069622219695" ESTIMABLE="YES" I2="81.30513572688324" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2010-05-12 14:37:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="1.0" P_Z="2.213778351273104E-10" Q="0.0" RANDOM="YES" SCALE="2.813384963909976" SORT_BY="STUDY" STUDIES="49" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2038137136462851" TOTALS="YES" TOTAL_1="2333" TOTAL_2="2256" UNITS="" WEIGHT="99.99999999999997" Z="6.345726770542443">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:41:23 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="645" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.8681349936675913"/>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="1" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="2.401116832474392"/>
<CONT_DATA CI_END="-0.9324135386472658" CI_START="-3.1925312217374806" EFFECT_SIZE="-2.0624723801923732" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" ORDER="2" SD_1="1.75" SD_2="1.57" SE="0.576571228072999" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.0983527466105767"/>
<CONT_DATA CI_END="1.3357360175712891" CI_START="-0.7097239111000927" EFFECT_SIZE="0.31300605323559816" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" ORDER="3" SD_1="0.4" SD_2="0.38" SE="0.5218105906041408" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="1.2371131277100431"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="4" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="2.285084813058597"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="5" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="2.5153572311207264"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:10:25 +0100" MODIFIED_BY="[Empty name]" ORDER="501" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="2.6683835572672585"/>
<CONT_DATA CI_END="0.2389221843349218" CI_START="-1.12409284982667" EFFECT_SIZE="-0.44258533274587414" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" ORDER="6" SD_1="3.7" SD_2="3.8" SE="0.3477143062099305" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.8138441360790514"/>
<CONT_DATA CI_END="-2.4281421645013817" CI_START="-3.2721552237414437" EFFECT_SIZE="-2.8501486941214127" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2009-07-15 18:24:22 +0100" MODIFIED_BY="[Empty name]" ORDER="544" SD_1="0.88" SD_2="0.46" SE="0.21531341032221238" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="2.354323632583029"/>
<CONT_DATA CI_END="0.11694054246356766" CI_START="-2.109699173491202" EFFECT_SIZE="-0.9963793155138172" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" ORDER="7" SD_1="3.56" SD_2="7.1" SE="0.5680307734015062" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="1.118746703623628"/>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" MODIFIED="2010-04-28 16:43:26 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="8" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="1.7064663433542875"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="9" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="2.321650992826896"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="10" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="2.7901669759542997"/>
<CONT_DATA CI_END="0.2910027693610696" CI_START="-0.6224820829564097" EFFECT_SIZE="-0.16573965679767005" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" ORDER="37" SD_1="15.88" SD_2="18.76" SE="0.23303613217460403" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="2.281847933864017"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="11" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="1.6934694151809122"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:39:56 +0000" MODIFIED_BY="[Empty name]" ORDER="475" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="2.6985940843753182"/>
<CONT_DATA CI_END="0.3900717854035153" CI_START="-0.9166799153692561" EFFECT_SIZE="-0.2633040649828704" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" ORDER="12" SD_1="24.2" SD_2="30.4" SE="0.3333611512967233" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="1.8701443567264493"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="13" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="2.4050884615855153"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="14" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="2.685756933816186"/>
<CONT_DATA CI_END="-0.2839711550665126" CI_START="-1.7232247022187397" EFFECT_SIZE="-1.0035979286426262" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" ORDER="15" SD_1="92.46" SD_2="114.2" SE="0.3671632638418041" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="1.7393688710599506"/>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="16" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="2.260022601738867"/>
<CONT_DATA CI_END="1.3601974313483065" CI_START="-0.3502275731217155" EFFECT_SIZE="0.5049849291132955" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="17" SD_1="1.13" SD_2="0.47" SE="0.43634092717050826" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="1.4941119533814677"/>
<CONT_DATA CI_END="-0.09342349292870544" CI_START="-1.043625167434067" EFFECT_SIZE="-0.5685243301813863" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" ORDER="18" SD_1="3.05" SD_2="3.6" SE="0.24240284056248768" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="2.2431472483254757"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="19" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.8058901673356085"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="20" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.139879209664761"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="21" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="1.5793535849251976"/>
<CONT_DATA CI_END="0.06680778818890176" CI_START="-1.1840691643188954" EFFECT_SIZE="-0.5586306880649968" ESTIMABLE="YES" MEAN_1="12.15" MEAN_2="18.67" ORDER="23" SD_1="8.68" SD_2="13.56" SE="0.31910712706318967" STUDY_ID="STD-Nelson-1993" TOTAL_1="20" TOTAL_2="21" WEIGHT="1.9270502794229605"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:43:23 +0100" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="2.568125206670948"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="24" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="1.6053838123457747"/>
<CONT_DATA CI_END="0.1271975369072953" CI_START="-1.2693933260669417" EFFECT_SIZE="-0.5710978945798232" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2009-03-26 17:17:04 +0000" MODIFIED_BY="[Empty name]" ORDER="483" SD_1="32.61" SD_2="50.48" SE="0.35627972605373553" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.7807752843324671"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2009-07-15 19:12:45 +0100" MODIFIED_BY="[Empty name]" ORDER="553" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="1.7018438559006965"/>
<CONT_DATA CI_END="-0.25946655506244953" CI_START="-2.275227346673512" EFFECT_SIZE="-1.2673469508679807" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" ORDER="25" SD_1="27.8" SD_2="45.7" SE="0.5142341409105284" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.2578515373332202"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="26" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.7469504286950164"/>
<CONT_DATA CI_END="-1.0351060875007732" CI_START="-2.2589958787867506" EFFECT_SIZE="-1.6470509831437619" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" ORDER="27" SD_1="0.23" SD_2="0.2" SE="0.31222252065340583" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="1.954849594356094"/>
<CONT_DATA CI_END="0.11249849116097704" CI_START="-0.2983425118174112" EFFECT_SIZE="-0.09292201032821709" ESTIMABLE="YES" MEAN_1="0.732" MEAN_2="0.78" MODIFIED="2010-01-08 15:11:23 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="663" SD_1="0.483" SD_2="0.544" SE="0.10480830418799775" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="2.742056314959166"/>
<CONT_DATA CI_END="-0.26608581280902066" CI_START="-1.1198082314680609" EFFECT_SIZE="-0.6929470221385408" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-01-08 15:10:51 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="529" SD_1="123.0" SD_2="133.6" SE="0.21779033323905278" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="2.344271207572148"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="28" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="2.4990425949773734"/>
<CONT_DATA CI_END="0.49320872759750967" CI_START="-0.40042776067015406" EFFECT_SIZE="0.04639048346367782" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="29" SD_1="23.12" SD_2="21.65" SE="0.2279726809565263" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="2.3026720725939183"/>
<CONT_DATA CI_END="0.11967300323055935" CI_START="-0.48860750084457977" EFFECT_SIZE="-0.1844672488070102" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2009-03-30 18:04:07 +0100" MODIFIED_BY="[Empty name]" ORDER="495" SD_1="1.48" SD_2="1.66" SE="0.15517644938202388" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="2.584495442680938"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="30" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="2.3969304290748417"/>
<CONT_DATA CI_END="-1.577152453569599" CI_START="-2.9099418458130546" EFFECT_SIZE="-2.243547149691327" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" ORDER="31" SD_1="1.5" SD_2="2.0" SE="0.340003541584521" STUDY_ID="STD-Tari-1990" TOTAL_1="30" TOTAL_2="28" WEIGHT="1.8439569176867978"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="32" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="1.482174301589907"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="33" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="1.7642278966843985"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="39" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="2.1212003929201724"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="38" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.90420065864919"/>
<CONT_DATA CI_END="1.0964805451389883" CI_START="-0.3491814293029491" EFFECT_SIZE="0.3736495579180196" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" ORDER="34" SD_1="154.0" SD_2="79.0" SE="0.36879809676227077" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.7332105291434345"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="35" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="2.2250979469649828"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:29:24 +0100" MODIFIED_BY="[Empty name]" ORDER="515" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="2.686827471067337"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="36" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="1.751388916068103"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="73.32233692806574" CI_END="-0.21129423120417318" CI_START="-0.4288819990579002" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3200881151310367" ESTIMABLE="YES" I2="49.53788770221611" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-02-09 12:32:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="3.4727507525877943E-4" P_Q="1.0" P_Z="8.092921297341646E-9" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="38" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04763086554970947" TOTALS="YES" TOTAL_1="1737" TOTAL_2="1642" UNITS="" WEIGHT="100.0" Z="5.766511451672089">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2009-11-24 16:46:13 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="646" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.9163072332466191"/>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="40" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="3.461406713724241"/>
<CONT_DATA CI_END="0.1989982019519022" CI_START="-1.621790652209877" EFFECT_SIZE="-0.7113962251289874" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" ORDER="41" SD_1="2.1" SD_2="4.9" SE="0.4644954878058804" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.1698187300538334"/>
<CONT_DATA CI_END="0.7565279698154648" CI_START="-1.2841058123860154" EFFECT_SIZE="-0.26378892128527526" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" ORDER="42" SD_1="1.04" SD_2="1.25" SE="0.5205794081671242" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="0.9669877157313935"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="43" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="3.0674612432103894"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="44" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="3.9327153668118817"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:11:22 +0100" MODIFIED_BY="[Empty name]" ORDER="502" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="4.778879188625486"/>
<CONT_DATA CI_END="0.5410421460977246" CI_START="-0.8051383415261049" EFFECT_SIZE="-0.13204809771419013" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" ORDER="45" SD_1="6.4" SD_2="6.9" SE="0.34341970011753514" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.8609576643218269"/>
<CONT_DATA CI_END="0.1735044751837487" CI_START="-0.4183562536348525" EFFECT_SIZE="-0.12242588922555189" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.18" MODIFIED="2009-07-15 18:29:45 +0100" MODIFIED_BY="[Empty name]" ORDER="549" SD_1="0.1" SD_2="1.92" SE="0.15098765423424182" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="4.37488436497436"/>
<CONT_DATA CI_END="0.8608625700733046" CI_START="-1.2102449762899692" EFFECT_SIZE="-0.17469120310833228" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" ORDER="46" SD_1="2.46" SD_2="2.22" SE="0.5283534704463719" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.94285810968954"/>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="47" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="1.5923576584921393"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="48" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="3.195886604374198"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="49" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="5.620643473619794"/>
<CONT_DATA CI_END="-0.10316912578131382" CI_START="-1.0339955625298705" EFFECT_SIZE="-0.5685823441555922" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" ORDER="70" SD_1="5.37" SD_2="8.23" SE="0.2374600870451694" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="2.9621266240384725"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="50" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="1.4419585636619718"/>
<CONT_DATA CI_END="0.12484259691974253" CI_START="-1.1960243659651422" EFFECT_SIZE="-0.5355908845226999" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" ORDER="51" SD_1="18.7" SD_2="26.4" SE="0.3369620496355328" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="1.9116880218201908"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="52" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="3.500271397089588"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="53" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="4.877792621714344"/>
<CONT_DATA CI_END="-0.542566709882387" CI_START="-2.0392054480960766" EFFECT_SIZE="-1.2908860789892318" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" ORDER="54" SD_1="25.72" SD_2="50.3" SE="0.38180261219567935" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="1.593114914726579"/>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="55" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="2.9644012559287662"/>
<CONT_DATA CI_END="0.10957132427633204" CI_START="-0.828869771805423" EFFECT_SIZE="-0.35964922376454544" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" ORDER="56" SD_1="0.37" SD_2="0.45" SE="0.23940263787601673" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="2.9359803534019386"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="57" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.8235839636039228"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="58" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.578650469464794"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="59" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="1.3484407841111326"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:45:11 +0100" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="4.253384141898656"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="61" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="1.345489108484194"/>
<CONT_DATA CI_END="0.1400226517700135" CI_START="-1.255120010640152" EFFECT_SIZE="-0.5575486794350692" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2009-03-26 17:25:30 +0000" MODIFIED_BY="[Empty name]" ORDER="490" SD_1="32.98" SD_2="65.05" SE="0.35591028034567795" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.767697450158921"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="62" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.620700400681183"/>
<CONT_DATA CI_END="-0.8011057902380112" CI_START="-1.976804225352927" EFFECT_SIZE="-1.388955007795469" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" ORDER="63" SD_1="44.0" SD_2="35.0" SE="0.29992858144044354" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.2394025128886654"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="64" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="3.877597215815541"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="65" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="3.0924645766726564"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="66" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="1.3217355682145169"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="67" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="1.6875796987496652"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="72" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="2.5737304578861497"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="71" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.9993961491430021"/>
<CONT_DATA CI_END="0.21336772239412094" CI_START="-1.2451382933933233" EFFECT_SIZE="-0.5158852854996011" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" ORDER="68" SD_1="30.0" SD_2="34.0" SE="0.37207469813015787" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.6559048595652328"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="69" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="2.842943191731419"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:30:55 +0100" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.902801631672812"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-05-12 14:37:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>SLIT versus placebo - seasonal allergen</NAME>
<CONT_OUTCOME CHI2="68.54242513629183" CI_END="-0.2495150352218552" CI_START="-0.43755718792011516" CI_STUDY="95" CI_TOTAL="95" DF="38" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3435361115709852" ESTIMABLE="YES" I2="44.559884006964076" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-05-12 14:37:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0017317737473574457" P_Q="1.0" P_Z="7.988285600763175E-13" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="39" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03287993942162923" TOTALS="YES" TOTAL_1="2081" TOTAL_2="2003" UNITS="" WEIGHT="100.0" Z="7.161356072630148">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:44:13 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="647" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="1.594198637812017"/>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="73" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="3.0944907949208966"/>
<CONT_DATA CI_END="-0.9324135386472658" CI_START="-3.1925312217374806" EFFECT_SIZE="-2.0624723801923732" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" ORDER="74" SD_1="1.75" SD_2="1.57" SE="0.576571228072999" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.6299231341064416"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="75" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="2.6505362335844307"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="76" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="3.639776340214044"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:15:48 +0100" MODIFIED_BY="[Empty name]" ORDER="503" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="4.62132771462525"/>
<CONT_DATA CI_END="0.2389221843349218" CI_START="-1.12409284982667" EFFECT_SIZE="-0.44258533274587414" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" ORDER="77" SD_1="3.7" SD_2="3.8" SE="0.3477143062099305" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.4963726961628248"/>
<CONT_DATA CI_END="0.11694054246356766" CI_START="-2.109699173491202" EFFECT_SIZE="-0.9963793155138172" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" ORDER="78" SD_1="3.56" SD_2="7.1" SE="0.5680307734015062" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.6472426571550849"/>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" ORDER="79" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="1.3208749275819687"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="80" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="2.780552761827801"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="81" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="5.729940673724021"/>
<CONT_DATA CI_END="0.2910027693610696" CI_START="-0.6224820829564097" EFFECT_SIZE="-0.16573965679767005" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" ORDER="99" SD_1="15.88" SD_2="18.76" SE="0.23303613217460403" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="2.639420626999006"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="82" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="1.3010920842010338"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:40:29 +0000" MODIFIED_BY="[Empty name]" ORDER="476" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="4.8626313956264715"/>
<CONT_DATA CI_END="0.3900717854035153" CI_START="-0.9166799153692561" EFFECT_SIZE="-0.2633040649828704" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" ORDER="83" SD_1="24.2" SD_2="30.4" SE="0.3333611512967233" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="1.5979486582034386"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="84" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="3.1114391750503496"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="85" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="4.757751837755289"/>
<CONT_DATA CI_END="-0.2839711550665126" CI_START="-1.7232247022187397" EFFECT_SIZE="-1.0035979286426262" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" ORDER="86" SD_1="92.46" SD_2="114.2" SE="0.3671632638418041" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="1.372303572433163"/>
<CONT_DATA CI_END="-0.09342349292870544" CI_START="-1.043625167434067" EFFECT_SIZE="-0.5685243301813863" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" ORDER="87" SD_1="3.05" SD_2="3.6" SE="0.24240284056248768" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="2.5111551794588696"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="88" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.4825845721703566"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="89" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.2061045811619917"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:46:52 +0100" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="3.9395767166198694"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="90" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="1.1743798188572903"/>
<CONT_DATA CI_END="0.1271975369072953" CI_START="-1.2693933260669417" EFFECT_SIZE="-0.5710978945798232" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2010-02-09 15:31:38 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="484" SD_1="32.61" SD_2="50.48" SE="0.35627972605373553" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.4399128913140578"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2009-07-15 19:13:38 +0100" MODIFIED_BY="[Empty name]" ORDER="554" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="1.313805173385037"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="91" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.3844364194725998"/>
<CONT_DATA CI_END="0.11249849116097704" CI_START="-0.2983425118174112" EFFECT_SIZE="-0.09292201032821709" ESTIMABLE="YES" MEAN_1="0.732" MEAN_2="0.78" MODIFIED="2010-01-08 15:12:14 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="665" SD_1="0.483" SD_2="0.544" SE="0.10480830418799775" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="5.246128128169746"/>
<CONT_DATA CI_END="-0.26608581280902066" CI_START="-1.1198082314680609" EFFECT_SIZE="-0.6929470221385408" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-02-09 15:31:34 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="659" SD_1="123.0" SD_2="133.6" SE="0.21779033323905278" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="2.865304216756356"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="92" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="3.553849056298234"/>
<CONT_DATA CI_END="0.49320872759750967" CI_START="-0.40042776067015406" EFFECT_SIZE="0.04639048346367782" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="93" SD_1="23.12" SD_2="21.65" SE="0.2279726809565263" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="2.7120320635621815"/>
<CONT_DATA CI_END="0.11967300323055935" CI_START="-0.48860750084457977" EFFECT_SIZE="-0.1844672488070102" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2009-03-30 18:04:33 +0100" MODIFIED_BY="[Empty name]" ORDER="496" SD_1="1.48" SD_2="1.66" SE="0.15517644938202388" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="4.040050481820407"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="94" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="3.076764857890099"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="95" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="1.4124945000742821"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="101" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="2.156007985757395"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="100" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="1.6629940461459751"/>
<CONT_DATA CI_END="1.0964805451389883" CI_START="-0.3491814293029491" EFFECT_SIZE="0.3736495579180196" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" ORDER="96" SD_1="154.0" SD_2="79.0" SE="0.36879809676227077" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.3625273839482184"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="97" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="2.454115718127731"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:33:04 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="4.766362518788486"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="98" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="1.3915897682372989"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="55.79775403752866" CI_END="-0.1900555300152088" CI_START="-0.40961586130101213" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29983569565811047" ESTIMABLE="YES" I2="44.442208230908534" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-04-28 09:33:59 +0100" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.004085681779455563" P_Q="1.0" P_Z="8.644714728947823E-8" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="32" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0368795728994978" TOTALS="YES" TOTAL_1="1557" TOTAL_2="1457" UNITS="" WEIGHT="99.99999999999999" Z="5.353126963581035">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2009-11-24 16:46:35 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="653" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="2.091031029818018"/>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="102" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="4.0086176175093895"/>
<CONT_DATA CI_END="0.1989982019519022" CI_START="-1.621790652209877" EFFECT_SIZE="-0.7113962251289874" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" ORDER="103" SD_1="2.1" SD_2="4.9" SE="0.4644954878058804" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.2418152220864351"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="104" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="3.4977083102411024"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="105" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="4.641249393363243"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:18:50 +0100" MODIFIED_BY="[Empty name]" ORDER="509" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="5.839708291565983"/>
<CONT_DATA CI_END="0.5410421460977246" CI_START="-0.8051383415261049" EFFECT_SIZE="-0.13204809771419013" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" ORDER="106" SD_1="6.4" SD_2="6.9" SE="0.34341970011753514" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.0264406013295306"/>
<CONT_DATA CI_END="0.8608625700733046" CI_START="-1.2102449762899692" EFFECT_SIZE="-0.17469120310833228" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" ORDER="107" SD_1="2.46" SD_2="2.22" SE="0.5283534704463719" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.9926901262367591"/>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="108" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="1.7167481806486982"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="109" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="3.662526807556295"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="110" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="7.119287912713242"/>
<CONT_DATA CI_END="-0.10316912578131382" CI_START="-1.0339955625298705" EFFECT_SIZE="-0.5685823441555922" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" ORDER="126" SD_1="5.37" SD_2="8.23" SE="0.2374600870451694" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="3.363753778029134"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="111" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="1.5460095520773565"/>
<CONT_DATA CI_END="0.12484259691974253" CI_START="-1.1960243659651422" EFFECT_SIZE="-0.5355908845226999" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" ORDER="112" SD_1="18.7" SD_2="26.4" SE="0.3369620496355328" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="2.0856303963015232"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="113" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="4.059888491219861"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="114" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="5.985371322597445"/>
<CONT_DATA CI_END="-0.542566709882387" CI_START="-2.0392054480960766" EFFECT_SIZE="-1.2908860789892318" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" ORDER="115" SD_1="25.72" SD_2="50.3" SE="0.38180261219567935" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="1.7176126471270983"/>
<CONT_DATA CI_END="0.10957132427633204" CI_START="-0.828869771805423" EFFECT_SIZE="-0.35964922376454544" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" ORDER="116" SD_1="0.37" SD_2="0.45" SE="0.23940263787601673" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="3.3306734022736046"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="117" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.9829778919854049"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="118" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.8852256718443297"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:50:50 +0100" MODIFIED_BY="[Empty name]" ORDER="538" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="5.085647174297197"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="119" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="1.4374837104333547"/>
<CONT_DATA CI_END="0.1400226517700135" CI_START="-1.255120010640152" EFFECT_SIZE="-0.5575486794350692" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2009-03-26 17:25:46 +0000" MODIFIED_BY="[Empty name]" ORDER="491" SD_1="32.98" SD_2="65.05" SE="0.35591028034567795" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.9182116191137206"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="120" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.7491366208536676"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="121" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="4.566022422497846"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="122" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="3.5296672711924986"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="123" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="1.825832225226875"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="128" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="2.8791775571338145"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="127" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.1884955259931913"/>
<CONT_DATA CI_END="0.21336772239412094" CI_START="-1.2451382933933233" EFFECT_SIZE="-0.5158852854996011" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" ORDER="124" SD_1="30.0" SD_2="34.0" SE="0.37207469813015787" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.789460908139118"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="125" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="3.2135058209504916"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:39:22 +0100" MODIFIED_BY="[Empty name]" ORDER="523" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="6.022392497643764"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-05-12 14:38:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>SLIT versus placebo - perennial allergen</NAME>
<CONT_OUTCOME CHI2="115.91067673402875" CI_END="-0.1678328829076955" CI_START="-1.6866510655300644" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.92724197421888" ESTIMABLE="YES" I2="92.2354003500026" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-05-12 14:38:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="9.992007221626409E-16" P_Q="1.0" P_Z="0.016705549026796607" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.3542577378107543" TOTALS="YES" TOTAL_1="252" TOTAL_2="253" UNITS="" WEIGHT="100.0" Z="2.393124990490954">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3357360175712891" CI_START="-0.7097239111000927" EFFECT_SIZE="0.31300605323559816" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" ORDER="129" SD_1="0.4" SD_2="0.38" SE="0.5218105906041408" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="9.229742353288144"/>
<CONT_DATA CI_END="-2.4281421645013817" CI_START="-3.2721552237414437" EFFECT_SIZE="-2.8501486941214127" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2009-07-15 18:24:59 +0100" MODIFIED_BY="[Empty name]" ORDER="545" SD_1="0.88" SD_2="0.46" SE="0.21531341032221238" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="10.718544661445982"/>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="130" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="10.639251344191436"/>
<CONT_DATA CI_END="1.3601974313483065" CI_START="-0.3502275731217155" EFFECT_SIZE="0.5049849291132955" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="131" SD_1="1.13" SD_2="0.47" SE="0.43634092717050826" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="9.719076309427141"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="132" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="9.854818567195977"/>
<CONT_DATA CI_END="0.06680778818890176" CI_START="-1.1840691643188954" EFFECT_SIZE="-0.5586306880649968" ESTIMABLE="YES" MEAN_1="12.15" MEAN_2="18.67" ORDER="134" SD_1="8.68" SD_2="13.56" SE="0.31910712706318967" STUDY_ID="STD-Nelson-1993" TOTAL_1="20" TOTAL_2="21" WEIGHT="10.310222763004909"/>
<CONT_DATA CI_END="-0.25946655506244953" CI_START="-2.275227346673512" EFFECT_SIZE="-1.2673469508679807" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" ORDER="135" SD_1="27.8" SD_2="45.7" SE="0.5142341409105284" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="9.27450017481738"/>
<CONT_DATA CI_END="-1.0351060875007732" CI_START="-2.2589958787867506" EFFECT_SIZE="-1.6470509831437619" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" ORDER="136" SD_1="0.23" SD_2="0.2" SE="0.31222252065340583" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="10.341091176952313"/>
<CONT_DATA CI_END="-1.577152453569599" CI_START="-2.9099418458130546" EFFECT_SIZE="-2.243547149691327" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" ORDER="137" SD_1="1.5" SD_2="2.0" SE="0.340003541584521" STUDY_ID="STD-Tari-1990" TOTAL_1="30" TOTAL_2="28" WEIGHT="10.213612747828078"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="138" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="9.699139901848636"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.210817004256814" CI_END="0.017579571597698185" CI_START="-0.8855828799073687" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.43400165415483527" ESTIMABLE="YES" I2="70.9485029167219" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-02-09 12:32:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.004116858787397537" P_Q="1.0" P_Z="0.0596103449848517" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.20536305690536216" TOTALS="YES" TOTAL_1="180" TOTAL_2="185" UNITS="" WEIGHT="100.0" Z="1.8836646938914805">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7565279698154648" CI_START="-1.2841058123860154" EFFECT_SIZE="-0.26378892128527526" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" ORDER="139" SD_1="1.04" SD_2="1.25" SE="0.5205794081671242" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="11.143839236815777"/>
<CONT_DATA CI_END="0.1735044751837487" CI_START="-0.4183562536348525" EFFECT_SIZE="-0.12242588922555189" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.18" MODIFIED="2009-07-15 18:30:03 +0100" MODIFIED_BY="[Empty name]" ORDER="550" SD_1="0.1" SD_2="1.92" SE="0.15098765423424182" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="23.266734837557376"/>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="140" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="20.28713651472806"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="141" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="13.744541073331359"/>
<CONT_DATA CI_END="-0.8011057902380112" CI_START="-1.976804225352927" EFFECT_SIZE="-1.388955007795469" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" ORDER="143" SD_1="44.0" SD_2="35.0" SE="0.29992858144044354" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="17.975558974419176"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="144" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="13.582189363148249"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-05-12 14:38:28 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>SLIT versus placebo - adults</NAME>
<CONT_OUTCOME CHI2="77.80638791659189" CI_END="-0.3131874095296183" CI_START="-0.5618425184446364" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.43751496398712736" ESTIMABLE="YES" I2="57.587029955206425" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-05-12 14:38:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.754354178684636E-5" P_Q="1.0" P_Z="5.3032796305911765E-12" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="34" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.06370823765789978" TOTALS="YES" TOTAL_1="1631" TOTAL_2="1566" UNITS="" WEIGHT="100.0" Z="6.897212575714081">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:44:30 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="648" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="2.297007375312709"/>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="145" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="3.825190053740305"/>
<CONT_DATA CI_END="-0.9324135386472658" CI_START="-3.1925312217374806" EFFECT_SIZE="-2.0624723801923732" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" ORDER="146" SD_1="1.75" SD_2="1.57" SE="0.576571228072999" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.01575047008681"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="147" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="3.420207170560553"/>
<CONT_DATA CI_END="0.11694054246356766" CI_START="-2.109699173491202" EFFECT_SIZE="-0.9963793155138172" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" ORDER="148" SD_1="3.56" SD_2="7.1" SE="0.5680307734015062" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="1.0414498282797946"/>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" ORDER="149" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="1.9623978622262832"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="150" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="3.542444776717758"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="151" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="5.6682100635396315"/>
<CONT_DATA CI_END="0.2910027693610696" CI_START="-0.6224820829564097" EFFECT_SIZE="-0.16573965679767005" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" ORDER="170" SD_1="15.88" SD_2="18.76" SE="0.23303613217460403" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="3.4096106405728626"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="152" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="1.9373694018372443"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:40:53 +0000" MODIFIED_BY="[Empty name]" ORDER="477" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="5.148680732749356"/>
<CONT_DATA CI_END="0.3900717854035153" CI_START="-0.9166799153692561" EFFECT_SIZE="-0.2633040649828704" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" ORDER="153" SD_1="24.2" SD_2="30.4" SE="0.3333611512967233" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="2.301457881922985"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="172" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="3.8399768799290803"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="154" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="5.080859371166992"/>
<CONT_DATA CI_END="-0.2839711550665126" CI_START="-1.7232247022187397" EFFECT_SIZE="-1.0035979286426262" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" ORDER="155" SD_1="92.46" SD_2="114.2" SE="0.3671632638418041" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="2.0269389952827352"/>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="156" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="3.3390825182332864"/>
<CONT_DATA CI_END="-0.09342349292870544" CI_START="-1.043625167434067" EFFECT_SIZE="-0.5685243301813863" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" ORDER="157" SD_1="3.05" SD_2="3.6" SE="0.24240284056248768" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="3.285626493741376"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="158" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.9775457696364644"/>
<CONT_DATA CI_END="0.06680778818890176" CI_START="-1.1840691643188954" EFFECT_SIZE="-0.5586306880649968" ESTIMABLE="YES" MEAN_1="12.15" MEAN_2="18.67" ORDER="160" SD_1="8.68" SD_2="13.56" SE="0.31910712706318967" STUDY_ID="STD-Nelson-1993" TOTAL_1="20" TOTAL_2="21" WEIGHT="2.4307592981975197"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:47:23 +0100" MODIFIED_BY="[Empty name]" ORDER="533" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="4.508954723595563"/>
<CONT_DATA CI_END="0.1271975369072953" CI_START="-1.2693933260669417" EFFECT_SIZE="-0.5710978945798232" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2009-03-26 17:22:49 +0000" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="32.61" SD_2="50.48" SE="0.35627972605373553" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.1106520367819868"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2010-02-12 15:55:09 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="665" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="1.953466446118594"/>
<CONT_DATA CI_END="-0.25946655506244953" CI_START="-2.275227346673512" EFFECT_SIZE="-1.2673469508679807" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" ORDER="161" SD_1="27.8" SD_2="45.7" SE="0.5142341409105284" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.2262325016139903"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="162" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0420559209307343"/>
<CONT_DATA CI_END="-1.0351060875007732" CI_START="-2.2589958787867506" EFFECT_SIZE="-1.6470509831437619" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" ORDER="163" SD_1="0.23" SD_2="0.2" SE="0.31222252065340583" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="2.496303773352577"/>
<CONT_DATA CI_END="0.11249849116097704" CI_START="-0.2983425118174112" EFFECT_SIZE="-0.09292201032821709" ESTIMABLE="YES" MEAN_1="0.732" MEAN_2="0.78" MODIFIED="2010-01-08 15:13:09 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="669" SD_1="0.483" SD_2="0.544" SE="0.10480830418799775" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="5.387144078606106"/>
<CONT_DATA CI_END="-0.26608581280902066" CI_START="-1.1198082314680609" EFFECT_SIZE="-0.6929470221385408" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-02-09 15:32:34 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="661" SD_1="123.0" SD_2="133.6" SE="0.21779033323905278" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="3.620468890982117"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="164" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="4.209871140276938"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="165" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="3.809673967535207"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="166" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="1.5640053574983948"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="167" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="2.076856620873039"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="171" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="2.378071612075058"/>
<CONT_DATA CI_END="1.0964805451389883" CI_START="-0.3491814293029491" EFFECT_SIZE="0.3736495579180196" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" ORDER="168" SD_1="154.0" SD_2="79.0" SE="0.36879809676227077" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.0147281166916056"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="169" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="2.050949229334339"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="47.76296094774287" CI_END="-0.2637750809289896" CI_START="-0.5316744863678564" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.397724783648423" ESTIMABLE="YES" I2="47.65818637719648" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-02-09 12:32:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.003981031871557517" P_Q="1.0" P_Z="5.900822341680627E-9" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.047917712427049515" TOTALS="YES" TOTAL_1="1168" TOTAL_2="1067" UNITS="" WEIGHT="100.0" Z="5.819544469931851">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2009-11-24 16:46:54 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="654" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="2.8997835365413582"/>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="173" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="5.230340020614658"/>
<CONT_DATA CI_END="0.1989982019519022" CI_START="-1.621790652209877" EFFECT_SIZE="-0.7113962251289874" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" ORDER="174" SD_1="2.1" SD_2="4.9" SE="0.4644954878058804" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.7714153201349614"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="175" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="4.6367659181962715"/>
<CONT_DATA CI_END="0.8608625700733046" CI_START="-1.2102449762899692" EFFECT_SIZE="-0.17469120310833228" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" ORDER="176" SD_1="2.46" SD_2="2.22" SE="0.5283534704463719" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="1.4280382508730731"/>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="177" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="2.4103040282199717"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="178" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="4.830317467187141"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="179" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="8.476059347943051"/>
<CONT_DATA CI_END="-0.10316912578131382" CI_START="-1.0339955625298705" EFFECT_SIZE="-0.5685823441555922" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" ORDER="194" SD_1="5.37" SD_2="8.23" SE="0.2374600870451694" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="4.477980276698875"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="180" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="2.1829546288662827"/>
<CONT_DATA CI_END="0.12484259691974253" CI_START="-1.1960243659651422" EFFECT_SIZE="-0.5355908845226999" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" ORDER="181" SD_1="18.7" SD_2="26.4" SE="0.3369620496355328" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="2.8928060976529535"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="196" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="5.288875544262379"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="182" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="7.360887318563494"/>
<CONT_DATA CI_END="-0.542566709882387" CI_START="-2.0392054480960766" EFFECT_SIZE="-1.2908860789892318" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" ORDER="183" SD_1="25.72" SD_2="50.3" SE="0.38180261219567935" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="2.411448566749854"/>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="184" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.481409476377485"/>
<CONT_DATA CI_END="0.10957132427633204" CI_START="-0.828869771805423" EFFECT_SIZE="-0.35964922376454544" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" ORDER="185" SD_1="0.37" SD_2="0.45" SE="0.23940263787601673" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="4.438561525416967"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="186" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="3.899650466825608"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:51:20 +0100" MODIFIED_BY="[Empty name]" ORDER="539" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Pajno-2003" TOTAL_1="123" TOTAL_2="60" WEIGHT="6.422333218513952"/>
<CONT_DATA CI_END="0.1400226517700135" CI_START="-1.255120010640152" EFFECT_SIZE="-0.5575486794350692" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2009-03-26 17:26:00 +0000" MODIFIED_BY="[Empty name]" ORDER="492" SD_1="32.98" SD_2="65.05" SE="0.35591028034567795" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.675274555328616"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="188" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.4531409533859247"/>
<CONT_DATA CI_END="-0.8011057902380112" CI_START="-1.976804225352927" EFFECT_SIZE="-1.388955007795469" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" ORDER="189" SD_1="44.0" SD_2="35.0" SE="0.29992858144044354" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="3.3876787627460403"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="190" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="5.85696038088569"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="191" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="2.001174920631112"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="192" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="2.5542126808279613"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="195" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.0252812738622628"/>
<CONT_DATA CI_END="0.21336772239412094" CI_START="-1.2451382933933233" EFFECT_SIZE="-0.5158852854996011" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" ORDER="193" SD_1="30.0" SD_2="34.0" SE="0.37207469813015787" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="2.5063454626940445"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-11-10 16:30:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="5">
<NAME>SLIT versus placebo - children</NAME>
<CONT_OUTCOME CHI2="177.60077288613863" CI_END="-0.09993401996267698" CI_START="-0.9356854209403658" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5178097204515214" ESTIMABLE="YES" I2="92.11715142198422" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2010-11-10 16:30:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="1" P_CHI2="-1.3322676295501878E-15" P_Q="1.0" P_Z="0.015153696099852444" Q="0.0" RANDOM="YES" SCALE="5.06" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5908243599461468" TOTALS="YES" TOTAL_1="702" TOTAL_2="690" UNITS="" WEIGHT="100.0" Z="2.4286848977877544">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3357360175712891" CI_START="-0.7097239111000927" EFFECT_SIZE="0.31300605323559816" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" ORDER="197" SD_1="0.4" SD_2="0.38" SE="0.5218105906041408" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="5.266615058208371"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="198" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="7.317941443065209"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:16:16 +0100" MODIFIED_BY="[Empty name]" ORDER="504" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="7.4796366719003045"/>
<CONT_DATA CI_END="0.2389221843349218" CI_START="-1.12409284982667" EFFECT_SIZE="-0.44258533274587414" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" ORDER="199" SD_1="3.7" SD_2="3.8" SE="0.3477143062099305" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="6.386795725889519"/>
<CONT_DATA CI_END="-2.4281421645013817" CI_START="-3.2721552237414437" EFFECT_SIZE="-2.8501486941214127" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2009-07-15 18:25:25 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SD_1="0.88" SD_2="0.46" SE="0.21531341032221238" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="7.133998902239473"/>
<CONT_DATA CI_END="1.3601974313483065" CI_START="-0.3502275731217155" EFFECT_SIZE="0.5049849291132955" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="200" SD_1="1.13" SD_2="0.47" SE="0.43634092717050826" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="5.818699682048901"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="201" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="6.373987282614007"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="202" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="5.9816077778100905"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="203" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="6.029584946169316"/>
<CONT_DATA CI_END="0.49320872759750967" CI_START="-0.40042776067015406" EFFECT_SIZE="0.04639048346367782" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="204" SD_1="23.12" SD_2="21.65" SE="0.2279726809565263" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="7.07171831090795"/>
<CONT_DATA CI_END="0.11967300323055935" CI_START="-0.48860750084457977" EFFECT_SIZE="-0.1844672488070102" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2009-03-30 18:05:17 +0100" MODIFIED_BY="[Empty name]" ORDER="497" SD_1="1.48" SD_2="1.66" SE="0.15517644938202388" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="7.392488731083043"/>
<CONT_DATA CI_END="-1.577152453569599" CI_START="-2.9099418458130546" EFFECT_SIZE="-2.243547149691327" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" ORDER="206" SD_1="1.5" SD_2="2.0" SE="0.340003541584521" STUDY_ID="STD-Tari-1990" TOTAL_1="30" TOTAL_2="28" WEIGHT="6.434738550815493"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="207" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="6.8389006801768435"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="205" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="6.974954812159691"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:33:36 +0100" MODIFIED_BY="[Empty name]" ORDER="518" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="7.49833142491179"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.310972945990176" CI_END="0.0037792810170766133" CI_START="-0.3201363764545814" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1581785477187524" ESTIMABLE="YES" I2="36.456488989268614" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2009-07-15 18:30:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09900777813178485" P_Q="1.0" P_Z="0.055590993223506635" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.026240785359929006" TOTALS="YES" TOTAL_1="569" TOTAL_2="575" UNITS="" WEIGHT="100.0" Z="1.9142282844584726">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7565279698154648" CI_START="-1.2841058123860154" EFFECT_SIZE="-0.26378892128527526" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" ORDER="208" SD_1="1.04" SD_2="1.25" SE="0.5205794081671242" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="2.29718008639789"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="209" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="11.98847968649678"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:19:15 +0100" MODIFIED_BY="[Empty name]" ORDER="510" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="15.848542802675409"/>
<CONT_DATA CI_END="0.5410421460977246" CI_START="-0.8051383415261049" EFFECT_SIZE="-0.13204809771419013" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" ORDER="210" SD_1="6.4" SD_2="6.9" SE="0.34341970011753514" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="4.735971573318302"/>
<CONT_DATA CI_END="0.1735044751837487" CI_START="-0.4183562536348525" EFFECT_SIZE="-0.12242588922555189" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.18" MODIFIED="2009-07-15 18:30:22 +0100" MODIFIED_BY="[Empty name]" ORDER="551" SD_1="0.1" SD_2="1.92" SE="0.15098765423424182" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="13.924334725753562"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="211" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="4.627072469641469"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="212" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="3.2969522718998174"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="213" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="3.2889918316100015"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="214" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="8.726829644635371"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="216" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="6.944527631670541"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="215" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="7.849544306141318"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="524" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="16.471572969759535"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-05-12 14:39:07 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>SLIT versus placebo &lt; 6 months</NAME>
<CONT_OUTCOME CHI2="157.81734471741262" CI_END="-0.2068448257192334" CI_START="-0.8649367442018832" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5358907849605583" ESTIMABLE="YES" I2="89.86169737638815" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2010-05-12 14:39:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-1.3322676295501878E-15" P_Q="1.0" P_Z="0.0014127358902213507" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.39372337811134633" TOTALS="YES" TOTAL_1="890" TOTAL_2="882" UNITS="" WEIGHT="100.0" Z="3.192036275392385">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3357360175712891" CI_START="-0.7097239111000927" EFFECT_SIZE="0.31300605323559816" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" ORDER="217" SD_1="0.4" SD_2="0.38" SE="0.5218105906041408" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="4.23190984011847"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="218" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="6.296006594091343"/>
<CONT_DATA CI_END="0.2389221843349218" CI_START="-1.12409284982667" EFFECT_SIZE="-0.44258533274587414" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" ORDER="219" SD_1="3.7" SD_2="3.8" SE="0.3477143062099305" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="5.476751168173897"/>
<CONT_DATA CI_END="-2.4281421645013817" CI_START="-3.2721552237414437" EFFECT_SIZE="-2.8501486941214127" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2009-07-15 18:27:02 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SD_1="0.88" SD_2="0.46" SE="0.21531341032221238" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="6.4044539863748255"/>
<CONT_DATA CI_END="0.11694054246356766" CI_START="-2.109699173491202" EFFECT_SIZE="-0.9963793155138172" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" ORDER="220" SD_1="3.56" SD_2="7.1" SE="0.5680307734015062" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="3.934341664268859"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="221" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="6.353624532302857"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="222" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="5.241657837715153"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="223" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="6.482233124607475"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="224" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="6.887630583853303"/>
<CONT_DATA CI_END="-0.2839711550665126" CI_START="-1.7232247022187397" EFFECT_SIZE="-1.0035979286426262" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" ORDER="225" SD_1="92.46" SD_2="114.2" SE="0.3671632638418041" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="5.332679187668216"/>
<CONT_DATA CI_END="-0.09342349292870544" CI_START="-1.043625167434067" EFFECT_SIZE="-0.5685243301813863" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" ORDER="226" SD_1="3.05" SD_2="3.6" SE="0.24240284056248768" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="6.22895423293226"/>
<CONT_DATA CI_END="0.06680778818890176" CI_START="-1.1840691643188954" EFFECT_SIZE="-0.5586306880649968" ESTIMABLE="YES" MEAN_1="12.15" MEAN_2="18.67" ORDER="227" SD_1="8.68" SD_2="13.56" SE="0.31910712706318967" STUDY_ID="STD-Nelson-1993" TOTAL_1="20" TOTAL_2="21" WEIGHT="5.687574036144808"/>
<CONT_DATA CI_END="0.11249849116097704" CI_START="-0.2983425118174112" EFFECT_SIZE="-0.09292201032821709" ESTIMABLE="YES" MEAN_1="0.732" MEAN_2="0.78" MODIFIED="2010-01-08 15:13:53 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="670" SD_1="0.483" SD_2="0.544" SE="0.10480830418799775" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="6.964260091324027"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="228" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="6.622464806633923"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="230" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.6457894943213764"/>
<CONT_DATA CI_END="1.0964805451389883" CI_START="-0.3491814293029491" EFFECT_SIZE="0.3736495579180196" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" ORDER="229" SD_1="154.0" SD_2="79.0" SE="0.36879809676227077" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.320567216234872"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:34:03 +0100" MODIFIED_BY="[Empty name]" ORDER="519" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="6.889101603234333"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.087071972564885" CI_END="-0.17913881901172005" CI_START="-0.4519527096693807" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.31554576434055037" ESTIMABLE="YES" I2="26.65192429659652" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2009-07-15 18:30:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.16164889417756168" P_Q="1.0" P_Z="5.789865214484539E-6" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.017423968695916815" TOTALS="YES" TOTAL_1="694" TOTAL_2="672" UNITS="" WEIGHT="99.99999999999999" Z="4.533921143756656">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7565279698154648" CI_START="-1.2841058123860154" EFFECT_SIZE="-0.26378892128527526" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" ORDER="231" SD_1="1.04" SD_2="1.25" SE="0.5205794081671242" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="1.6793493074590022"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="232" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="6.89598529131486"/>
<CONT_DATA CI_END="0.5410421460977246" CI_START="-0.8051383415261049" EFFECT_SIZE="-0.13204809771419013" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" ORDER="233" SD_1="6.4" SD_2="6.9" SE="0.34341970011753514" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.578351848491281"/>
<CONT_DATA CI_END="0.1735044751837487" CI_START="-0.4183562536348525" EFFECT_SIZE="-0.12242588922555189" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.18" MODIFIED="2009-07-15 18:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="552" SD_1="0.1" SD_2="1.92" SE="0.15098765423424182" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="12.04262949102554"/>
<CONT_DATA CI_END="0.8608625700733046" CI_START="-1.2102449762899692" EFFECT_SIZE="-0.17469120310833228" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" ORDER="234" SD_1="2.46" SD_2="2.22" SE="0.5283534704463719" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="1.6331757960076634"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="235" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="7.316433084255493"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="236" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="2.6400301804982367"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="237" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="8.37732358812527"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="238" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="14.695682563185182"/>
<CONT_DATA CI_END="-0.542566709882387" CI_START="-2.0392054480960766" EFFECT_SIZE="-1.2908860789892318" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" ORDER="239" SD_1="25.72" SD_2="50.3" SE="0.38180261219567935" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="2.9680012041545787"/>
<CONT_DATA CI_END="0.10957132427633204" CI_START="-0.828869771805423" EFFECT_SIZE="-0.35964922376454544" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" ORDER="240" SD_1="0.37" SD_2="0.45" SE="0.23940263787601673" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="6.4809352964024525"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="241" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="9.834238278884486"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="243" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="3.9094495305919628"/>
<CONT_DATA CI_END="0.21336772239412094" CI_START="-1.2451382933933233" EFFECT_SIZE="-0.5158852854996011" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" ORDER="242" SD_1="30.0" SD_2="34.0" SE="0.37207469813015787" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.107650872272534"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="525" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="14.840763667331462"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-05-12 14:39:28 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>SLIT versus placebo 6 to 12 months</NAME>
<CONT_OUTCOME CHI2="25.472972155146422" CI_END="-0.16074346230466635" CI_START="-0.45730242306893193" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.30902294268679914" ESTIMABLE="YES" I2="41.11405646486572" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2010-05-12 14:39:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04394102294465563" P_Q="1.0" P_Z="4.4138100306006926E-5" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.030066884064518788" TOTALS="YES" TOTAL_1="867" TOTAL_2="869" UNITS="" WEIGHT="100.0" Z="4.08467737074491">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:44:47 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="649" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="4.043907173548276"/>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="244" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="7.999229333363628"/>
<CONT_DATA CI_END="-0.9324135386472658" CI_START="-3.1925312217374806" EFFECT_SIZE="-2.0624723801923732" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" ORDER="245" SD_1="1.75" SD_2="1.57" SE="0.576571228072999" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="1.5789064624431008"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="246" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="9.474424200212882"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:16:53 +0100" MODIFIED_BY="[Empty name]" ORDER="505" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="12.182406407414263"/>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" ORDER="256" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="3.3392047957102067"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="247" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="15.324970243801827"/>
<CONT_DATA CI_END="0.2910027693610696" CI_START="-0.6224820829564097" EFFECT_SIZE="-0.16573965679767005" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" ORDER="255" SD_1="15.88" SD_2="18.76" SE="0.23303613217460403" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="6.783656731903963"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:41:11 +0000" MODIFIED_BY="[Empty name]" ORDER="478" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="12.858714845012436"/>
<CONT_DATA CI_END="0.3900717854035153" CI_START="-0.9166799153692561" EFFECT_SIZE="-0.2633040649828704" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" ORDER="248" SD_1="24.2" SD_2="30.4" SE="0.3333611512967233" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="4.053609139564019"/>
<CONT_DATA CI_END="1.3601974313483065" CI_START="-0.3502275731217155" EFFECT_SIZE="0.5049849291132955" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="249" SD_1="1.13" SD_2="0.47" SE="0.43634092717050826" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="2.5961845249547686"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="250" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="2.873502522845941"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="251" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.5026560450410664"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="252" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="3.5748908972233884"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="253" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="6.292669295557281"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="254" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="3.521067381402956"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.901874666993074" CI_END="-0.11517976185250481" CI_START="-0.5011334396049186" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3081566007287117" ESTIMABLE="YES" I2="55.3934432133711" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2010-02-09 12:32:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.007982467228926593" P_Q="1.0" P_Z="0.0017493483193409087" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.05660359996936992" TOTALS="YES" TOTAL_1="705" TOTAL_2="693" UNITS="" WEIGHT="100.0" Z="3.1297840846797684">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2009-11-24 16:48:06 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="655" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="5.710611602997753"/>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="258" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="9.893392652376468"/>
<CONT_DATA CI_END="0.1989982019519022" CI_START="-1.621790652209877" EFFECT_SIZE="-0.7113962251289874" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" ORDER="259" SD_1="2.1" SD_2="4.9" SE="0.4644954878058804" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.5593558859257515"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="260" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="11.102062746018966"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:19:28 +0100" MODIFIED_BY="[Empty name]" ORDER="511" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="13.198964086968195"/>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="268" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="4.788021206605869"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="261" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="15.196848576825166"/>
<CONT_DATA CI_END="-0.10316912578131382" CI_START="-1.0339955625298705" EFFECT_SIZE="-0.5685823441555922" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" ORDER="267" SD_1="5.37" SD_2="8.23" SE="0.2374600870451694" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="8.57967334719047"/>
<CONT_DATA CI_END="0.12484259691974253" CI_START="-1.1960243659651422" EFFECT_SIZE="-0.5355908845226999" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" ORDER="262" SD_1="18.7" SD_2="26.4" SE="0.3369620496355328" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="5.6975722292868936"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="263" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="4.082305892944456"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="264" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.869403308847141"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="265" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="5.060930014792496"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="266" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="8.260858449220375"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-05-12 14:39:43 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>SLIT versus placebo &gt; 12 months</NAME>
<CONT_OUTCOME CHI2="74.88323439562045" CI_END="-0.33525882954271446" CI_START="-0.9203948460961392" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6278268378194268" ESTIMABLE="YES" I2="79.96881395273002" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2010-05-12 14:39:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.94377436158311E-10" P_Q="1.0" P_Z="2.600208191382988E-5" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.26615840214785064" TOTALS="YES" TOTAL_1="580" TOTAL_2="509" UNITS="" WEIGHT="100.0" Z="4.205921207522853">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="270" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="6.8994246075975685"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="280" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="5.73552712159915"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="271" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="6.600384084500373"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:48:28 +0100" MODIFIED_BY="[Empty name]" ORDER="534" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="7.638968775676585"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="272" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="5.191212287472749"/>
<CONT_DATA CI_END="0.1271975369072953" CI_START="-1.2693933260669417" EFFECT_SIZE="-0.5710978945798232" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2009-03-26 17:23:07 +0000" MODIFIED_BY="[Empty name]" ORDER="486" SD_1="32.61" SD_2="50.48" SE="0.35627972605373553" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="5.668412735241245"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2009-07-15 19:14:20 +0100" MODIFIED_BY="[Empty name]" ORDER="555" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="5.455516215406195"/>
<CONT_DATA CI_END="-0.25946655506244953" CI_START="-2.275227346673512" EFFECT_SIZE="-1.2673469508679807" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" ORDER="273" SD_1="27.8" SD_2="45.7" SE="0.5142341409105284" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="4.199467351611189"/>
<CONT_DATA CI_END="-1.0351060875007732" CI_START="-2.2589958787867506" EFFECT_SIZE="-1.6470509831437619" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" ORDER="274" SD_1="0.23" SD_2="0.2" SE="0.31222252065340583" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="6.12751356220625"/>
<CONT_DATA CI_END="-0.26608581280902066" CI_START="-1.1198082314680609" EFFECT_SIZE="-0.6929470221385408" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-02-09 15:33:14 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="662" SD_1="123.0" SD_2="133.6" SE="0.21779033323905278" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="7.105487090831094"/>
<CONT_DATA CI_END="0.49320872759750967" CI_START="-0.40042776067015406" EFFECT_SIZE="0.04639048346367782" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="275" SD_1="23.12" SD_2="21.65" SE="0.2279726809565263" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="7.004109665126138"/>
<CONT_DATA CI_END="0.11967300323055935" CI_START="-0.48860750084457977" EFFECT_SIZE="-0.1844672488070102" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2009-03-30 18:05:54 +0100" MODIFIED_BY="[Empty name]" ORDER="498" SD_1="1.48" SD_2="1.66" SE="0.15517644938202388" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="7.677202873122458"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="276" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="7.232796757938153"/>
<CONT_DATA CI_END="-1.622149325677061" CI_START="-2.8697884990900766" EFFECT_SIZE="-2.2459689123835687" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" ORDER="277" SD_1="1.5" SD_2="2.0" SE="0.31828114783083616" STUDY_ID="STD-Tari-1990" TOTAL_1="34" TOTAL_2="32" WEIGHT="6.063814281126518"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="278" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="4.846828549776252"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="279" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="6.55333404076808"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.134006944353516" CI_END="-0.04110117101951494" CI_START="-0.6438214106768086" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3424612908481618" ESTIMABLE="YES" I2="66.8312902754937" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2009-07-15 17:51:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.001329122666767324" P_Q="1.0" P_Z="0.025928914644252617" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.14835269789157454" TOTALS="YES" TOTAL_1="338" TOTAL_2="277" UNITS="" WEIGHT="99.99999999999997" Z="2.227274785207625">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="281" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.55159713454193"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="288" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="8.76640913481555"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="282" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="10.735958804726915"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:51:45 +0100" MODIFIED_BY="[Empty name]" ORDER="540" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="13.652849955978331"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="283" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="7.1701737393661436"/>
<CONT_DATA CI_END="0.1400226517700135" CI_START="-1.255120010640152" EFFECT_SIZE="-0.5575486794350692" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2009-03-26 17:26:13 +0000" MODIFIED_BY="[Empty name]" ORDER="493" SD_1="32.98" SD_2="65.05" SE="0.35591028034567795" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.596139997815333"/>
<CONT_DATA CI_END="-0.8011057902380112" CI_START="-1.976804225352927" EFFECT_SIZE="-1.388955007795469" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" ORDER="284" SD_1="44.0" SD_2="35.0" SE="0.29992858144044354" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="9.92049587905212"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="285" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="11.799759330504095"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="286" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="7.0817816906920505"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="287" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="10.724834332507504"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-05-12 14:39:56 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Major allergen content &lt; 5 mcg</NAME>
<CONT_OUTCOME CHI2="15.17603167828113" CI_END="0.05079206665215591" CI_START="-0.6861174849616933" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.31766270915476874" ESTIMABLE="YES" I2="53.874635027166505" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2010-05-12 14:39:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03380805585009006" P_Q="1.0" P_Z="0.09107007321462297" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.1480983864327417" TOTALS="YES" TOTAL_1="141" TOTAL_2="134" UNITS="" WEIGHT="100.0" Z="1.6897798863137108">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" ORDER="289" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="12.21010109553006"/>
<CONT_DATA CI_END="1.3854010452517982" CI_START="-0.3614589986573289" EFFECT_SIZE="0.5119710232972347" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="290" SD_1="1.13" SD_2="0.47" SE="0.4456357508832142" STUDY_ID="STD-Hirsch-1997" TOTAL_1="11" TOTAL_2="10" WEIGHT="10.193688849712986"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="291" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="11.140838020053337"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="292" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="11.357333765259847"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2009-07-15 19:14:37 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="12.170680079487159"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="293" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="12.557118025498713"/>
<CONT_DATA CI_END="0.49320872759750967" CI_START="-0.40042776067015406" EFFECT_SIZE="0.04639048346367782" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="294" SD_1="23.12" SD_2="21.65" SE="0.2279726809565263" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="17.664053793180884"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="295" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="12.706186371277031"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.4323770730884675" CI_END="-0.24395929766167895" CI_START="-0.9361186780004978" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5900389878310883" ESTIMABLE="YES" I2="32.72677165285038" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2010-05-12 14:39:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1904181015171713" P_Q="1.0" P_Z="8.3301103897686E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.060402272556653626" TOTALS="YES" TOTAL_1="110" TOTAL_2="109" UNITS="" WEIGHT="99.99999999999999" Z="3.341586341161206">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="296" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="15.11559607094388"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="297" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="12.922757962883002"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="298" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="12.89596490071068"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="299" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="15.367705771615446"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="300" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="27.7375703034907"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="301" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="15.96040499035627"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-05-12 14:40:16 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Major allergen content 5 to 20 mcg</NAME>
<CONT_OUTCOME CHI2="13.515186491819051" CI_END="-0.2372849523660686" CI_START="-0.44905757257276857" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3431712624694186" ESTIMABLE="YES" I2="18.610076104695498" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2010-05-12 14:40:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26098962756229027" P_Q="1.0" P_Z="2.1235754789396324E-10" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.006195849846462276" TOTALS="YES" TOTAL_1="1006" TOTAL_2="966" UNITS="" WEIGHT="100.0" Z="6.352127242064722">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:45:08 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="650" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="2.480497994602758"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="302" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="7.987670482500127"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:17:13 +0100" MODIFIED_BY="[Empty name]" ORDER="506" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="12.628815497507407"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="303" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="5.2047901924874385"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="304" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="21.65679880512142"/>
<CONT_DATA CI_END="0.3900717854035153" CI_START="-0.9166799153692561" EFFECT_SIZE="-0.2633040649828704" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" ORDER="310" SD_1="24.2" SD_2="30.4" SE="0.3333611512967233" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="2.4876599080793387"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="305" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="6.173760033448199"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="306" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="13.460415559976534"/>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="307" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.633206120358486"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="308" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="7.666918602648489"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:34:26 +0100" MODIFIED_BY="[Empty name]" ORDER="520" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="13.514877113202454"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="309" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="2.1045896900673475"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.840855755885435" CI_END="-0.07299097265209939" CI_START="-0.3521666043541799" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21257878850313963" ESTIMABLE="YES" I2="49.59894813491762" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2010-05-12 14:40:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03079439072557888" P_Q="1.0" P_Z="0.0028373019053900403" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.02463359837192695" TOTALS="YES" TOTAL_1="992" TOTAL_2="948" UNITS="" WEIGHT="100.00000000000001" Z="2.9848362251611666">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2009-11-24 16:48:23 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="656" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="3.6811695695739055"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="311" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="9.16402560493702"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:19:44 +0100" MODIFIED_BY="[Empty name]" ORDER="512" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="12.229002008425468"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="312" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="6.909208873285248"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="313" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="15.939787924342637"/>
<CONT_DATA CI_END="0.12484259691974253" CI_START="-1.1960243659651422" EFFECT_SIZE="-0.5355908845226999" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" ORDER="318" SD_1="18.7" SD_2="26.4" SE="0.3369620496355328" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="3.6708193762776844"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="314" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="7.799978817038267"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="315" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="12.627028527452811"/>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="316" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="6.266569567995924"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="317" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="8.983277203813174"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="526" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="12.729132526857883"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2010-05-12 14:40:33 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Major allergen content &gt; 20 mcg</NAME>
<CONT_OUTCOME CHI2="15.192439865595924" CI_END="-0.17310074388171856" CI_START="-0.48530533457567504" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3292030392286968" ESTIMABLE="YES" I2="27.59556662843816" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2010-05-12 14:40:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17385544740812375" P_Q="1.0" P_Z="3.575068969470181E-5" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.01962476886823875" TOTALS="YES" TOTAL_1="541" TOTAL_2="500" UNITS="" WEIGHT="100.00000000000003" Z="4.133354343414287">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="319" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="10.380436366305554"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="320" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="8.62285938677871"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="321" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="3.877111864689897"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:41:30 +0000" MODIFIED_BY="[Empty name]" ORDER="479" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="18.619291709536192"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="322" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="4.468437993919316"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="323" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="6.966535830888686"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:49:14 +0100" MODIFIED_BY="[Empty name]" ORDER="535" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="14.047387723652303"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="324" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="10.30816693893842"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="325" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="2.9754256056505755"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="326" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="6.785906466366435"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="327" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.069786812121338"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="328" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="7.87865330115259"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.704697718052119" CI_END="0.00182946171334325" CI_START="-0.4344363781306056" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21630345820863117" ESTIMABLE="YES" I2="42.69230671243836" I2_Q="0.0" ID="CMP-011.02" MODIFIED="2010-05-12 14:40:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07331031547944467" P_Q="1.0" P_Z="0.05195264454978155" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04976917916074838" TOTALS="YES" TOTAL_1="360" TOTAL_2="301" UNITS="" WEIGHT="99.99999999999999" Z="1.9435259380932808">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="330" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="13.588663954895612"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="329" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="12.074363857764645"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="331" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="5.739337786129236"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="332" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="7.239314400887268"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="333" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="10.184099165674061"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:52:11 +0100" MODIFIED_BY="[Empty name]" ORDER="541" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="16.608635190086503"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="334" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="5.265171140033238"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="335" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="10.165009096051847"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="336" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="7.92770653175623"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="337" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="11.207698876721365"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2010-11-10 15:57:44 +0000" MODIFIED_BY="Suzana Radulovic" NO="12">
<NAME>SLIT versus placebo - immunoglobulins</NAME>
<CONT_OUTCOME CHI2="68.63405347599024" CI_END="0.546913576846987" CI_START="-0.005665104410487232" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2706242362182499" ESTIMABLE="YES" I2="81.05896513230462" I2_Q="0.0" ID="CMP-012.01" MODIFIED="2010-05-12 14:40:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.430847329508822E-9" P_Q="1.0" P_Z="0.05488614880330607" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.20144914721608626" TOTALS="YES" TOTAL_1="675" TOTAL_2="659" UNITS="" WEIGHT="100.00000000000001" Z="1.9197764022469896">
<NAME>IgE levels - post-treatment</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>SLIT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1433052295961719" CI_START="-0.18616311181116751" EFFECT_SIZE="0.4785710588925022" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="11.55" MODIFIED="2009-11-24 16:53:40 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="661" SD_1="32.2" SD_2="16.6" SE="0.3391563191706623" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="6.279008672581708"/>
<CONT_DATA CI_END="0.9426649592449761" CI_START="0.01625839659269357" EFFECT_SIZE="0.4794616779188348" ESTIMABLE="YES" MEAN_1="41.11" MEAN_2="25.51" ORDER="338" SD_1="36.75" SD_2="27.49" SE="0.2363325474242535" STUDY_ID="STD-Bowen-2004" TOTAL_1="35" TOTAL_2="39" WEIGHT="7.723044624516309"/>
<CONT_DATA CI_END="0.4898529671281011" CI_START="-0.1937945911113501" EFFECT_SIZE="0.1480291880083755" ESTIMABLE="YES" MEAN_1="63.29" MEAN_2="47.75" ORDER="339" SD_1="113.62" SD_2="93.54" SE="0.17440309200372453" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="8.570295252566211"/>
<CONT_DATA CI_END="0.5924017877012815" CI_START="-0.8437671895125078" EFFECT_SIZE="-0.12568270090561323" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="22.2" ORDER="340" SD_1="24.7" SD_2="20.3" SE="0.36637636929609596" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="5.919780281224257"/>
<CONT_DATA CI_END="0.8374128283758322" CI_START="0.34337966269992504" EFFECT_SIZE="0.5903962455378786" ESTIMABLE="YES" MEAN_1="99.5" MEAN_2="40.7" ORDER="341" SD_1="129.4" SD_2="53.1" SE="0.12603118464746743" STUDY_ID="STD-Durham-2006" TOTAL_1="133" TOTAL_2="130" WEIGHT="9.14337200084204"/>
<CONT_DATA CI_END="0.5991674375607554" CI_START="-0.3259081296484335" EFFECT_SIZE="0.13662965395616092" ESTIMABLE="YES" MEAN_1="48.2" MEAN_2="40.5" ORDER="342" SD_1="59.0" SD_2="52.3" SE="0.23599300153116765" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="7.727861392307907"/>
<CONT_DATA CI_END="1.7059466824480967" CI_START="0.18528866293079604" EFFECT_SIZE="0.9456176726894463" ESTIMABLE="YES" MEAN_1="75.7" MEAN_2="48.3" ORDER="343" SD_1="26.6" SD_2="29.7" SE="0.38793009246905985" STUDY_ID="STD-Hirsch-1997" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.646311069080725"/>
<CONT_DATA CI_END="1.0963807268103158" CI_START="0.026754783383681868" EFFECT_SIZE="0.5615677550969989" ESTIMABLE="YES" MEAN_1="415.0" MEAN_2="246.0" ORDER="344" SD_1="317.0" SD_2="275.0" SE="0.2728687751059986" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="7.202281989833406"/>
<CONT_DATA CI_END="1.5098316411498924" CI_START="-0.15024978037342718" EFFECT_SIZE="0.6797909303882326" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="19.5" ORDER="345" SD_1="32.4" SD_2="16.1" SE="0.4234979404259032" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="5.218377995073525"/>
<CONT_DATA CI_END="-0.29484469533217317" CI_START="-0.7119767093585306" EFFECT_SIZE="-0.5034107023453519" ESTIMABLE="YES" MEAN_1="43863.0" MEAN_2="140862.0" MODIFIED="2010-04-28 09:37:43 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="666" SD_1="106216.0" SD_2="254114.0" SE="0.10641318343516555" STUDY_ID="STD-Peter-2009" TOTAL_1="189" TOTAL_2="176" WEIGHT="9.339330378652965"/>
<CONT_DATA CI_END="0.6244479025043872" CI_START="-0.07734579153027232" EFFECT_SIZE="0.27355105548705744" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="144.0" ORDER="346" SD_1="459.0" SD_2="231.0" SE="0.17903229334067325" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="8.510244034918264"/>
<CONT_DATA CI_END="1.0308070985696918" CI_START="0.09415384320369724" EFFECT_SIZE="0.5624804708866945" ESTIMABLE="YES" MEAN_1="88.84" MEAN_2="72.21" ORDER="347" SD_1="23.95" SD_2="33.85" SE="0.23894654768000734" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="37" TOTAL_2="36" WEIGHT="7.685933218265359"/>
<CONT_DATA CI_END="1.1835718812544318" CI_START="-0.5091886536638918" EFFECT_SIZE="0.33719161379526996" ESTIMABLE="YES" MEAN_1="116.78" MEAN_2="61.0" ORDER="348" SD_1="228.1" SD_2="58.98" SE="0.43183460213315206" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="5.122458024021179"/>
<CONT_DATA CI_END="0.17255232482139382" CI_START="-1.266068724516283" EFFECT_SIZE="-0.5467581998474446" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="13.7" ORDER="349" SD_1="5.7" SD_2="5.7" SE="0.3670019093935746" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="5.911701066116153"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0129665025740493" CI_END="1.1205575569391937" CI_START="0.7794539446300609" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.9500057507846273" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" MODIFIED="2010-11-10 15:57:44 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.6026111570992878" P_Q="1.0" P_Z="9.521370533970047E-28" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="286" TOTAL_2="304" UNITS="" WEIGHT="100.00000000000001" Z="10.917369323877727">
<NAME>IgG levels - post-treatment</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLIT</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3551128420325786" CI_START="0.7535389569343909" EFFECT_SIZE="1.0543258994834848" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="0.02" ORDER="350" SD_1="0.05" SD_2="0.02" SE="0.15346554575577045" STUDY_ID="STD-Durham-2006" TOTAL_1="95" TOTAL_2="99" WEIGHT="32.15101496467085"/>
<CONT_DATA CI_END="1.1345837996732118" CI_START="0.7026544808988836" EFFECT_SIZE="0.9186191402860476" ESTIMABLE="YES" MEAN_1="6.547" MEAN_2="0.92" MODIFIED="2010-04-28 09:40:23 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="667" SD_1="8.387" SD_2="2.583" SE="0.11018807543948037" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="62.36591070284384"/>
<CONT_DATA CI_END="1.4236617531311873" CI_START="-0.03305210520460433" EFFECT_SIZE="0.6953048239632914" ESTIMABLE="YES" MEAN_1="34.6" MEAN_2="28.1" ORDER="351" SD_1="7.9" SD_2="10.1" SE="0.37161750670577737" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="5.483074332485325"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="174.241706678643" CI_END="0.6348675335629382" CI_START="0.2900318509410541" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="0.46244969225199617" ESTIMABLE="YES" I2="93.11301511633388" I2_Q="0.0" ID="CMP-012.03" MODIFIED="2010-11-10 15:57:27 +0000" MODIFIED_BY="Suzana Radulovic" NO="3" P_CHI2="1.3322676295501878E-15" P_Q="1.0" P_Z="1.4649749532527665E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="599" UNITS="" WEIGHT="100.0" Z="5.256908070441216">
<NAME>IgG4 levels- post-treatment</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SLIT</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6425351718415719" CI_START="-0.48253517184157185" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.44" MODIFIED="2009-11-24 16:54:42 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="662" SD_1="0.76" SD_2="0.94" SE="0.2870130146669926" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="9.394313391079208"/>
<CONT_DATA CI_END="8.853818260579482" CI_START="2.2261817394205177" EFFECT_SIZE="5.54" ESTIMABLE="YES" MEAN_1="5.98" MEAN_2="0.44" ORDER="352" SD_1="9.98" SD_2="0.71" SE="1.6907546703503011" STUDY_ID="STD-Bowen-2004" TOTAL_1="35" TOTAL_2="39" WEIGHT="0.27071170442630416"/>
<CONT_DATA CI_END="67.99749328616778" CI_START="16.84250671383223" EFFECT_SIZE="42.42" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="22.58" ORDER="353" SD_1="105.33" SD_2="21.39" SE="13.049981269002785" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="0.0045441059425046625"/>
<CONT_DATA CI_END="0.41192917648010624" CI_START="-0.3919291764801058" EFFECT_SIZE="0.010000000000000231" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.59" ORDER="354" SD_1="0.4" SD_2="0.7" SE="0.20506967457079417" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="18.402013300376424"/>
<CONT_DATA CI_END="0.7985312340798835" CI_START="0.2814687659201166" EFFECT_SIZE="0.54" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.26" ORDER="360" SD_1="0.92" SD_2="0.27" SE="0.13190611466289423" STUDY_ID="STD-de-Blay-2003" TOTAL_1="53" TOTAL_2="51" WEIGHT="44.47729516173481"/>
<CONT_DATA CI_END="0.7540504840550001" CI_START="-1.1540504840550003" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="5.0" ORDER="362" SD_1="1.8" SD_2="2.3" SE="0.4867693955503411" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="3.266041466265938"/>
<CONT_DATA CI_END="9.267008175509353" CI_START="2.7329918244906457" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="8.61" MEAN_2="2.61" ORDER="355" SD_1="8.25" SD_2="3.12" SE="1.666871535027734" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.2785248597462526"/>
<CONT_DATA CI_END="1063.3377535178488" CI_START="510.87824648215104" EFFECT_SIZE="787.108" ESTIMABLE="YES" MEAN_1="995.615" MEAN_2="208.507" MODIFIED="2010-04-28 09:40:55 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="668" SD_1="1736.043" SD_2="719.477" SE="140.93613744778676" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="3.8960407886180255E-5"/>
<CONT_DATA CI_END="4.811916577182771" CI_START="-1.0119165771827725" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="6.8" ORDER="356" SD_1="10.9" SD_2="4.5" SE="1.4856990231206277" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="0.3505956708448496"/>
<CONT_DATA CI_END="0.6502218676346904" CI_START="-0.09022186763469053" EFFECT_SIZE="0.2799999999999999" ESTIMABLE="YES" MEAN_1="1.18" MEAN_2="0.9" ORDER="357" SD_1="0.76" SD_2="0.85" SE="0.18889217891499704" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="37" TOTAL_2="36" WEIGHT="21.689037122090657"/>
<CONT_DATA CI_END="9.389425319964174" CI_START="6.4705746800358295" EFFECT_SIZE="7.9300000000000015" ESTIMABLE="YES" MEAN_1="10.71" MEAN_2="2.78" ORDER="361" SD_1="3.81" SD_2="2.02" SE="0.7446184376222891" STUDY_ID="STD-Tari-1990" TOTAL_1="34" TOTAL_2="32" WEIGHT="1.3957275576238342"/>
<CONT_DATA CI_END="4.955391231300695" CI_START="-0.7153912313006949" EFFECT_SIZE="2.12" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="5.28" ORDER="358" SD_1="4.31" SD_2="1.68" SE="1.4466547618557786" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="0.36977574684605935"/>
<CONT_DATA CI_END="5.015069307390963" CI_START="-5.81506930739096" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="27.8" MEAN_2="28.2" ORDER="359" SD_1="8.2" SD_2="7.1" SE="2.7628412308105337" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="0.1013809526152743"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2010-05-12 14:41:14 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>SLIT v placebo - house dust mite</NAME>
<CONT_OUTCOME CHI2="110.42381629623046" CI_END="-0.12981118384976276" CI_START="-1.8040650418114654" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9669381128306141" ESTIMABLE="YES" I2="92.75518609270064" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2010-05-12 14:41:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1102230246251565E-16" P_Q="1.0" P_Z="0.023580837560740295" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.489308841682987" TOTALS="YES" TOTAL_1="232" TOTAL_2="232" UNITS="" WEIGHT="99.99999999999997" Z="2.263890708586298">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3357360175712891" CI_START="-0.7097239111000927" EFFECT_SIZE="0.31300605323559816" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" ORDER="363" SD_1="0.4" SD_2="0.38" SE="0.5218105906041408" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="10.355720999561688"/>
<CONT_DATA CI_END="-2.4281421645013817" CI_START="-3.2721552237414437" EFFECT_SIZE="-2.8501486941214127" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2009-07-15 18:27:29 +0100" MODIFIED_BY="[Empty name]" ORDER="548" SD_1="0.88" SD_2="0.46" SE="0.21531341032221238" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="11.879246902691104"/>
<CONT_DATA CI_END="0.0557752070426043" CI_START="-0.8784393839762761" EFFECT_SIZE="-0.4113320884668359" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" ORDER="364" SD_1="1.9" SD_2="2.4" SE="0.23832442799659734" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="11.799043211611712"/>
<CONT_DATA CI_END="1.3601974313483065" CI_START="-0.3502275731217155" EFFECT_SIZE="0.5049849291132955" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" ORDER="365" SD_1="1.13" SD_2="0.47" SE="0.43634092717050826" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="10.860608040776933"/>
<CONT_DATA CI_END="0.578965843463403" CI_START="-1.0330592858767225" EFFECT_SIZE="-0.2270467212066598" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" ORDER="366" SD_1="332.55" SD_2="548.18" SE="0.41123845694501887" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="10.999941336993725"/>
<CONT_DATA CI_END="-0.25946655506244953" CI_START="-2.275227346673512" EFFECT_SIZE="-1.2673469508679807" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" ORDER="368" SD_1="27.8" SD_2="45.7" SE="0.5142341409105284" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="10.402071881177411"/>
<CONT_DATA CI_END="-1.0351060875007732" CI_START="-2.2589958787867506" EFFECT_SIZE="-1.6470509831437619" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" ORDER="369" SD_1="0.23" SD_2="0.2" SE="0.31222252065340583" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="11.496522963033858"/>
<CONT_DATA CI_END="-1.577152453569599" CI_START="-2.9099418458130546" EFFECT_SIZE="-2.243547149691327" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" ORDER="370" SD_1="1.5" SD_2="2.0" SE="0.340003541584521" STUDY_ID="STD-Tari-1990" TOTAL_1="30" TOTAL_2="28" WEIGHT="11.366726804205442"/>
<CONT_DATA CI_END="0.2542916864269673" CI_START="-1.470335885956649" EFFECT_SIZE="-0.6080220997648409" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="4.11" ORDER="371" SD_1="2.14" SD_2="2.19" SE="0.43996409780670936" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="10.840117859948116"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.923955949829764" CI_END="0.05028439773196369" CI_START="-1.0924032302579296" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5210594162629829" ESTIMABLE="YES" I2="69.04972428312333" I2_Q="0.0" ID="CMP-013.02" MODIFIED="2010-02-09 12:32:57 +0000" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.011653422424596216" P_Q="1.0" P_Z="0.07386218910441579" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.28144907402571107" TOTALS="YES" TOTAL_1="95" TOTAL_2="94" UNITS="" WEIGHT="100.0" Z="1.7874660837580076">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7565279698154648" CI_START="-1.2841058123860154" EFFECT_SIZE="-0.26378892128527526" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" ORDER="372" SD_1="1.04" SD_2="1.25" SE="0.5205794081671242" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="15.381699814198722"/>
<CONT_DATA CI_END="0.1451591805559544" CI_START="-0.7850082423620501" EFFECT_SIZE="-0.3199245309030479" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" ORDER="373" SD_1="5.5" SD_2="6.8" SE="0.23729196818284584" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="25.159099599872615"/>
<CONT_DATA CI_END="0.11040121948049719" CI_START="-1.5566807979214112" EFFECT_SIZE="-0.7231397892204571" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" ORDER="374" SD_1="30.45" SD_2="83.77" SE="0.4252838395377769" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="18.380634524758182"/>
<CONT_DATA CI_END="-0.8011057902380112" CI_START="-1.976804225352927" EFFECT_SIZE="-1.388955007795469" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" ORDER="376" SD_1="44.0" SD_2="35.0" SE="0.29992858144044354" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="22.879666781646144"/>
<CONT_DATA CI_END="1.1227658951239403" CI_START="-0.565458624635117" EFFECT_SIZE="0.27865363524441167" ESTIMABLE="YES" MEAN_1="18.16" MEAN_2="12.6" ORDER="377" SD_1="22.37" SD_2="16.14" SE="0.43067743414561616" STUDY_ID="STD-Tonnel-2004" TOTAL_1="10" TOTAL_2="12" WEIGHT="18.198899279524337"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2010-05-12 14:41:28 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>SLIT versus placebo - grass pollen</NAME>
<CONT_OUTCOME CHI2="39.58421130090069" CI_END="-0.23721520165176124" CI_START="-0.4528072136433944" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3450112076475778" ESTIMABLE="YES" I2="44.4222853582549" I2_Q="0.0" ID="CMP-014.01" MODIFIED="2010-05-12 14:41:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01208574906429738" P_Q="1.0" P_Z="3.540472459837494E-10" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.026420327804062494" TOTALS="YES" TOTAL_1="1549" TOTAL_2="1464" UNITS="" WEIGHT="100.00000000000004" Z="6.273048198818847">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6835751634501848" CI_START="-0.6251666842925805" EFFECT_SIZE="0.029204239578802194" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2009-11-24 16:45:27 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="651" SD_1="4.9" SD_2="2.7" SE="0.33386885117939763" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="2.1937157948351564"/>
<CONT_DATA CI_END="0.28409730758325313" CI_START="-0.39873242438594814" EFFECT_SIZE="-0.057317558401347474" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" ORDER="378" SD_1="0.77" SD_2="0.96" SE="0.17419445901947053" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="5.328879263503742"/>
<CONT_DATA CI_END="0.03448755774563428" CI_START="-0.47533311725988003" EFFECT_SIZE="-0.22042277975712288" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2009-04-10 14:17:30 +0100" MODIFIED_BY="[Empty name]" ORDER="507" SD_1="2.38" SD_2="2.14" SE="0.13005868450311198" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="6.9801451194861075"/>
<CONT_DATA CI_END="0.2389221843349218" CI_START="-1.12409284982667" EFFECT_SIZE="-0.44258533274587414" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" ORDER="379" SD_1="3.7" SD_2="3.8" SE="0.3477143062099305" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.0531989706519966"/>
<CONT_DATA CI_END="-0.19351185609803584" CI_START="-1.068986872519647" EFFECT_SIZE="-0.6312493643088414" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" ORDER="380" SD_1="1.7" SD_2="2.2" SE="0.22333956728981916" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="3.9644190402564177"/>
<CONT_DATA CI_END="-0.35138012136641394" CI_START="-0.6858633434634865" EFFECT_SIZE="-0.5186217324149502" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" ORDER="381" SD_1="1.6" SD_2="2.2" SE="0.08532892051472211" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="8.975565647175317"/>
<CONT_DATA CI_END="0.2910027693610696" CI_START="-0.6224820829564097" EFFECT_SIZE="-0.16573965679767005" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" ORDER="391" SD_1="15.88" SD_2="18.76" SE="0.23303613217460403" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="3.7470960648768354"/>
<CONT_DATA CI_END="-0.19730870519328855" CI_START="-0.6684217489012295" EFFECT_SIZE="-0.43286522704725905" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2009-03-18 17:41:50 +0000" MODIFIED_BY="[Empty name]" ORDER="480" SD_1="2.976" SD_2="3.229" SE="0.12018410731626207" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="7.402228102853381"/>
<CONT_DATA CI_END="0.4101920578616225" CI_START="-1.3447713035819453" EFFECT_SIZE="-0.4672896228601614" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="37.4" ORDER="382" SD_1="19.9" SD_2="37.0" SE="0.4477029617091168" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="19" TOTAL_2="7" WEIGHT="1.3333818597357594"/>
<CONT_DATA CI_END="0.015469201716813152" CI_START="-0.47235997056327605" EFFECT_SIZE="-0.22844538442323145" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" ORDER="383" SD_1="2.1" SD_2="2.09" SE="0.12444850418885843" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="7.217964310883703"/>
<CONT_DATA CI_END="-0.2839711550665126" CI_START="-1.7232247022187397" EFFECT_SIZE="-1.0035979286426262" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" ORDER="384" SD_1="92.46" SD_2="114.2" SE="0.3671632638418041" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="1.876141047176046"/>
<CONT_DATA CI_END="-0.09342349292870544" CI_START="-1.043625167434067" EFFECT_SIZE="-0.5685243301813863" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" ORDER="385" SD_1="3.05" SD_2="3.6" SE="0.24240284056248768" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="3.551192789020566"/>
<CONT_DATA CI_END="0.5383350937011595" CI_START="-0.5093245427933908" EFFECT_SIZE="0.014505275453884343" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" ORDER="386" SD_1="2326.0" SD_2="1537.0" SE="0.2672650224081554" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="3.091321998443631"/>
<CONT_DATA CI_END="-0.2000998379805234" CI_START="-0.8264598344562764" EFFECT_SIZE="-0.5132798362183999" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2009-07-15 17:49:32 +0100" MODIFIED_BY="[Empty name]" ORDER="536" SD_1="4.54" SD_2="4.54" SE="0.15978864954060398" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="5.8223820281036565"/>
<CONT_DATA CI_END="0.1271975369072953" CI_START="-1.2693933260669417" EFFECT_SIZE="-0.5710978945798232" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2009-03-26 17:23:20 +0000" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="32.61" SD_2="50.48" SE="0.35627972605373553" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.9724663382676384"/>
<CONT_DATA CI_END="-0.5219872482208834" CI_START="-2.000560811980397" EFFECT_SIZE="-1.2612740301006402" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2009-07-15 19:14:54 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SD_1="114.91" SD_2="211.22" SE="0.3771940646415733" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="1.7931027237143085"/>
<CONT_DATA CI_END="-0.26608581280902066" CI_START="-1.1198082314680609" EFFECT_SIZE="-0.6929470221385408" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-02-09 15:33:44 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="663" SD_1="123.0" SD_2="133.6" SE="0.21779033323905278" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="4.09582383213297"/>
<CONT_DATA CI_END="0.17428954831284588" CI_START="-0.5255287294284787" EFFECT_SIZE="-0.17561959055781645" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="2.65" ORDER="387" SD_1="1.6" SD_2="2.0" SE="0.1785283513527294" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="5.189135198294397"/>
<CONT_DATA CI_END="0.49319787577226687" CI_START="-0.4004385534232164" EFFECT_SIZE="0.046379661174525244" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" ORDER="388" SD_1="23.13" SD_2="21.65" SE="0.2279726658868156" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="3.8586746812205868"/>
<CONT_DATA CI_END="0.11967300323055935" CI_START="-0.48860750084457977" EFFECT_SIZE="-0.1844672488070102" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2009-03-30 18:06:22 +0100" MODIFIED_BY="[Empty name]" ORDER="499" SD_1="1.48" SD_2="1.66" SE="0.15517644938202388" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="5.989868370181193"/>
<CONT_DATA CI_END="0.5247440634117341" CI_START="-0.27776856980762116" EFFECT_SIZE="0.12348774680205644" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.32" ORDER="389" SD_1="2.48" SD_2="1.67" SE="0.20472637241027702" STUDY_ID="STD-Smith-2004" TOTAL_1="45" TOTAL_2="51" WEIGHT="4.426671567735744"/>
<CONT_DATA CI_END="-0.19058186737763708" CI_START="-0.6770329573098156" EFFECT_SIZE="-0.43380741234372633" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2009-04-10 15:36:58 +0100" MODIFIED_BY="[Empty name]" ORDER="521" SD_1="2.86" SD_2="2.931" SE="0.12409694610953124" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="7.23304529415193"/>
<CONT_DATA CI_END="0.15778882870302513" CI_START="-1.269004885151385" EFFECT_SIZE="-0.55560802822418" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" ORDER="390" SD_1="0.26" SD_2="0.38" SE="0.36398467653201205" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="1.9035799572989487"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="34.54709717510012" CI_END="-0.09749209115335758" CI_START="-0.37116492009789215" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23432850562562485" ESTIMABLE="YES" I2="53.68641272838394" I2_Q="0.0" ID="CMP-014.02" MODIFIED="2010-04-28 13:09:01 +0100" MODIFIED_BY="Suzana Radulovic" NO="2" P_CHI2="0.00458160960588172" P_Q="1.0" P_Z="7.896909190726253E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.03764935570941995" TOTALS="YES" TOTAL_1="1201" TOTAL_2="1107" UNITS="" WEIGHT="100.00000000000003" Z="3.3563831188400357">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9894415065584283" CI_START="-0.3291637430747653" EFFECT_SIZE="0.33013888174183154" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2010-04-28 13:09:01 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="657" SD_1="1.2" SD_2="0.24" SE="0.336385071367174" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="3.232165165196793"/>
<CONT_DATA CI_END="0.6574656382559951" CI_START="-0.029537436248085303" EFFECT_SIZE="0.31396410100395494" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" ORDER="392" SD_1="0.19" SD_2="0.19" SE="0.17525910678029624" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="7.12972323153218"/>
<CONT_DATA CI_END="0.13202060582022423" CI_START="-0.3767167056973584" EFFECT_SIZE="-0.12234804993856706" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2009-04-10 14:19:58 +0100" MODIFIED_BY="[Empty name]" ORDER="513" SD_1="3.48" SD_2="3.03" SE="0.12978231118797018" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="8.944746438328703"/>
<CONT_DATA CI_END="0.5410421460977246" CI_START="-0.8051383415261049" EFFECT_SIZE="-0.13204809771419013" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" ORDER="393" SD_1="6.4" SD_2="6.9" SE="0.34341970011753514" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.132819899494968"/>
<CONT_DATA CI_END="-0.01685982513313894" CI_START="-0.8826137631492792" EFFECT_SIZE="-0.4497367941412091" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" ORDER="394" SD_1="3.9" SD_2="4.1" SE="0.22085965478067374" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="5.639635085597907"/>
<CONT_DATA CI_END="-0.23825482831400813" CI_START="-0.5705848160519287" EFFECT_SIZE="-0.4044198221829684" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="395" SD_1="1.9" SD_2="2.5" SE="0.08477961594174614" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="10.871043508946055"/>
<CONT_DATA CI_END="-0.10316912578131382" CI_START="-1.0339955625298705" EFFECT_SIZE="-0.5685823441555922" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" ORDER="403" SD_1="5.37" SD_2="8.23" SE="0.2374600870451694" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="5.183344170136739"/>
<CONT_DATA CI_END="0.27447797370802884" CI_START="-1.4957510336304494" EFFECT_SIZE="-0.6106365299612103" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="24.3" ORDER="396" SD_1="19.9" SD_2="31.4" SE="0.45159733069123176" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="19" TOTAL_2="7" WEIGHT="2.0175723898412365"/>
<CONT_DATA CI_END="-0.03331773920118622" CI_START="-0.5219115251255585" EFFECT_SIZE="-0.27761463216337234" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" ORDER="397" SD_1="2.13" SD_2="2.39" SE="0.12464356227418913" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="9.164630876379425"/>
<CONT_DATA CI_END="-0.542566709882387" CI_START="-2.0392054480960766" EFFECT_SIZE="-1.2908860789892318" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" ORDER="398" SD_1="25.72" SD_2="50.3" SE="0.38180261219567935" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="2.657384314114261"/>
<CONT_DATA CI_END="0.10957132427633204" CI_START="-0.828869771805423" EFFECT_SIZE="-0.35964922376454544" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" ORDER="399" SD_1="0.37" SD_2="0.45" SE="0.23940263787601673" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="5.132782491292325"/>
<CONT_DATA CI_END="0.31441903252653824" CI_START="-0.736355931194112" EFFECT_SIZE="-0.21096844933378686" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" ORDER="400" SD_1="2616.0" SD_2="2052.0" SE="0.2680597633448954" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.451144402296079"/>
<CONT_DATA CI_END="0.37519357058641994" CI_START="-0.24223042062704997" EFFECT_SIZE="0.06648157497968497" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2009-07-15 17:52:31 +0100" MODIFIED_BY="[Empty name]" ORDER="542" SD_1="11.55" SD_2="2.47" SE="0.1575090144726208" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="7.803977697902088"/>
<CONT_DATA CI_END="0.1400226517700135" CI_START="-1.255120010640152" EFFECT_SIZE="-0.5575486794350692" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2009-03-26 17:26:24 +0000" MODIFIED_BY="[Empty name]" ORDER="494" SD_1="32.98" SD_2="65.05" SE="0.35591028034567795" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.9662847764732474"/>
<CONT_DATA CI_END="0.20700179679268793" CI_START="-0.49234470125219243" EFFECT_SIZE="-0.14267145222975225" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="2.13" ORDER="401" SD_1="2.3" SD_2="2.7" SE="0.17840799717781455" STUDY_ID="STD-Pradalier-1999" TOTAL_1="63" TOTAL_2="63" WEIGHT="7.015442564707355"/>
<CONT_DATA CI_END="0.3645876704551589" CI_START="-0.5293213252329066" EFFECT_SIZE="-0.0823668273888739" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" ORDER="402" SD_1="3.58" SD_2="3.87" SE="0.22804219943302673" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="5.436811784673865"/>
<CONT_DATA CI_END="-0.05920390121172123" CI_START="-0.5427045031708422" EFFECT_SIZE="-0.3009542021912817" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2009-04-10 15:41:01 +0100" MODIFIED_BY="[Empty name]" ORDER="527" SD_1="0.611" SD_2="0.647" SE="0.1233442567753571" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="9.220491203086793"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2010-05-12 14:41:49 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>SLIT versus placebo - ragweed</NAME>
<CONT_OUTCOME CHI2="0.0030923214292562346" CI_END="-0.13776045442539392" CI_START="-0.7380306442042213" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.43789554931480756" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.01" MODIFIED="2010-05-12 14:41:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9556536054849962" P_Q="1.0" P_Z="0.004242060134450716" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="2.859577304558923">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.04616318632402505" CI_START="-0.8445636750665108" EFFECT_SIZE="-0.4453634306952679" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" ORDER="440" SD_1="1.42" SD_2="2.14" SE="0.20367733668581842" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="56.52648288666746"/>
<CONT_DATA CI_END="0.027016812311375538" CI_START="-0.8833876708922371" EFFECT_SIZE="-0.4281854292904308" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" ORDER="441" SD_1="2.45" SD_2="2.54" SE="0.23225030928750912" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="43.473517113332534"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8178115148902978" CI_END="-0.0027816248764476748" CI_START="-0.5998843517739163" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.301332988325182" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" MODIFIED="2010-05-12 14:41:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36582086615076537" P_Q="1.0" P_Z="0.04790331697066478" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="90" UNITS="" WEIGHT="100.0" Z="1.9782251122514147">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.024554491485765773" CI_START="-0.8219829809801797" EFFECT_SIZE="-0.42326873623297273" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" ORDER="442" SD_1="3.09" SD_2="4.24" SE="0.20342937313757498" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="56.06794182899173"/>
<CONT_DATA CI_END="0.3047175577060117" CI_START="-0.5961444663411063" EFFECT_SIZE="-0.1457134543175473" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" ORDER="443" SD_1="1.6" SD_2="1.24" SE="0.2298159637506104" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="43.93205817100828"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>SLIT versus placebo - Parietaria</NAME>
<CONT_OUTCOME CHI2="2.9522655247673013" CI_END="-0.03774206202325736" CI_START="-0.6859379399002898" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3618400009617736" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" MODIFIED="2010-05-12 14:42:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5658452276168462" P_Q="1.0" P_Z="0.02865452938695657" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="2.18820697340366">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.11541900946348327" CI_START="-1.3582751552209138" EFFECT_SIZE="-0.6214280728787153" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" ORDER="430" SD_1="514.2" SD_2="678.2" SE="0.3759492971066582" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="19.34629483093835"/>
<CONT_DATA CI_END="0.44301295589491946" CI_START="-0.9280400604149206" EFFECT_SIZE="-0.24251355226000054" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" ORDER="431" SD_1="1.66" SD_2="1.56" SE="0.34976484953920867" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="22.351364070548996"/>
<CONT_DATA CI_END="-0.03243453032782018" CI_START="-1.615378154996858" EFFECT_SIZE="-0.8239063426623391" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" ORDER="432" SD_1="5.18" SD_2="8.65" SE="0.40381956942961583" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="16.76801421915727"/>
<CONT_DATA CI_END="0.6980877530563241" CI_START="-0.7332994834855815" EFFECT_SIZE="-0.017605865214628664" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" ORDER="433" SD_1="113.0" SD_2="108.0" SE="0.36515651507693647" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="20.50681667673204"/>
<CONT_DATA CI_END="0.4896876084710748" CI_START="-0.9238661793093286" EFFECT_SIZE="-0.21708928541912692" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" ORDER="434" SD_1="76.0" SD_2="58.0" SE="0.3606070823061891" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="21.027510202623343"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.300254621097287" CI_END="-0.23942752840316645" CI_START="-1.00323817289812" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6213328506506431" ESTIMABLE="YES" I2="24.53192750253386" I2_Q="0.0" ID="CMP-016.02" NO="2" P_CHI2="0.2578532371007809" P_Q="1.0" P_Z="0.0014290309642861802" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04657145190319284" TOTALS="YES" TOTAL_1="74" TOTAL_2="77" UNITS="" WEIGHT="99.99999999999999" Z="3.188722279439014">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SLIT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.040201569205475574" CI_START="-1.5373123798319488" EFFECT_SIZE="-0.7887569745187122" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" ORDER="435" SD_1="46.6" SD_2="121.0" SE="0.38192304104450187" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="19.730015493090455"/>
<CONT_DATA CI_END="0.6627996626743151" CI_START="-0.7026094767798856" EFFECT_SIZE="-0.019904907052785255" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" ORDER="436" SD_1="3.89" SD_2="3.95" SE="0.3483250585787223" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="22.613088985350675"/>
<CONT_DATA CI_END="-0.399280496523714" CI_START="-2.0686710568669264" EFFECT_SIZE="-1.2339757766953203" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" ORDER="437" SD_1="7.26" SD_2="16.5" SE="0.4258727643750478" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="16.656988279973195"/>
<CONT_DATA CI_END="0.04931831481183857" CI_START="-1.4303252489043339" EFFECT_SIZE="-0.6905034670462477" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" ORDER="438" SD_1="49.5" SD_2="65.0" SE="0.37746702882997135" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="20.083162537908027"/>
<CONT_DATA CI_END="0.16067486412900733" CI_START="-1.2793167041450233" EFFECT_SIZE="-0.5593209200080079" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" ORDER="439" SD_1="21.0" SD_2="33.0" SE="0.36735153799572345" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="20.91674470367765"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>SLIT versus placebo - tree</NAME>
<CONT_OUTCOME CHI2="20.168362196247763" CI_END="-0.060564720144577644" CI_START="-0.7745726499250944" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.417568685034836" ESTIMABLE="YES" I2="60.333913472218555" I2_Q="0.0" ID="CMP-017.01" MODIFIED="2010-05-12 14:43:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.009717515831180634" P_Q="1.0" P_Z="0.021878745952142488" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.16517853737880614" TOTALS="YES" TOTAL_1="197" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="2.2924663707631567">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.9324135386472658" CI_START="-3.1925312217374806" EFFECT_SIZE="-2.0624723801923732" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" ORDER="449" SD_1="1.75" SD_2="1.57" SE="0.576571228072999" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.667426707352714"/>
<CONT_DATA CI_END="0.11694054246356766" CI_START="-2.109699173491202" EFFECT_SIZE="-0.9963793155138172" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" ORDER="451" SD_1="3.56" SD_2="7.1" SE="0.5680307734015062" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="6.801030431682101"/>
<CONT_DATA CI_END="-0.233107093725624" CI_START="-1.7205470996667698" EFFECT_SIZE="-0.9768270966961969" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" ORDER="444" SD_1="0.3" SD_2="0.5" SE="0.37945595369962987" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="10.73146642872443"/>
<CONT_DATA CI_END="0.9548805664737311" CI_START="-1.0268729165339034" EFFECT_SIZE="-0.035996175030086154" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="35.0" ORDER="445" SD_1="27.8" SD_2="21.9" SE="0.5055586476688992" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="18" TOTAL_2="5" WEIGHT="7.885098208310068"/>
<CONT_DATA CI_END="-0.026553415270698932" CI_START="-0.8210463824250163" EFFECT_SIZE="-0.4237998988478576" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" ORDER="446" SD_1="0.3" SD_2="0.43" SE="0.20268050163706489" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="16.08567376210291"/>
<CONT_DATA CI_END="0.03961956574599351" CI_START="-1.0256660773739008" EFFECT_SIZE="-0.4930232558139536" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="448" SD_1="1.4" SD_2="1.4" SE="0.2717615352942022" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="13.880089670987905"/>
<CONT_DATA CI_END="0.7627997429198285" CI_START="-0.5104043814031989" EFFECT_SIZE="0.1261976807583148" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" ORDER="450" SD_1="1.64" SD_2="2.06" SE="0.3248029388207893" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="12.257473721651206"/>
<CONT_DATA CI_END="1.0964805451389883" CI_START="-0.3491814293029491" EFFECT_SIZE="0.3736495579180196" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" ORDER="447" SD_1="154.0" SD_2="79.0" SE="0.36879809676227077" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="11.01560923055271"/>
<CONT_DATA CI_END="0.31567605874105453" CI_START="-0.6515938392938466" EFFECT_SIZE="-0.16795889027639602" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" ORDER="452" SD_1="1.63" SD_2="2.01" SE="0.24675705922777222" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="14.676131838635957"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.244355844260912" CI_END="-0.13278849405788964" CI_START="-0.6218275970608765" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3773080455593831" ESTIMABLE="YES" I2="21.908218324124732" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2010-05-12 14:43:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2482926602863117" P_Q="1.0" P_Z="0.0024917650287175634" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.029808688932281176" TOTALS="YES" TOTAL_1="197" TOTAL_2="183" UNITS="" WEIGHT="99.99999999999997" Z="3.0243396727687526">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1989982019519022" CI_START="-1.621790652209877" EFFECT_SIZE="-0.7113962251289874" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" ORDER="458" SD_1="2.1" SD_2="4.9" SE="0.4644954878058804" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.338185983572853"/>
<CONT_DATA CI_END="0.8608625700733046" CI_START="-1.2102449762899692" EFFECT_SIZE="-0.17469120310833228" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" ORDER="460" SD_1="2.46" SD_2="2.22" SE="0.5283534704463719" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="5.037559608511023"/>
<CONT_DATA CI_END="-0.6819515230190969" CI_START="-2.279278775745098" EFFECT_SIZE="-1.4806151493820974" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" ORDER="453" SD_1="0.7" SD_2="1.5" SE="0.40748892972664663" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="7.9468369598192705"/>
<CONT_DATA CI_END="0.5938576576569483" CI_START="-1.4043990875931345" EFFECT_SIZE="-0.405270714968093" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="23.2" ORDER="454" SD_1="17.4" SD_2="20.7" SE="0.5097687409085261" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="18" TOTAL_2="5" WEIGHT="5.373078611086213"/>
<CONT_DATA CI_END="0.17448940442550886" CI_START="-0.6133591056001998" EFFECT_SIZE="-0.21943485058734546" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" ORDER="455" SD_1="0.17" SD_2="0.19" SE="0.20098545591657732" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="22.170225796487454"/>
<CONT_DATA CI_END="0.2837514105331681" CI_START="-0.7686923178911552" EFFECT_SIZE="-0.24247045367899356" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" ORDER="457" SD_1="3.4" SD_2="4.6" SE="0.2684854764490228" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="15.275170029491516"/>
<CONT_DATA CI_END="0.35244475334131287" CI_START="-0.9266364567041259" EFFECT_SIZE="-0.2870958516814065" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" ORDER="459" SD_1="3.94" SD_2="5.0" SE="0.3263022229323263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="11.420708414247853"/>
<CONT_DATA CI_END="0.21336772239412094" CI_START="-1.2451382933933233" EFFECT_SIZE="-0.5158852854996011" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" ORDER="456" SD_1="30.0" SD_2="34.0" SE="0.37207469813015787" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.250823435000816"/>
<CONT_DATA CI_END="0.3796168985461663" CI_START="-0.5865320313521794" EFFECT_SIZE="-0.10345756640300652" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" ORDER="461" SD_1="3.41" SD_2="3.85" SE="0.246471092713745" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="17.18741116178299"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Allergen sensitivity</NAME>
<CONT_OUTCOME CHI2="12.466363103525289" CI_END="0.5119111177779916" CI_START="-0.26391816262043055" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12399647757878049" ESTIMABLE="YES" I2="59.892071500900855" I2_Q="0.0" ID="CMP-018.01" MODIFIED="2009-11-24 16:52:23 +0000" MODIFIED_BY="Suzana Radulovic" NO="1" P_CHI2="0.028927215090064795" P_Q="1.0" P_Z="0.5309868576179911" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.13026134633996306" TOTALS="YES" TOTAL_1="183" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="0.6265002788743222">
<NAME>Skin reactivity after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9970047455877931" CI_START="-0.32204575532887864" EFFECT_SIZE="0.33747949512945724" ESTIMABLE="YES" MEAN_1="8255.0" MEAN_2="3693.0" MODIFIED="2009-11-24 16:52:23 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="660" SD_1="16489.0" SD_2="8085.0" SE="0.3364986579654457" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="16.087561708344953"/>
<CONT_DATA CI_END="-0.08877049853477392" CI_START="-2.3596588196076924" EFFECT_SIZE="-1.2242146590712333" ESTIMABLE="YES" MEAN_1="4.63" MEAN_2="6.29" ORDER="465" SD_1="0.74" SD_2="1.7" SE="0.5793188902922186" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="8.408331163536765"/>
<CONT_DATA CI_END="0.39012914780605884" CI_START="-0.2926605938761571" EFFECT_SIZE="0.048734276964950855" ESTIMABLE="YES" MEAN_1="19.64" MEAN_2="18.67" ORDER="466" SD_1="21.15" SD_2="18.23" SE="0.17418425722818742" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="24.390828744251174"/>
<CONT_DATA CI_END="1.2968749490129667" CI_START="5.090800024816211E-4" EFFECT_SIZE="0.6486920145077242" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="3.2" ORDER="462" SD_1="2.5" SD_2="2.2" SE="0.3307116557334863" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="36" TOTAL_2="13" WEIGHT="16.34677820557607"/>
<CONT_DATA CI_END="0.3975782833179277" CI_START="-1.1268375502552819" EFFECT_SIZE="-0.3646296334686771" ESTIMABLE="YES" MEAN_1="250.08" MEAN_2="277.3" ORDER="463" SD_1="59.53" SD_2="84.13" SE="0.3888887361190326" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="13.915674018414467"/>
<CONT_DATA CI_END="0.9761732554214868" CI_START="0.03533592613723141" EFFECT_SIZE="0.5057545907793591" ESTIMABLE="YES" MEAN_1="1.67" MEAN_2="1.26" ORDER="464" SD_1="0.89" SD_2="0.69" SE="0.24001393308893945" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="38" TOTAL_2="34" WEIGHT="20.850826159876572"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.3910194605542" CI_END="0.7814035292516854" CI_START="-0.13477660140954134" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3233134639210721" ESTIMABLE="YES" I2="63.394589247854306" I2_Q="0.0" ID="CMP-018.02" MODIFIED="2010-06-30 09:40:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.011802212139659596" P_Q="1.0" P_Z="0.1665683767326715" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.23727998066460346" TOTALS="YES" TOTAL_1="111" TOTAL_2="109" UNITS="" WEIGHT="100.00000000000001" Z="1.383314751750508">
<NAME>Nasal reactivity after treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.789195898697617" CI_START="-0.5211119060133332" EFFECT_SIZE="0.13404199634214187" ESTIMABLE="YES" MEAN_1="9643.0" MEAN_2="6330.0" MODIFIED="2009-11-24 16:51:03 +0000" MODIFIED_BY="Suzana Radulovic" ORDER="659" SD_1="24181.0" SD_2="24151.0" SE="0.3342683373384641" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="15.65168490309694"/>
<CONT_DATA CI_END="3.11745611778688" CI_START="0.8840391142554354" EFFECT_SIZE="2.0007476160211577" ESTIMABLE="YES" MEAN_1="28.26" MEAN_2="11.0" ORDER="470" SD_1="10.2" SD_2="5.7" SE="0.5697597050630402" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.721691065945178"/>
<CONT_DATA CI_END="1.1681059733470094" CI_START="-0.4529587989280092" EFFECT_SIZE="0.3575735872095001" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="4.4" ORDER="468" SD_1="2.8" SD_2="3.7" SE="0.41354453068060704" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="13.379108783304957"/>
<CONT_DATA CI_END="0.42473390933229366" CI_START="-0.9472287140491573" EFFECT_SIZE="-0.26124740235843186" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.17" MODIFIED="2009-04-03 18:05:30 +0100" MODIFIED_BY="[Empty name]" ORDER="489" SD_1="1.39" SD_2="2.14" SE="0.34999689642343357" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="15.183475493447533"/>
<CONT_DATA CI_END="0.290794854549661" CI_START="-0.8998227342064875" EFFECT_SIZE="-0.3045139398284133" ESTIMABLE="YES" MEAN_1="4.74" MEAN_2="5.1" ORDER="469" SD_1="1.29" SD_2="1.0" SE="0.30373455791728526" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="23" TOTAL_2="21" WEIGHT="16.576943665626512"/>
<CONT_DATA CI_END="1.388160003770551" CI_START="-0.06414294473085802" EFFECT_SIZE="0.6620085295198466" ESTIMABLE="YES" MEAN_1="8.73" MEAN_2="5.56" ORDER="471" SD_1="5.2" SD_2="4.1" SE="0.3704922539283858" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="14.584856182318175"/>
<CONT_DATA CI_END="1.0642760632724655" CI_START="-0.34519598498366716" EFFECT_SIZE="0.3595400391443992" ESTIMABLE="YES" MEAN_1="180.0" MEAN_2="138.0" ORDER="472" SD_1="115.0" SD_2="113.0" SE="0.35956580308971703" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="14.902239906260716"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Quality of life</NAME>
<CONT_OUTCOME CHI2="4.169444221677906" CI_END="-0.11977191791136088" CI_START="-0.726629497662208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4232007077867844" ESTIMABLE="YES" I2="76.01598805901351" I2_Q="0.0" ID="CMP-019.01" MODIFIED="2010-06-11 15:44:57 +0100" MODIFIED_BY="Suzana Radulovic" NO="1" P_CHI2="0.04115942638858683" P_Q="1.0" P_Z="0.0062642833636592276" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="203" UNITS="" WEIGHT="100.0" Z="2.733617155558975">
<NAME>Adults</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.40822469353930724" CI_START="-2.2517753064606927" EFFECT_SIZE="-1.33" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.83" ORDER="473" SD_1="1.52" SD_2="1.14" SE="0.47030216561709237" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="10.835861139310166"/>
<CONT_DATA CI_END="0.00833769586981542" CI_START="-0.6343376958698155" EFFECT_SIZE="-0.31300000000000006" ESTIMABLE="YES" MEAN_1="-1.127" MEAN_2="-0.814" MODIFIED="2010-04-28 13:09:31 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="669" SD_1="1.531" SD_2="1.601" SE="0.16395081664994163" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="89.16413886068983"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>SLIT versus placebo - tablets</NAME>
<CONT_OUTCOME CHI2="39.07438548756373" CI_END="-0.38374942637190446" CI_START="-0.582954867609196" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.48335214699055024" ESTIMABLE="YES" I2="74.40778690382037" I2_Q="0.0" ID="CMP-020.01" MODIFIED="2010-05-12 14:43:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.4638344305327742E-5" P_Q="1.0" P_Z="1.8826829647670366E-21" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="945" TOTAL_2="936" UNITS="" WEIGHT="99.99999999999999" Z="9.511314490883928">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07564782563358652" CI_START="-1.0756478256335864" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="2.67" MEAN_2="3.17" MODIFIED="2010-04-16 14:54:09 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="666" SD_1="2.38" SD_2="2.14" SE="0.2937032670876726" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="2.9938405425215016"/>
<CONT_DATA CI_END="0.8212069544999996" CI_START="-4.2212069544999995" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.9" MODIFIED="2010-04-16 14:54:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="667" SD_1="3.7" SD_2="3.8" SE="1.2863537158779235" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.15607214873341949"/>
<CONT_DATA CI_END="-0.3264911963224314" CI_START="-2.073508803677568" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.3" MODIFIED="2010-04-16 14:55:18 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="669" SD_1="1.7" SD_2="2.2" SE="0.445675946378451" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="1.3001930182539807"/>
<CONT_DATA CI_END="-0.6839586723504694" CI_START="-1.3160413276495306" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.4" MODIFIED="2010-04-16 14:55:18 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="670" SD_1="1.6" SD_2="2.2" SE="0.1612485383111242" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="9.932410202063277"/>
<CONT_DATA CI_END="-0.6283424106058602" CI_START="-2.071657589394139" EFFECT_SIZE="-1.3499999999999996" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.93" MODIFIED="2010-04-16 14:56:08 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="671" SD_1="2.976" SD_2="3.229" SE="0.36819941340069634" STUDY_ID="STD-Didier-2007" TOTAL_1="136" TOTAL_2="148" WEIGHT="1.904934449650393"/>
<CONT_DATA CI_END="0.02930923729542545" CI_START="-0.9893092372954254" EFFECT_SIZE="-0.48" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="2.96" MODIFIED="2010-04-16 14:56:34 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="672" SD_1="2.1" SD_2="2.09" SE="0.25985642660415786" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="3.824540783198451"/>
<CONT_DATA CI_END="4.480836165825721" CI_START="-53.90083616582572" EFFECT_SIZE="-24.71" ESTIMABLE="YES" MEAN_1="31.15" MEAN_2="55.86" MODIFIED="2010-04-28 17:34:55 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2021" SD_1="32.61" SD_2="50.48" SE="14.893557430687151" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.001164258270038725"/>
<CONT_DATA CI_END="-15.028114412018134" CI_START="-83.97188558798186" EFFECT_SIZE="-49.49999999999999" ESTIMABLE="YES" MEAN_1="59.6" MEAN_2="109.1" MODIFIED="2010-04-16 15:07:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="690" SD_1="27.8" SD_2="45.7" SE="17.588019912555378" STUDY_ID="STD-Passalacqua-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="8.348574424509765E-4"/>
<CONT_DATA CI_END="77.10261831571258" CI_START="-81.10261831571258" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="189.0" MEAN_2="191.0" MODIFIED="2010-04-16 15:01:28 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="688" SD_1="113.0" SD_2="108.0" SE="40.359220342651156" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.5854796949657372E-4"/>
<CONT_DATA CI_END="-0.24710442175518316" CI_START="-0.47289557824481704" EFFECT_SIZE="-0.3600000000000001" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.18" MODIFIED="2010-04-16 15:01:28 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="675" SD_1="0.23" SD_2="0.2" SE="0.057600843247795804" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="77.83743888329673"/>
<CONT_DATA CI_END="-0.5640748802899082" CI_START="-1.9559251197100913" EFFECT_SIZE="-1.2599999999999998" ESTIMABLE="YES" MEAN_1="3.25" MEAN_2="4.51" MODIFIED="2010-04-16 15:01:47 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="676" SD_1="2.86" SD_2="2.931" SE="0.35507036108798945" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="2.0484123086002564"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="50.39345206900678" CI_END="-0.19588287907708893" CI_START="-0.4621993025975336" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.32904109083731126" ESTIMABLE="YES" I2="84.12492164846115" I2_Q="0.0" ID="CMP-020.02" MODIFIED="2010-05-12 14:43:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.433487727466655E-8" P_Q="1.0" P_Z="1.2777985318408936E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="799" TOTAL_2="779" UNITS="" WEIGHT="100.0" Z="4.843176240877942">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>SLIT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4301156662387984" CI_START="-1.2301156662387982" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="2.53" MODIFIED="2010-04-16 15:02:37 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="677" SD_1="3.48" SD_2="3.03" SE="0.4235361837190095" STUDY_ID="STD-Bufe-2009" TOTAL_1="117" TOTAL_2="121" WEIGHT="2.57311198819125"/>
<CONT_DATA CI_END="3.573700979705327" CI_START="-5.373700979705328" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="9.0" MODIFIED="2010-04-16 15:03:24 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="679" SD_1="6.4" SD_2="6.9" SE="2.282542442102666" STUDY_ID="STD-Caffarelli-2000" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0885935293062675"/>
<CONT_DATA CI_END="-0.07494578272774444" CI_START="-3.525054217272256" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.2" MODIFIED="2010-04-16 15:03:59 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="681" SD_1="3.9" SD_2="4.1" SE="0.8801458755769307" STUDY_ID="STD-Dahl-2006a" TOTAL_1="61" TOTAL_2="32" WEIGHT="0.5958410358649032"/>
<CONT_DATA CI_END="-0.5351382651995557" CI_START="-1.2648617348004443" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" MODIFIED="2010-04-16 15:03:59 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="682" SD_1="1.9" SD_2="2.5" SE="0.18615736701206095" STUDY_ID="STD-Dahl-2006b" TOTAL_1="282" TOTAL_2="286" WEIGHT="13.319234674708529"/>
<CONT_DATA CI_END="-0.07941869820359626" CI_START="-1.1805813017964035" EFFECT_SIZE="-0.6299999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.03" MODIFIED="2010-04-28 17:38:57 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2022" SD_1="2.13" SD_2="2.39" SE="0.28091398930761924" STUDY_ID="STD-Durham-2006" TOTAL_1="131" TOTAL_2="129" WEIGHT="5.849153136766464"/>
<CONT_DATA CI_END="6.330804577204965" CI_START="-64.71080457720495" EFFECT_SIZE="-29.189999999999998" ESTIMABLE="YES" MEAN_1="15.38" MEAN_2="44.57" MODIFIED="2010-04-28 17:39:33 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2023" SD_1="32.98" SD_2="65.05" SE="18.123192496080815" STUDY_ID="STD-Palma-Carlos-2006" TOTAL_1="17" TOTAL_2="16" WEIGHT="0.0014053041204813244"/>
<CONT_DATA CI_END="0.3462598008884541" CI_START="-82.34625980088845" EFFECT_SIZE="-41.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="83.0" MODIFIED="2010-04-16 15:06:42 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="686" SD_1="49.5" SD_2="65.0" SE="21.09541814391615" STUDY_ID="STD-Passalacqua-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0010372022493966228"/>
<CONT_DATA CI_END="-35.1751767867098" CI_START="-76.8248232132902" EFFECT_SIZE="-56.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="166.0" MODIFIED="2010-04-16 15:06:42 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="687" SD_1="44.0" SD_2="35.0" SE="10.625105041497573" STUDY_ID="STD-Passalacqua-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0040885871734255945"/>
<CONT_DATA CI_END="-0.038808296503557466" CI_START="-0.3411917034964427" EFFECT_SIZE="-0.19000000000000006" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.79" MODIFIED="2010-04-16 15:08:02 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="689" SD_1="0.611" SD_2="0.647" SE="0.07714004169924726" STUDY_ID="STD-Wahn-2009" TOTAL_1="131" TOTAL_2="135" WEIGHT="77.5675345416193"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2010-06-30 10:27:39 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>SLIT versus placebo - drops</NAME>
<CONT_OUTCOME CHI2="436.12007485534474" CI_END="-0.2849532928043412" CI_START="-0.41741917456662897" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35118623368548507" ESTIMABLE="YES" I2="92.20398189391365" I2_Q="0.0" ID="CMP-021.01" MODIFIED="2010-05-12 14:44:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.1094237467877974E-15" P_Q="1.0" P_Z="2.6880126959210186E-25" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="35" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1270" TOTAL_2="1194" UNITS="" WEIGHT="99.99999999999999" Z="10.392296653790535">
<NAME>Allergic rhinitis symptom scores</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6698428945090367" CI_START="-2.4298428945090365" EFFECT_SIZE="0.1200000000000001" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="3.71" MODIFIED="2010-04-28 16:29:22 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="691" SD_1="4.9" SD_2="2.7" SE="1.300964157822221" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0674716347480373"/>
<CONT_DATA CI_END="-0.10843747978134044" CI_START="-1.5315625202186594" EFFECT_SIZE="-0.8199999999999998" ESTIMABLE="YES" MEAN_1="2.27" MEAN_2="3.09" MODIFIED="2010-04-28 16:30:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="692" SD_1="1.42" SD_2="2.14" SE="0.36304877325878115" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="0.8664069928189411"/>
<CONT_DATA CI_END="-2.122835648064889" CI_START="-5.037164351935111" EFFECT_SIZE="-3.58" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="5.38" MODIFIED="2010-04-28 16:30:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="693" SD_1="1.75" SD_2="1.57" SE="0.7434648613081858" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.20660032571792938"/>
<CONT_DATA CI_END="0.5250607346807413" CI_START="-0.2650607346807413" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.4" MODIFIED="2010-04-28 16:30:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="694" SD_1="0.4" SD_2="0.38" SE="0.20156530313665452" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="2.8107378630847326"/>
<CONT_DATA CI_END="0.04190668691118127" CI_START="-2.2019066869111814" EFFECT_SIZE="-1.08" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="5.03" MODIFIED="2010-04-28 16:30:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="695" SD_1="2.45" SD_2="2.54" SE="0.5724118890758392" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.34852553698131755"/>
<CONT_DATA CI_END="0.24801197696059019" CI_START="-0.3480119769605903" EFFECT_SIZE="-0.050000000000000044" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.59" MODIFIED="2010-04-28 16:32:21 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="696" SD_1="0.77" SD_2="0.96" SE="0.15204972097001304" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="4.93947328702902"/>
<CONT_DATA CI_END="-1.7804042065256882" CI_START="-2.199595793474312" EFFECT_SIZE="-1.9900000000000002" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="2.64" MODIFIED="2010-04-28 16:42:47 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="697" SD_1="0.88" SD_2="0.46" SE="0.1069385943453945" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="9.985802071175566"/>
<CONT_DATA CI_END="0.6187387524432388" CI_START="-11.65873875244324" EFFECT_SIZE="-5.5200000000000005" ESTIMABLE="YES" MEAN_1="5.46" MEAN_2="10.98" MODIFIED="2010-04-28 16:42:47 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="698" SD_1="3.56" SD_2="7.1" SE="3.1320671200414023" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.011640986223996695"/>
<CONT_DATA CI_END="39.7020113349634" CI_START="-815.8220113349632" EFFECT_SIZE="-388.05999999999995" ESTIMABLE="YES" MEAN_1="509.0" MEAN_2="897.06" MODIFIED="2010-04-28 16:43:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1340" SD_1="514.2" SD_2="678.2" SE="218.24993454425464" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="2.3974173933277556E-6"/>
<CONT_DATA CI_END="4.905027349610977" CI_START="-10.785027349610973" EFFECT_SIZE="-2.9399999999999977" ESTIMABLE="YES" MEAN_1="20.55" MEAN_2="23.49" MODIFIED="2010-04-28 16:44:05 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="700" SD_1="15.88" SD_2="18.76" SE="4.002638523713471" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="0.007127859887239403"/>
<CONT_DATA CI_END="-0.10368129818650129" CI_START="-0.6963187018134988" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.8" MODIFIED="2010-04-28 16:44:43 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="701" SD_1="0.3" SD_2="0.5" SE="0.15118578920369088" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="4.9960865516331125"/>
<CONT_DATA CI_END="11.985088672049766" CI_START="-25.785088672049763" EFFECT_SIZE="-6.899999999999999" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="36.4" MODIFIED="2010-04-28 16:45:05 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="702" SD_1="24.2" SD_2="30.4" SE="9.635426375695133" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="0.0012300139061213965"/>
<CONT_DATA CI_END="-0.01592501037597735" CI_START="-0.3040749896240227" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.64" MODIFIED="2010-04-28 16:45:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="703" SD_1="0.3" SD_2="0.43" SE="0.07350899851245625" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="21.133473527111935"/>
<CONT_DATA CI_END="-35.70376044736635" CI_START="-176.49623955263365" EFFECT_SIZE="-106.10000000000001" ESTIMABLE="YES" MEAN_1="109.7" MEAN_2="215.8" MODIFIED="2010-04-28 16:46:05 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="704" SD_1="92.46" SD_2="114.2" SE="35.91710873664527" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="8.852158004045018E-5"/>
<CONT_DATA CI_END="0.09992317968687436" CI_START="-1.899923179686875" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.2" MODIFIED="2010-04-28 16:46:05 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1339" SD_1="1.9" SD_2="2.4" SE="0.5101742621671322" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.4387476526514214"/>
<CONT_DATA CI_END="1.1725817077236123" CI_START="-0.2325817077236123" EFFECT_SIZE="0.47" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="0.52" MODIFIED="2010-04-28 16:50:15 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1341" SD_1="1.13" SD_2="0.47" SE="0.358466641869691" STUDY_ID="STD-Hirsch-1997" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.8886984062360987"/>
<CONT_DATA CI_END="-0.36953876152699916" CI_START="-3.4704612384730007" EFFECT_SIZE="-1.92" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="5.13" MODIFIED="2010-04-28 16:50:15 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="705" SD_1="3.05" SD_2="3.6" SE="0.7910661883089899" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="0.1824846132316626"/>
<CONT_DATA CI_END="0.7006867737847611" CI_START="-1.5006867737847613" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.61" MODIFIED="2010-04-28 16:53:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="708" SD_1="1.66" SD_2="1.56" SE="0.5615852038439675" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.3620933779050497"/>
<CONT_DATA CI_END="1061.6508138796084" CI_START="-1003.6508138796084" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="2494.0" MEAN_2="2465.0" MODIFIED="2010-04-28 16:53:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="709" SD_1="2326.0" SD_2="1537.0" SE="526.8723415455725" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="4.11378030650466E-7"/>
<CONT_DATA CI_END="266.6230131867796" CI_START="-475.3230131867795" EFFECT_SIZE="-104.34999999999997" ESTIMABLE="YES" MEAN_1="412.92" MEAN_2="517.27" MODIFIED="2010-04-28 16:54:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="710" SD_1="332.55" SD_2="548.18" SE="189.27542348378202" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="3.1875972463795052E-6"/>
<CONT_DATA CI_END="0.4158929318975062" CI_START="-13.455892931897509" EFFECT_SIZE="-6.520000000000001" ESTIMABLE="YES" MEAN_1="12.15" MEAN_2="18.67" MODIFIED="2010-04-28 16:54:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1343" SD_1="8.68" SD_2="13.56" SE="3.5387859096427006" STUDY_ID="STD-Nelson-1993" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.009118918144951258"/>
<CONT_DATA CI_END="-0.9387961954924009" CI_START="-3.741203804507599" EFFECT_SIZE="-2.34" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="1.32" MODIFIED="2010-04-28 16:54:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="711" SD_1="4.54" SD_2="4.54" SE="0.714913036953799" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="0.22343204600992436"/>
<CONT_DATA CI_END="-0.5711555819788154" CI_START="-11.428844418021185" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="10.0" MODIFIED="2010-04-28 16:54:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="712" SD_1="5.18" SD_2="8.65" SE="2.7698694776246993" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.014884466974926057"/>
<CONT_DATA CI_END="-92.09042725024374" CI_START="-328.4095727497563" EFFECT_SIZE="-210.25000000000003" ESTIMABLE="YES" MEAN_1="111.35" MEAN_2="321.6" MODIFIED="2010-04-28 16:55:39 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1344" SD_1="114.91" SD_2="211.22" SE="60.28660408139329" STUDY_ID="STD-Panzner-2008" TOTAL_1="20" TOTAL_2="15" WEIGHT="3.1420294708443495E-5"/>
<CONT_DATA CI_END="0.057388935138883074" CI_START="-0.15338893513888316" EFFECT_SIZE="-0.04800000000000004" ESTIMABLE="YES" MEAN_1="0.732" MEAN_2="0.78" MODIFIED="2010-04-28 16:56:25 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="713" SD_1="0.483" SD_2="0.544" SE="0.05377085291881768" STUDY_ID="STD-Peter-2009" TOTAL_1="176" TOTAL_2="189" WEIGHT="39.49644845601386"/>
<CONT_DATA CI_END="-36.96974813811438" CI_START="-143.03025186188563" EFFECT_SIZE="-90.0" ESTIMABLE="YES" MEAN_1="146.2" MEAN_2="236.2" MODIFIED="2010-04-28 16:56:25 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="714" SD_1="123.0" SD_2="133.6" SE="27.056748124037725" STUDY_ID="STD-Pfaar-2008" TOTAL_1="42" TOTAL_2="48" WEIGHT="1.5599141536391342E-4"/>
<CONT_DATA CI_END="11.051735367755509" CI_START="-8.951735367755507" EFFECT_SIZE="1.0500000000000007" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="12.66" MODIFIED="2010-04-28 16:57:06 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="715" SD_1="23.12" SD_2="21.65" SE="5.103019977228112" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="0.004385280310892254"/>
<CONT_DATA CI_END="0.18952009023017968" CI_START="-0.7695200902301798" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.74" MODIFIED="2010-04-28 16:57:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="716" SD_1="1.48" SD_2="1.66" SE="0.24465760290116195" STUDY_ID="STD-R_x0151_der-2007" TOTAL_1="91" TOTAL_2="77" WEIGHT="1.9078071121708893"/>
<CONT_DATA CI_END="-3.0851834921254473" CI_START="-4.914816507874553" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="12.0" MODIFIED="2010-04-28 16:59:04 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1346" SD_1="1.5" SD_2="2.0" SE="0.4667516929344155" STUDY_ID="STD-Tari-1990" TOTAL_1="30" TOTAL_2="28" WEIGHT="0.5241795726303593"/>
<CONT_DATA CI_END="32.82138078592975" CI_START="-62.82138078592975" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="102.0" MODIFIED="2010-04-28 16:59:31 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1347" SD_1="76.0" SD_2="58.0" SE="24.39911200569944" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="1.91824402761547E-4"/>
<CONT_DATA CI_END="0.033819518527468895" CI_START="-1.4338195185274691" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" MODIFIED="2010-04-28 17:00:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="717" SD_1="1.4" SD_2="1.4" SE="0.37440459330668513" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.8146471824091478"/>
<CONT_DATA CI_END="1.4239630660943805" CI_START="-0.9439630660943801" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="2.68" MEAN_2="2.44" MODIFIED="2010-04-28 17:00:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="718" SD_1="1.64" SD_2="2.06" SE="0.6040738888231263" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.3129477033273579"/>
<CONT_DATA CI_END="134.5894140831847" CI_START="-40.58941408318471" EFFECT_SIZE="47.0" ESTIMABLE="YES" MEAN_1="130.0" MEAN_2="83.0" MODIFIED="2010-04-28 17:00:46 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1348" SD_1="154.0" SD_2="79.0" SE="44.68929774938663" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.71800901478761E-5"/>
<CONT_DATA CI_END="0.5761058574979074" CI_START="-1.196105857497907" EFFECT_SIZE="-0.30999999999999983" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.38" MODIFIED="2010-04-28 17:01:06 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1349" SD_1="1.63" SD_2="2.01" SE="0.45210313275519204" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.5586976739921865"/>
<CONT_DATA CI_END="0.03218414575023426" CI_START="-0.41218414575023427" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="0.51" MODIFIED="2010-04-28 17:02:01 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="719" SD_1="0.26" SD_2="0.38" SE="0.11336134107707817" STUDY_ID="STD-Wessner-2001" TOTAL_1="14" TOTAL_2="18" WEIGHT="8.886319953497631"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="82.89123705681482" CI_END="0.03786199975353669" CI_START="-0.0531902078933" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.007664104069881655" ESTIMABLE="YES" I2="68.6335963568993" I2_Q="0.0" ID="CMP-021.02" MODIFIED="2010-05-12 14:44:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.460721329621833E-8" P_Q="1.0" P_Z="0.7414372452214733" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="865" TOTAL_2="788" UNITS="" WEIGHT="100.00000000000001" Z="0.3299506588351625">
<NAME>Medication scores</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8515051301276819" CI_START="-0.2515051301276819" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.14" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1984" SD_1="1.2" SD_2="0.24" SE="0.28138533895412565" STUDY_ID="STD-Amar-2009" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.6814309511702932"/>
<CONT_DATA CI_END="-0.13457567927568714" CI_START="-3.0454243207243126" EFFECT_SIZE="-1.5899999999999999" ESTIMABLE="YES" MEAN_1="2.41" MEAN_2="4.0" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1985" SD_1="3.09" SD_2="4.24" SE="0.7425770739689678" STUDY_ID="STD-Andre-2003" TOTAL_1="48" TOTAL_2="51" WEIGHT="0.09784569292626878"/>
<CONT_DATA CI_END="0.5041528367211936" CI_START="-6.104152836721193" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="5.3" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1986" SD_1="2.1" SD_2="4.9" SE="1.6858232410309215" STUDY_ID="STD-Ariano-2001" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.018984567748271224"/>
<CONT_DATA CI_END="0.8533855799863603" CI_START="-1.4933855799863605" EFFECT_SIZE="-0.32000000000000006" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="1.57" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1987" SD_1="1.04" SD_2="1.25" SE="0.598677113070381" STUDY_ID="STD-Bahceciler-2001" TOTAL_1="8" TOTAL_2="7" WEIGHT="0.15053568925987795"/>
<CONT_DATA CI_END="0.4359407074855668" CI_START="-0.8559407074855667" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.26" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1988" SD_1="1.6" SD_2="1.24" SE="0.3295676413345677" STUDY_ID="STD-Bowen-2004" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.4967474647234678"/>
<CONT_DATA CI_END="0.12485511208458833" CI_START="-0.004855112084588331" EFFECT_SIZE="0.06" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.18" MODIFIED="2010-04-28 17:20:54 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1989" SD_1="0.19" SD_2="0.19" SE="0.03308995093591371" STUDY_ID="STD-Bufe-2004" TOTAL_1="68" TOTAL_2="64" WEIGHT="49.27567027294423"/>
<CONT_DATA CI_END="0.22505570622360777" CI_START="-0.5650557062236077" EFFECT_SIZE="-0.16999999999999998" ESTIMABLE="YES" MEAN_1="0.01" MEAN_2="0.18" MODIFIED="2010-04-28 17:22:20 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1990" SD_1="0.1" SD_2="1.92" SE="0.2015627375501574" STUDY_ID="STD-Cao-2007" TOTAL_1="85" TOTAL_2="91" WEIGHT="1.3280190063338544"/>
<CONT_DATA CI_END="1.9554897591834717" CI_START="-2.8354897591834716" EFFECT_SIZE="-0.43999999999999995" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="2.13" MODIFIED="2010-04-28 17:23:16 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1991" SD_1="2.46" SD_2="2.22" SE="1.2222111110606058" STUDY_ID="STD-Casanovas-1994" TOTAL_1="9" TOTAL_2="6" WEIGHT="0.03611871839642979"/>
<CONT_DATA CI_END="-12.152692838925319" CI_START="-140.38730716107472" EFFECT_SIZE="-76.27000000000001" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="124.37" MODIFIED="2010-04-28 17:23:43 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1993" SD_1="46.6" SD_2="121.0" SE="32.71351293535179" STUDY_ID="STD-D_x0027_Ambrosio-1999" TOTAL_1="14" TOTAL_2="16" WEIGHT="5.041623618378558E-5"/>
<CONT_DATA CI_END="-0.9993825474886258" CI_START="-7.180617452511374" EFFECT_SIZE="-4.09" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="7.57" MODIFIED="2010-04-28 17:24:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1994" SD_1="5.37" SD_2="8.23" SE="1.5768746144774954" STUDY_ID="STD-de-Blay-2003" TOTAL_1="33" TOTAL_2="42" WEIGHT="0.021698537526382254"/>
<CONT_DATA CI_END="-0.8503233814308235" CI_START="-2.549676618569177" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" MODIFIED="2010-04-28 17:24:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1995" SD_1="0.7" SD_2="1.5" SE="0.4335164448282302" STUDY_ID="STD-Di-Rienzo-2006" TOTAL_1="18" TOTAL_2="14" WEIGHT="0.2870870706973792"/>
<CONT_DATA CI_END="4.80645420599857" CI_START="-27.40645420599857" EFFECT_SIZE="-11.3" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="23.8" MODIFIED="2010-04-28 17:24:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1996" SD_1="18.7" SD_2="26.4" SE="8.217729679241163" STUDY_ID="STD-Drachenberg-2001" TOTAL_1="37" TOTAL_2="12" WEIGHT="7.989527292744935E-4"/>
<CONT_DATA CI_END="0.030559402833877147" CI_START="-0.11055940283387716" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.17" MODIFIED="2010-04-28 17:24:36 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1997" SD_1="0.17" SD_2="0.19" SE="0.036000356838411685" STUDY_ID="STD-Dubakiene-2003" TOTAL_1="47" TOTAL_2="53" WEIGHT="41.630456751828085"/>
<CONT_DATA CI_END="-24.4788994608549" CI_START="-79.2011005391451" EFFECT_SIZE="-51.84" ESTIMABLE="YES" MEAN_1="24.06" MEAN_2="75.9" MODIFIED="2010-04-28 17:25:14 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1998" SD_1="25.72" SD_2="50.3" SE="13.960001691340235" STUDY_ID="STD-Feliziani-1995" TOTAL_1="18" TOTAL_2="16" WEIGHT="2.768559395388489E-4"/>
<CONT_DATA CI_END="0.8569271817952204" CI_START="-4.85692718179522" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.1" MODIFIED="2010-04-28 17:25:42 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="1999" SD_1="5.5" SD_2="6.8" SE="1.4576426936057485" STUDY_ID="STD-Guez-2000" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.025393503666637805"/>
<CONT_DATA CI_END="0.04139957589721502" CI_START="-0.34139957589721504" EFFECT_SIZE="-0.15" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.31" MODIFIED="2010-04-28 17:26:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2001" SD_1="0.37" SD_2="0.45" SE="0.09765463927243073" STUDY_ID="STD-Hordijk-1998" TOTAL_1="35" TOTAL_2="36" WEIGHT="5.657688424599024"/>
<CONT_DATA CI_END="2.595584421692871" CI_START="-2.755584421692871" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.36" MODIFIED="2010-04-28 17:26:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2002" SD_1="3.89" SD_2="3.95" SE="1.3651191770856708" STUDY_ID="STD-La-Rosa-1999" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.028952338760078685"/>
<CONT_DATA CI_END="728.4930026679606" CI_START="-1734.4930026679606" EFFECT_SIZE="-503.0" ESTIMABLE="YES" MEAN_1="2334.0" MEAN_2="2837.0" MODIFIED="2010-04-28 17:26:38 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2003" SD_1="2616.0" SD_2="2052.0" SE="628.3243020697422" STUDY_ID="STD-Lima-2002" TOTAL_1="28" TOTAL_2="28" WEIGHT="1.3666492642918422E-7"/>
<CONT_DATA CI_END="6.667999005480723" CI_START="-97.72799900548073" EFFECT_SIZE="-45.53" ESTIMABLE="YES" MEAN_1="21.92" MEAN_2="67.45" MODIFIED="2010-04-28 17:27:41 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2004" SD_1="30.45" SD_2="83.77" SE="26.632121517135968" STUDY_ID="STD-Marcucci-2005" TOTAL_1="13" TOTAL_2="11" WEIGHT="7.606997252606625E-5"/>
<CONT_DATA CI_END="2.774701175507959" CI_START="-1.494701175507959" EFFECT_SIZE="0.64" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.92" MODIFIED="2010-04-28 17:27:41 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2006" SD_1="11.55" SD_2="2.47" SE="1.089153266257038" STUDY_ID="STD-Ott--2009" TOTAL_1="123" TOTAL_2="60" WEIGHT="0.04548275786922475"/>
<CONT_DATA CI_END="-6.2577494112283585" CI_START="-25.74225058877164" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="26.27" MODIFIED="2010-04-28 17:28:17 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2007" SD_1="7.26" SD_2="16.5" SE="4.970627351123424" STUDY_ID="STD-Pajno-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0021837472770884284"/>
<CONT_DATA CI_END="1.356262881055544" CI_START="-1.976262881055544" EFFECT_SIZE="-0.31000000000000005" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.85" MODIFIED="2010-04-28 17:29:24 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2011" SD_1="3.58" SD_2="3.87" SE="0.8501497446885825" STUDY_ID="STD-Rolinck_x002d_Werninghaus-2004" TOTAL_1="39" TOTAL_2="38" WEIGHT="0.07465070773258076"/>
<CONT_DATA CI_END="3.3493715740822267" CI_START="-35.34937157408223" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="33.0" MODIFIED="2010-04-28 17:30:20 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2014" SD_1="21.0" SD_2="33.0" SE="9.872309760132124" STUDY_ID="STD-Troise-1995" TOTAL_1="15" TOTAL_2="16" WEIGHT="5.53588729414768E-4"/>
<CONT_DATA CI_END="1.108946129800763" CI_START="-3.108946129800763" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.9" MODIFIED="2010-04-28 17:32:11 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2015" SD_1="3.4" SD_2="4.6" SE="1.0760126953535172" STUDY_ID="STD-Valovirta-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.04660043772754091"/>
<CONT_DATA CI_END="1.5423668956990317" CI_START="-4.182366895699031" EFFECT_SIZE="-1.3199999999999998" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="4.71" MODIFIED="2010-04-28 17:32:12 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2016" SD_1="3.94" SD_2="5.0" SE="1.460418108841293" STUDY_ID="STD-Vervloet-2006" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.025297078474546927"/>
<CONT_DATA CI_END="5.946371296782594" CI_START="-39.946371296782594" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="39.0" MODIFIED="2010-04-28 17:33:01 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2017" SD_1="30.0" SD_2="34.0" SE="11.707547423208101" STUDY_ID="STD-Voltolini-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.936343011229584E-4"/>
<CONT_DATA CI_END="1.378739874282158" CI_START="-2.138739874282158" EFFECT_SIZE="-0.3800000000000001" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.77" MODIFIED="2010-04-28 17:33:01 +0100" MODIFIED_BY="Suzana Radulovic" ORDER="2018" SD_1="3.41" SD_2="3.85" SE="0.8973327510887311" STUDY_ID="STD-Vourdas-1998" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.06700662576573552"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-10 22:31:59 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-10 22:31:59 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-10 22:31:59 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-06-30 11:32:49 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 SLIT versus placebo - all, outcome: 1.1 Allergic rhinitis symptom scores.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-06-30 11:33:04 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 SLIT versus placebo - all, outcome: 1.2 Medication scores.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-10 23:06:58 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-10 23:06:58 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-17 19:39:08 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-10 23:06:58 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>PubMed</P>
</TH>
<TH>
<P>EMBASE (Ovid)</P>
</TH>
<TH>
<P>CINAHL (EBSCO)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1 "IMMUNOTHERAPY" [MeSH] OR "DESENSITIZATION, IMMUNOLOGIC" [MeSH]<BR/>#2 ("Allergens/administration and dosage"[Mesh] OR "Allergens/immunology"[Mesh])<BR/>#3 ALLERGEN* [tiab] OR IMMUNOLOGIC [tiab]) AND (HYPOSENSITIZ* [tiab] OR HYPOSENSITIS* [tiab] OR DESENSITIZ* [tiab] OR DESENSITIS* [tiab])<BR/>#4 #1 OR #2 OR #3<BR/>#5 "ADMINISTRATION, SUBLINGUAL" [Mesh]<BR/>#6 (SUBLINGUAL* [tiab] OR ORAL* [tiab] OR TONGUE [tiab] OR MUCOSA [tiab])<BR/>#7 #5 OR #6<BR/>#8 #4 AND #7<BR/>#9 (SLIT [tiab] OR (SUBLINGUAL* [tiab] AND IMMUNOTHERAP* [tiab]))<BR/>#10 #8 OR #9<BR/>#11 (((("rhinitis, allergic, perennial"[Mesh]) OR ("rhinitis, allergic, seasonal"[Mesh]) OR ((("rhinitis"[Mesh]) OR (rhinit*[tiab])) AND (allerg*[tiab] OR "hypersensitivity"[Mesh])) OR (((("rhinitis"[Mesh]) OR (rhinit*[tiab])) OR (allerg*[tiab] OR "hypersensitivity"[Mesh])) AND ((perennial[ti] OR persistent[ti] OR nonseaosnal[ti] OR nose[ti] OR nasal[ti] OR cat*[ti] OR fur[ti] OR hair*[ti] OR dander[ti] OR dust*[ti] OR mite*[ti] OR pet*[ti] OR dog*[ti] OR cockroach*[ti]) OR (seasonal[ti] OR intermittent[ti] AND spring[ti] OR summer[ti] OR pollen[ti] OR grass*[ti] OR birch[ti] OR ragweed[ti] OR tree*[ti] OR weed*[ti] OR mugwort[ti] OR willow[ti] OR alder[ti]))) OR (hayfever[tiab] OR "hay fever"[tiab] OR pollenosis[tiab] OR pollinosis[tiab] OR SAR [tiab] OR PAR [tiab]))<BR/>#12 #10 AND #11<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 IMMUNOTHERAPY/ or IMMUNOLOGICAL TOLERANCE/ or exp IMMUNOMODULATING AGENT/ or exp IMMUNOSUPPRESSIVE TREATMENT/<BR/>2 ((ALLERGEN* or IMMUNOLOGIC) and (HYPOSENSITIZ* or HYPOSENSITIS* or DESENSITIZ* or DESENSITIS*)).tw.<BR/>3 1 or 2<BR/>4 (SUBLINGUAL* or ORAL* or TONGUE or MUCOSA).tw.<BR/>5 4 and 3<BR/>6 (SLIT or (SUBLINGUAL* and IMMUNOTHERAP*)).tw.<BR/>7 6 or 5<BR/>8 exp Allergic Rhinitis/<BR/>9 Rhinitis/<BR/>10 Rhinit*.tw.<BR/>1110 or 9<BR/>12 exp Hypersensitivity/<BR/>13 allerg*.tw.<BR/>14 13 or 12<BR/>15 11 and 14<BR/>16 (perennial or persistent or nonseasonal or nose or nasal or cat* or fur or hair* or dander or dust* or mite* or pet* or dog* or cockroach*).ti.<BR/>17 (seasonal or intermittent or spring or summer or pollen or grass* or birch or ragweed or tree* or weed* or mugwort or willow or alder).ti.<BR/>18 17 or 16<BR/>19 11 or 14<BR/>20 18 and 19<BR/>21 (hayfever or "hay fever" or pollenosis or pollinosis or SAR).tw.<BR/>22 15 or 8 or 20 or 21<BR/>23 22 and 7</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MH "Rhinitis, Allergic, Perennial") or (MH "Rhinitis, Allergic, Seasonal")<BR/>S2 (MH "Rhinitis")<BR/>S3 TX rhinit*<BR/>S4 S2 or S3<BR/>S5 TX allerg*<BR/>S6 (MH "Hypersensitivity")<BR/>S7 S5 or S6<BR/>S8 S4 and S7<BR/>S9 TI perennial or persistent or nonseasonal or nose or nasal or cat* or fur or hair* or dander or dust* or mite* or pet* or dog* or cockroach*<BR/>S10 TI seasonal or intermittent or spring or summer or pollen or grass* or birch or ragweed or tree* or weed* or mugwort or willow or alder<BR/>S11 S9 or S10<BR/>S12 S5 OR S6<BR/>S13 S11 and S12<BR/>S14 TX hayfever OR "hay fever" OR pollenosis OR pollinosis OR SAR<BR/>S15 S1 or S8 or S13 or S14<BR/>S16 (MH "Immunotherapy")<BR/>S17 (MH "Desensitization, Immunologic")<BR/>S18 TX ( ALLERGEN* OR IMMUNOLOGIC* ) and TX ( HYPOSENSITIZ* OR HYPOSENSITIS* OR DESENSITIZ* OR DESENSITIS* )<BR/>S19 S16 or S17 or S18<BR/>S20 (MH "Administration, Sublingual")<BR/>S21 TX SUBLINGUAL* OR ORAL* OR TONGUE OR MUCOSA<BR/>S22 S20 or S21<BR/>S23 S19 and S22<BR/>s24 TX SLIT OR TX (sublingual AND immunotherap*)<BR/>S25 S23 OR S24<BR/>S26 S15 AND S25<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Web of Science</P>
</TH>
<TH>
<P>BIOSIS Previews/CAB Abstracts (Ovid)</P>
</TH>
<TH>
<P>mRCT</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1 TS=rhiniti*<BR/>#2 TS=(allerg* OR hypersensitivty)<BR/>#3 #2 AND #1<BR/>#4 TI=(perennial or persistent or nonseasonal or nose or nasal or cat* or fur or hair* or dander or dust* or mite* or pet* or dog* or cockroach*)<BR/>#5 TI=(seasonal or intermittent or spring or summer or pollen or grass* or birch or ragweed or tree* or weed* or mugwort or willow or alder)<BR/>#6 #5 OR #4<BR/>#7 #6 AND #2<BR/>#8 TS=(hayfever OR "hay fever" OR pollenosis OR pollinosis OR SAR OR PAR)<BR/>#9 #3 OR #7 OR #8<BR/>#10 TS=((ALLERGEN* OR IMMUNOLOGIC*) AND (HYPOSENSITIZ* OR HYPOSENSITIS* OR DESENSITIZ* OR DESENSITIS* ))<BR/>#11 TS=(immunotherap*)<BR/>#12 #10 OR #11<BR/>#13 TS=(SUBLINGUAL* or ORAL* or TONGUE or MUCOSA)<BR/>#14 #12 AND #13<BR/>#15 SLIT<BR/>#16 #14 OR #15<BR/>#17 #9 AND #16<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 IMMUNOTHERAPY/ or IMMUNOLOGICAL TOLERANCE/ or exp IMMUNOMODULATING AGENT/ or exp IMMUNOSUPPRESSIVE TREATMENT/77<BR/>2 ((ALLERGEN* or IMMUNOLOGIC) and (HYPOSENSITIZ* or HYPOSENSITIS* or DESENSITIZ* or DESENSITIS*)).tw.<BR/>3 1 or 2<BR/>4 (SUBLINGUAL* or ORAL* or TONGUE or MUCOSA).tw.<BR/>5 4 and 3<BR/>6 (SLIT or (SUBLINGUAL* and IMMUNOTHERAP*)).tw.<BR/>7 6 or 5<BR/>8 Rhinitis/<BR/>9 Rhinit*.tw.<BR/>10 9 or 10<BR/>11 exp Hypersensitivity/<BR/>12 allerg*.tw.<BR/>13 11 or 12<BR/>14 10 and 13<BR/>15 (perennial or persistent or nonseasonal or nose or nasal or cat* or fur or hair* or dander or dust* or mite* or pet* or dog* or cockroach*).ti.<BR/>16 (seasonal or intermittent or spring or summer or pollen or grass* or birch or ragweed or tree* or weed* or mugwort or willow or alder).ti.<BR/>17 15 or 16<BR/>18 13 AND 17<BR/>19 (hayfever or "hay fever" or pollenosis or pollinosis or SAR).tw.<BR/>20 10 or 18 OR 19<BR/>21 7 AND 20</P>
</TD>
<TD VALIGN="TOP">
<P>(rhinit% OR hayfever OR allerg%) AND (sublingual% OR oral% OR tongue OR mucosa)</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>